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Thesis Summary 
Understanding the mechanisms used by HIV-1 to evade antibody neutralisation may contribute 
to the design of a high-coverage vaccine. This thesis explores the mechanism used by a Tier 3 
virus leading to its high antibody neutralisation resistance phenotype. This thesis also describes 
how the glycans at the base of the V3 loop contribute to (i) breadth and potency in a cohort of 
unselected HIV-1-infected individuals and (ii) the selective pressures resulting from the 
V3/glycans shielding the virus from neutralisation and the glycans themselves being targets of 
broad antibody responses. 
HIV-1 isolates that are highly resistant to broadly neutralising antibodies could limit the 
efficacy of an antibody-based vaccine. For this reason, it is important to understand the 
mechanisms behind high HIV-1 resistance to neutralising antibodies. Chapter 2 and Chapter 3 
of this thesis describe virus 253-11, a highly neutralisation resistant virus, which is particularly 
resistant to commonly-elicited, anti-membrane proximal external region (MPER) antibodies in 
sera. To further understand its resistance, mutations in the MPER were introduced that are 
known to delay fusion following CD4-binding and thus increase the time the virus spends in 
the open conformation. Interestingly, we found that these mutations affect the 253-11 Envelope 
(Env) spike before CD4-binding by destabilising the closed trimer structure. From these data, 
we hypothesized that the neutralisation resistance of 253-11 was due to an unusually tight, 
compact pre-fusion Env trimer that resists transient changes to the open conformation. The 
open conformation frequently exposes narrowly-neutralising antibody epitopes. Because the 
unliganded 253-11 Env presumably transitions infrequently into the open conformation, it 
would be able to evade these responses.  
253-11 was sensitive to most but not all of the most potent broadly neutralising antibodies
(bnAbs) tested, most likely because those broadly neutralising antibodies can access their 
epitopes in the pre-fusion Env conformation. To gain further information about the structure of 
the 253-11 Env, we designed a recombinant 253-11 SOSIP trimer and found it to be stable and 
predominantly adopt a closed conformation. The crystal structure of the SOSIP trimer revealed 
structural elements likely responsible for 253-11 Env compactness including the inward 
disposition of the heptad repeat helices and gp120 protomers towards the trimer axis. Taken 
together, the data from Chapter 2 and Chapter 3 highlight an underappreciated Env 
Thesis summary Page xiii 
compactness mechanism of HIV-1 resistance to neutralising antibodies and these data may be 
useful in HIV-1 immunogen design research. 
Previous candidate HIV vaccines have failed to induce wide-coverage neutralising antibodies 
capable of substantially protecting vaccinees. A key approach in HIV immunogen development 
has been to define and model epitopes recognised by anti-HIV bnAbs. Candidate immunogen 
models identified by bnAbs include the V3/glycans, the V2/apex and the MPER epitopes. 
Autoreactivity and polyreactivity of anti-V3/glycan and anti-MPER antibodies are thought to 
pose both direct and indirect barriers to achieving neutralisation breadth. Chapter 4 of this 
thesis explored which of these bnAb epitopes were associated with breadth and potency in a 
South African cohort of chronically HIV-infected individuals. The study found that antibodies 
targeting the V3/glycans were associated with breadth and potency. In contrast, antibodies to 
the V2/apex were not associated with neutralisation breadth/potency. This suggests that 
auto/polyreactivity are not critical factors in the development of breadth and potency and that 
the V3/glycans should remain a high-priority vaccine candidate.  
Since targeting the V3/glycans was associated with breadth and potency in this cohort, the 
study continued to look at this epitope to investigate the role of these glycans in neutralisation 
resistance of Tier 2 viruses. The HIV-1 Env is surrounded by glycans that often prevent 
antibody neutralisation, leading to the term the “glycan shield”, however some bnAbs have 
evolved to recognise these carbohydrates. Chapter 4 of this thesis describes how the N-linked 
glycan at position N301 is critical for maintaining neutralisation resistance of one subtype C 
virus (Du156.12), but not for another subtype-matched virus (CAP45.2.00.G3). Thus, the loss 
of the N301 glycan may have a substantial antibody-related fitness cost for some viruses but 
not others. The N301 glycan, as well as glycans at positions 332 and 334, are the primary 
targets of the anti-V3/glycan class of neutralising antibodies, which may select for loss of the 
targeted glycan. The evidence presented in Chapter 4 suggests that in some viruses, loss of the 
N301 glycan may result in evasion of anti-V3/glycan antibody responses while maintaining 
overall neutralisation resistance. This phenomenon may impair efficacy of passively-infused 
anti-V3/glycan bnAbs or a therapeutic vaccine.
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The human immunodeficiency virus type 1 (HIV-1) was found to be the cause of acquired 
immune deficiency syndrome (AIDS) in 1983 (Barre-Sinoussi et al., 1983, Chermann et al., 
1983) and since that time it has become a major global health concern, with approximately 36 
million people living with the virus worldwide as of 2015 (UNAIDS, 2017). Sub-Saharan 
Africa is home to the majority of HIV-1-infected individuals, with approximately 25 million 
people living with the virus in this region alone (UNAIDS, 2017, Vermund, 2014).  
 
Upon introduction of anti-retroviral therapy (ART) in the 1990s (Sasson et al., 2005) and 
specifically highly active anti-retroviral therapy (HAART), there has been a tremendous 
reduction in the mortality and morbidity of the infection (Montaner et al., 2014, Crum et al., 
2006, Casseb et al., 1999). Although HAART is effective, it does bear some challenges. 
Lifelong treatment comes at a high financial cost to governments and individuals (SANAC, 
2016) and not all HIV-infected individuals have access to treatment as shown by statistics from 
2014 which revealed that approximately 73% of HIV-positive adults living in South Africa 
were receiving ART (SANAC, 2016), leaving 27% without the life-saving therapy. Another 
challenge with ART is the need for infected individuals to adhere to the treatment to reduce the 
probability of the emergence of drug-resistant isolates (Viswanathan et al., 2015). Non-
adherence predominantly occurs in sex workers, intravenous blood users, adolescents and 
individuals in low-resource areas due to factors including the difficulty in retaining them in 
care (Mtetwa et al., 2013, McGowan et al., 2011, Rudy et al., 2009, Hankins et al., 2002). 
 
Another concern with relying on ART to control the HIV/AIDS pandemic is adverse drug 
reactions (Mouton et al., 2016). As more HIV-infected people are enrolled in therapy and live 
longer, the population risk of ART-related complications rises (Hima Bindu and Naga Anusha, 
2011), leading to increased burdens on the healthcare system caused by HIV-1 infections. 
 
There is still no cure for HIV-1 that completely eliminates the virus from the body and there 
are only two reported cases of a functional cure (Violari et al., 2017, Hutter et al., 2009), with 
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other reported cure cases experiencing viral rebound at a later date (Henrich et al., 2014, 
Ledford, 2014). As a result of the disadvantages of ART and the absence of an HIV-1 cure; 
there is a need for new strategies to fight the pandemic (Dangeti, 2014). 
 
1.2 HIV-1 prevention 
 
Current HIV-1 preventative strategies have shown varying success in preventing HIV-1 
infection. These include microbicide vaginal gels (Abdool Karim et al., 2010), pre- and post- 
exposure prophylaxis (Vissers et al., 2008) and male circumcision (Wamai et al., 2011). These 
preventative measures are relatively inexpensive compared to developing potential HIV-1 
cures or vaccines; however, it is highly unlikely that they will be adequately effective on their 
own in decreasing HIV-1 incidence enough to control and eventually eradicate the virus 
(Phillips and Pirkle, 2011, Burns et al., 2010). 
 
Microbiocide gels contain ART drugs such as tenofovir and are applied to the vagina or rectum 
prior to sexual intercourse (Abdool Karim et al., 2010). Before the tenofovir gel, six candidate 
gels were tested in trials but none were able to protect against HIV-1 acquisition (Abdool Karim 
et al., 2010). The tenofovir gel was able to prevent infection by up to 54% in women with high 
adherence, however, the women who adhered the most to gel application also had fewer coital 
acts (Abdool Karim et al., 2010). As the risk of HIV-1 infection increases with the number of 
coital acts (Hughes et al., 2012, Varghese et al., 2002) and the tenofovir gel requires adherence 
to work well, the gel may not be effective in reducing transmission in at-risk groups such as 
female sex workers. 
 
Pre-exposure prophylaxis employs the use of ART such as Truvada in the prevention of HIV-
1 before an exposure (Naswa and Marfatia, 2011); for example, for use by an HIV-negative 
individual participating in unprotected sexual intercourse with a person with an undisclosed 
HIV status. Post-exposure prophylaxis is taken after a suspected exposure (Moorhouse et al., 
2015, Smith et al., 2005), such as a healthcare worker being exposed to the blood of an HIV-
infected individual through a needlestick injury (Krakower et al., 2015). Although the use of 
pre- and post-exposure prophylaxis is highly effective in preventing HIV acquistion, there has 
been limited uptake of and benefit from this preventative method due to factors such as lack of 
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awareness and adherence, low perception of HIV acquisition risk and adverse side-effects 
(Cowan et al., 2016, Deutsch et al., 2015, Krakower et al., 2015). 
Another HIV-1 prevention strategy that has shown moderate effectiveness, with up to 60% 
reduction in HIV-1 acquisition, is male circumsion (Bailey et al., 2007, Gray et al., 2007b, 
Auvert et al., 2005). Although the mechanism behind this is not fully understood, one 
explanation is that the foreskin is a conducive environment for HIV-1 replication as it harbours 
Langerhans cells and cluster of differentiation 4 (CD4)+ T cells that express C-C chemokine 
receptor type 5 (CCR5), a co-receptor used by HIV-1 to enter cells (Lemos et al., 2014). 
However, many men do not undergo the procedure because they do not believe it is effective 
in preventing HIV-1 (Wamai et al., 2011) and because of a lack of adequate healthcare services 
providing this option in some developing countries (Bulled and Green, 2016). 
 
ART can be used as a preventative strategy as HIV-infected individuals on treatment are less 
likely to transmit when they have undetectable blood viral loads (Donnell et al., 2010). 
According to UNAIDS,  19.5 million out of the 36 million HIV-infected individuals worldwide 
were accessing ART in 2016 (UNAIDS, 2017). However, among the individuals on ART, a 
large proportion may not be adherent to the medication which usually diminishes the 
preventative effects (Donnell et al., 2010). 
 
Due to the inability of these preventative measures to effectively control HIV-1 infections, 
there is still a need for an HIV-1 vaccine (Gray et al., 2016). Providing an HIV-1 vaccine to 
the population would be less expensive than maintaining ART because a vaccine is given once, 
with perhaps a few boosters, as compared to ART which is a life-long therapy (Harmon et al., 
2016). Recent epidemiological models predict that an HIV-1 vaccine with 70% efficacy would 
reduce infections by as much as 44% within the first decade and 78% by 2070 (Harmon et al., 
2016). 
 
One of the leading research areas in HIV-1 vaccine design is the elicitation of broadly 
neutralising antibodies (bnAbs) by HIV-1 immunogens (Haynes and Mascola, 2017, Morris et 
al., 2017, Klasse et al., 2016, de Taeye et al., 2015, Sanders et al., 2015). BnAbs bind to diverse 
HIV-1 isolates and prevent entry into host cells and therefore are attractive in the development 




Chapter 1: Literature Review Page 4 
 
1.3 HIV-1 diversity 
 
Cohen et al., (2014) dates the transmission of HIV-1 from primates in Cameroon to the early 
1900s, which led to the widespread dissemination of the virus, resulting in the AIDS pandemic 
(Cohen, 2014). Although there are currently 4 main groups of HIV-1: M, N, O and P, HIV-1 
group M is the only group which has spread worldwide and is the leading cause of HIV-1 
infections, while groups N, O and P remain in West Africa (Faria et al., 2014).  
 
HIV-2 is another type of HIV which is thought to have originated from sooty mangabey 
monkeys in West Africa (McCutchan, 2006). It is less prevalent than HIV-1 and has 
predominantly remained in that region (McCutchan, 2006). HIV-2 is less transmissible than 
HIV-1 and progression to AIDS is much slower in HIV-2 infection (Nyamweya et al., 2013). 
HIV-1 and HIV-2 isolates differ at the nucleotide level by approximately 50% (Arien et al., 
2007) but have similar gene arrangement, transmission and replication models as well as the 
eventual clinical outcome; AIDS (Nyamweya et al., 2013).  
 
There is enormous HIV-1 diversity within group M itself (Fig 1.1), with at least 9 different 
“pure” subtypes (also known as clades). Subtype C is responsible for most HIV-1 infections 
and is the dominant subtype in sub-Saharan Africa and India (Hemelaar, 2012). There are 
numerous circulating and unique recombinant isolates (Hemelaar, 2012, Tongo et al., 2016). 
Circulating recombinant forms (CRFs) are HIV-1 isolates which contain sequences attributed 
to two different “pure” subtype lineages and are known to be circulating within human 
populations (McCutchan, 2006) . With the emergence of more sophisticated computational 
methods and more sequences available to analyse them, evidence has emerged that some 
“pure” subtypes and many presumed recombinants may have been incorrectly characterised 
(Tongo et al., 2016, Abecasis et al., 2007, Robertson et al., 2000). For example, one study 
suggests that the CRF02_AG recombinant is actually the parent of a recombinant subtype G 
rather than a CRF (Abecasis et al., 2007). 
 
 













Figure 1.1 Global distribution of HIV-1 group M. HIV-1 group M has disseminated around the world 
more than any other HIV-1 group. There are at least 9 “pure” subtypes and numerous recombinants of 
the virus. The largest percentage of infections is in sub-Saharan Africa and the largest diversity of HIV-
1 isolates in one region is in West and Central Africa. Source: (Hemelaar, 2012). 
 
 
Within HIV-1 Group M subtypes, the env gene has greater diversity than the rest of the HIV-1 
genome (Lynch et al., 2009). The HIV-1 Envelope (Env) protein can differ up to 30% within a 
subtype and up to 36% between subtypes (Korber et al., 2001). HIV-1 diversity presents a 
challenge in vaccine development because an effective, global vaccine should protect against 
most, if not all, circulating variants (Burton et al., 2012). The Env glycoprotein is the sole target 
for bnAbs and therefore an important vaccine target (Wyatt et al., 1998). Understanding its 
diversity, structure and function is therefore essential for antibody-based immunogen design 
(Haynes and Burton, 2017, Wyatt and Sodroski, 1998, Freed and Martin, 1995). 
 
1.4 HIV-1 Envelope structure and function 
 
1.4.1 Role of HIV-1 Envelope in viral entry 
 
The Env precursor, known as gp160, is made in the rough endoplasmic reticulum and 
eventually cleaved by furin in the Golgi apparatus, into the surface (gp120) and transmembrane 
(gp41) subunits forming the mature Env structure (Ward and Wilson, 2015). The mature HIV-
1 Env exists as a trimer that is made up of 3 gp120 and 3 gp41 monomers (Fig 1.2a) (Freed 
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and Martin, 1995). Env contains hypervariable loop regions resulting in increased HIV-1 Env 
diversity, as well as conserved regions (Didigu and Doms, 2012). Env is heavily glycosylated 
(Doores, 2015) with a high density of N-linked glycans (Zhu et al., 2000) and possibly O-linked 
glycans (Go et al., 2015); this glycosylation is found mainly in gp120 but also in gp41 (Doores, 







Figure 1.2 Schematic of the HIV-1 Envelope and host cell entry. (a) HIV-1 Env is a trimer made up 
of gp120 and gp41 heterodimers (b) The initial contact of the HIV-1 trimer with the host cell is through 
the host cell CD4 receptor which binds to the viral CD4-binding site (c) Subsequently, the trimer binds 
to the co-receptor (CCR5 or CXCR4) and the fusion peptide enters the host membrane (d) The viral 
and host membranes fuse, leading to the formation of a six-helix bundle and the entry of the virus into 
the host cell. Adapted from: (Didigu and Doms, 2012). 
 
The HIV-1 Env trimer initiates viral entry by binding to CD4 on the host cell through the CD4-
binding site (CD4-bs) on Env (Fig 1.2b), followed by the binding of the Env V3 loop-located 
co-receptor binding site to CCR5 or C-X-C chemokine receptor type 4 (CXCR4) on the host 
cell; a process inhibited by the anti-HIV drug maraviroc (Didigu and Doms, 2012) (Fig 1.2c). 
While most chronic HIV-1 isolates can use one or both of the co-receptors to facilitate entry 
into cells (Vicenzi et al., 2013, Moore et al., 2004), transmitted/founder (T/F) viruses 
preferentially bind to CCR5 (Kariuki et al., 2017, Parrish et al., 2013). During co-receptor 
binding, the fusion peptide (FP) embeds itself into the membrane of the cell (Fig 1.2c). The 
final step in viral entry is the formation of the six-helix bundle (6HB), which promotes fusion 
of the two membranes (Fig 1.2d) (Gallo et al., 2003). The N- and C-terminal portions of gp41 
– Heptad Repeat (HR) helices 1 and 2, respectively – coil together to form the stable 6HD 
structure (Gallo et al., 2003). Developing drugs which lock the trimer in the closed pre-fusion 
state (Fig 1.2a) may be effective in inhibiting viral fusion and subsequent entry into the cell 
(Munro et al., 2014). 
 
A B C D 
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1.4.2 The different conformations of Env 
 
Env changes conformation throughout the entry process (Munro et al., 2014). Initially, the Env 
trimer is in a closed, prefusion state (Bartesaghi et al., 2013) and upon CD4 and co-receptor 
binding, it changes to an open, bound state (Wang et al., 2016, Tran et al., 2012). Strikingly, 
free unliganded HIV-1 Env is constantly shifting between closed, partially open and open states 










Figure 1.3 Model of the dynamic conformations of unliganded Env. HIV-1 Env continually 
fluctuates between closed, partially open and open conformations. Epitopes of non- and poorly 
neutralising antibodies are often occluded in the closed conformation and become more exposed as the 
trimer structure opens. Adapted from: (Cai et al., 2017). 
 
HIV-1 isolates are categorised into Tiers based on their antibody neutralisation resistance 
profiles (Seaman et al., 2010). As grouped by Seaman et al., Tier 1 viruses can be neutralised 
by most antibodies including narrowly neutralising antibodies. Tier 2 viruses are moderately 
neutralisation resistant and Tier 3 viruses are resistant to neutralisation by most antibodies 
(Seaman et al., 2010). The epitopes of common, poorly neutralising antibodies are most 
exposed in the open conformation (Fig 1.3), in essence, it seems that unliganded, neutralisation 
sensitive Tier 1 viruses tend to spend more time in the transient open conformation while 
neutralisation-resistant Tier 3 viruses have been found to favour the closed conformations with 
less fluctuations to an open state (Cai et al., 2017, Munro et al., 2014).  
 
Researchers further explored this by using hydrogen/deuterium exchange coupled with mass 
spectrometry which is a sensitive technique used to monitor structural changes in Env upon 
ligand binding (Guttman et al., 2015). They confirmed that most poorly-neutralising antibodies 
access their epitope in the open, exposed trimer conformation and found that most potent bnAbs 
 
Chapter 1: Literature Review Page 8 
 
can bind to both conformations (Guttman et al., 2015). The degree to which the Env 
conformation must change for an antibody to bind is usually correlated with the potency of that 
antibody (Haim et al., 2013). Both the Haim et al., and Guttman et al., studies concluded that 
the binding of poorly neutralising antibodies results in large, irreversible Env conformational 
changes in the open state whilst potent neutralising antibodies usually bind with smaller, 
localised conformational effects. BnAbs can therefore be used to lock the trimer in the closed 
conformation which is especially useful in X-ray crystallography of the closed trimer (Stewart-
Jones et al., 2016, Julien et al., 2013a). 
 
1.4.3 HIV-1 Env glycans  
 
The HIV-1 Env trimer is a heavily glycosylated protein with up to 50% of its mass comprising 
of glycans (Doores, 2015, Korber et al., 2001). Glycans are added to the protein at potential N-
linked glycosylation sites (PNGs) which are characterised by an N-X-T/S motif; where X ≠ P 
(Marshall, 1972). There are approximately 25 (ranges between 18-33) PNGs on Env (Korber 
et al., 2001). Glycans serve various roles including protection from antibody neutralisation 
(Moore et al., 2012, Pantophlet and Burton, 2006, Wei et al., 2003) and correct folding of the 
Env protein which, in turn, affects Env antigenicity and immunogenicity (Li et al., 1993). Some 
studies have found that T/F isolates from subtypes A, C and D have fewer Env PNGs (Ping et 
al., 2013, Derdeyn et al., 2004) which helps the virus avoid glycan-specific mucosal immunity 
and improves the ability of the virus to attach to host cells (Moore et al., 2014). However, this 
phenotype seems to be subtype specific as it has not been observed in subtype B isolates (Liu 
et al., 2008, Frost et al., 2005a). Interestingly, glycans also serve a role in viral dissemination 
as dendritic cells attach to the gp120 glycans on virions through dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) lectins and transport the 
virions to the lymphoid tissues (Lama and Planelles, 2007).  
 
HIV-1 Env glycan production (Fig 1.4) starts in the endoplasmic reticulum (Bonomelli et al., 
2014). N-linked glycans are attached to the asparagine residue of the glycosylation motif 
through a N-glycosidic bond with the N-acetylglucosamine (GlcNAc) portion of the glycan 
(Corfield, 2017). This is followed by addition of other building blocks to produce a glycan 
precursor known as Glc3Man9GlcNAc2 (Glc: glucose, Man: mannose) (Kornfeld and Kornfeld, 
1985). This high mannose glycan (9 mannose sugars) is subsequently cleaved by other 
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endoplasmic reticulum enzymes known as α-glucosidase I and II, forming an intermediate 
which is monoglucosylated (Bonomelli et al., 2014).  
 
α-glucosidase II further cleaves the intermediate into Man9 GlcNAc2 - the high mannose glycan 
referred to as Man9 (Fig 1.4), which is present on the mature Env trimer (Doores et al., 2010). 
Man9 can be further trimmed in the endoplasmic reticulum or in the Golgi apparatus to Man5-
8GlcNAc2 (Man5-8) glycans  (Fig 1.4) (Bonomelli et al., 2014). The types of glycans found at 
PNGs are dependent on multiple factors including the type of cell the virus was expressed in, 
post-translational processing in the ER and Golgi apparatus as well as the presence of nearby 
glycans (Hioe et al., 2014).  
 
One unusual features of HIV-1 Env is the presence of mainly under-processed oligomannose-
type glycans on gp120 which result from the numerous gp120 Env glycans restricting access 
of enzymes which further process the glycans in the endoplasmic reticulum (Behrens et al., 
2016, Doores, 2015, Doores et al., 2010). The gp41 Env subunit consists mainly of highly 
processed, complex glycans as there is lower glycan density in this region so the enzymes can 
easily penetrate to process them further (Behrens et al., 2016, Pritchard et al., 2015). 
 
Complex and hybrid glycans are formed from Man9 in the Golgi apparatus by an enzyme 
known as N-acetylglucosaminyltransferase I (GnT I) and other Golgi enzymes (Bonomelli et 
al., 2014, Freed and Martin, 1995). Cells which lack this enzyme such as human embryonic 
kidney (HEK) 293S cells (Chaudhary et al., 2012) are used widely in HIV-1 research to 
produce recombinant trimers enriched for high mannose glycans to control glycan 
heterogeneity which aids in the ease of protein crystallization (Sanders et al., 2015, Blattner et 
al., 2014, Julien et al., 2013a). (Fig 1.4). The reagents kifunensine and swainsonine inhibit the 
formation of both hybrid and complex glycans in the case of kifunensine and only complex 
glycans in the case of swainsonine (Hioe et al., 2014). This is achieved  through the inhibition 
of mannosidase I in the endoplasmic reticulum or mannosidase II in Golgi apparatus, 
respectively (Hioe et al., 2014), resulting in predominantly high mannose glycans. These 
reagents can be used to manipulate the glycans that are created on Env to help elucidate glycan 
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Figure 1.4 Developmental pathway of HIV-1 Env N-linked glycans. Schematic of the production of 
HIV-1 Env glycans from the endoplasmic reticulum to the cis-, medial-, and trans-Golgi. The three 
types of glycans found on the HIV-1 Env are: high mannose (oligomannose), hybrid and complex 
glycans, with the latter two arising from the high mannose glycans. The high mannose glycans are 
produced in the endoplasmic reticulum and the Golgi apparatus, while the hybrid and complex glycans 
are solely produced in the Golgi apparatus. Reagents used to inhibit the formation of hybrid/complex 
glycans, kifunensine and swainsonine, are shown above the enzymes they inhibit. ER: endoplasmic 
reticulum Source: (Hioe et al., 2014) 
 
Although glycans have a role in protecting the virus from antibody responses, and therefore 
have been called the “glycan shield” (Wei et al., 2003), some bnAbs have developed the ability 
to recognise certain oligomannose HIV-1 glycans on Env or use the glycans to facilitate 
recognition (Lee et al., 2015b, Falkowska et al., 2014, Huang et al., 2014, Scharf et al., 2014, 
Doores and Burton, 2010). Therefore, the HIV-1 glycan shield is dynamic and is continuously 
changing in response to neutralising antibody pressure (Wei et al., 2003). 
 
1.5 HIV-1 Transmission 
 
The most common route of transmission of HIV-1 is through sexual contact, with the virus 
entering the body through the genital or rectal mucosa (Hladik and Hope, 2009). The other 
common routes of transmission include direct blood contact through blood transfusions or use 
of HIV-1 contaminated needles (commonly during intravenous drug use) and mother-to-child 
transfer of the virus (Hladik and Hope, 2009). 
 
 HIV-1 sexual transmission is a very inefficient process, with some estimates placing the risk 
at 0.01% per coital act (Gray et al., 2001). Although Gray et al., did not find a significant 
difference in HIV-1 transmission between individuals who had a sexually transmitted infection 
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(STI) and those who did not, other studies have found that pre-existing STIs, such as herpes 
simplex virus II infection, increase the risk of HIV-1 acquisition (Freeman et al., 2006, Galvin 
and Cohen, 2004). This is most likely due to these infections increasing the proportion of HIV-
1 target cells in the genital tract (Shaw and Hunter, 2012) and/or compromising the mucosal 
lining, thereby increasing the probability of viral entry (Sagar et al., 2004). 
 
Although HIV-1 diversity in an infected individual is very high, transmission usually results in 
a single virion establishing the new infection in the recipient in approximately 75-90% of 
heterosexual cases (Abrahams et al., 2009, Haaland et al., 2009, Keele et al., 2008), 36-83% of 
men who have sex with men (Tully et al., 2016, Li et al., 2010), 80% of in utero mother to 
child transmissions, 56% mother to child transmissions during delivery (Russell et al., 2011)  
and 40-80% in intravenous drug users (Tully et al., 2016, Bar et al., 2010, Masharsky et al., 
2010). This phenomenon is known as the transmission bottleneck (Kariuki et al., 2017, Joseph 
et al., 2015).  
 
The bottleneck is influenced by the mucosal lining as damage to the genital lining as a result 
of STIs and ulceration is thought to facilitate the entry of multiple variants (Haaland et al., 
2009). However, the fact that transmission through contaminated needles also results in a 
bottleneck effect implies that a physical barrier may not be the only factor facilitating this 
phenomenon (Kariuki et al., 2017). The transmitted variant is usually part of a minor population 
from the host viral community which suggests that transmission is not by chance but that there 
is a type of pressure selecting for a particular variant (Joseph et al., 2015), however the nature 
of this selective pressure is not yet fully understand (Kariuki et al., 2017). 
 
1.5.1 Cell-free versus cell-to-cell transmission 
 
The most studied transmission model of HIV-1 entry into cells is the cell-free route where free 
virions travel in the blood until they encounter a target cell to infect (Piguet and Sattentau, 
2004). Cell-free HIV-1 virions predominantly infect CD4+ T cells but can also infect monocyte-
derived dendritic cells (Dutartre et al., 2016) through the mechanism described in section 1.4.1. 
The risk of detection by the immune system when exposed in the blood is high for cell-free 
viruses (Piguet and Sattentau, 2004) so an alternative route of transmission could be beneficial 
to escape the immune response. 
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Cell-to-cell transmission is an alternate method of viral transmission where a virion passes 
directly from a host cell such as lymphocytes to a recipient cell such as another lymphocyte or 
macrophage (Malbec et al., 2013, Schiffner et al., 2013, Abela et al., 2012). The host and 
recipient cells form conjugates through the host intercellular adhesion molecule 1 (ICAM-1) 
binding to the recipient cell lymphocyte function-associated antigen-1 (LFA-1) (Schiffner et 
al., 2013) and the virion binding to the host cell CD4 (Malbec et al., 2013).  
 
Studies have differing views on whether virus transmitted by cell-to-cell transmission is as 
susceptible to antibody neutralisation as cell-free virus. Studies have shown that cell-to-cell 
transmitted virions were more protected from neutralisation by some but not all neutralising 
antibodies, suggesting that neutralisation sensitive viruses perhaps could survive and replicate 
in the presence of antibody responses (Li et al., 2017, Abela et al., 2012). However, if that was 
the case, HIV-1 isolates which favour cell-to-cell transmission over cell-free transmission 
likely would have been selected for and dominate in the population.  
 
Another study found that cell-to-cell transmitted viruses were susceptible to antibody 
neutralisation by some of the most broad and potent neutralising antibodies and therefore this 
method of transmission may not entirely escape the humoral response (Malbec et al., 2013). 
Cell-to-cell transmission-based antibody neutralisation assays are not as standardised as cell-
free virus neutralisation assays (Montefiori, 2005) which could explain the different 
conclusions drawn by various studies. Reaching a consensus on which in vitro model 
corresponds more to cell-to-cell transmission in vivo would be important for a better 
understanding of this phenomenon and its role in immune escape. 
 
1.6 Non-neutralising antibodies in HIV-1 infection 
 
Antibodies have diverse functions apart from neutralisation which include, but are not limited 
to, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular 
phagocytosis (ADCP), and complement activation (Forthal et al., 2013) (Fig 1.5).  
 
The fragment crystallisable (Fc) domain of an antibody is responsible for these effector 
functions (Janeway Jr et al., 2001). Activation-induced cytidine deaminase (AID) drives class 
switching of the Fc domain leading to different antibody isotypes which results in different 
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immune responses (Janeway Jr et al., 2001). HIV-1-specific IgG3 responses are present weeks 
after infection, however they rapidly decline and a predominantly IgG1 response takes over in 










Figure 1.5 Role of non-neutralising antibodies in the immune response against HIV-1 infection. 
Non-neutralising antibodies have been implicated in antibody-dependent cellular cytotoxicity through 
the recruitment of natural killer (NK) cells, antibody-dependent cellular phagocytosis with the help of 
phagocytes, as well as complement activation. Non-neutralising antibodies also interact with mucins on 
the mucosal membranes and prevent virus from infecting cells. Source: (Forthal et al., 2013). 
 
Individuals who are able to control their viremia have been found to have high levels of gp120-
specific IgG1 and maintain their initial IgG3 response (Banerjee et al., 2010), while higher 
IgG4 production has been associated with progression to AIDS (Ljunggren et al., 1988). These 
data suggest that poorly functional non-neutralising antibodies may be associated with HIV-1 
progression (Forthal et al., 2013). However, non-neutralising antibodies have also been shown 
to increase viral infectivity through complement-mediated antibody-dependent enhancement, 
which in one study resulted in over 350-fold enhancement of HIV-1 infection of SupT1/R5 T 
cells (Willey et al., 2011). 
 
Most HIV-1 vaccine research focuses on neutralising antibodies because some studies have 
shown that non-neutralising antibodies do not protect nonhuman primate models against 
simian/human immunodeficiency virus (SHIV) infection (Santra et al., 2015, Walker and 
Burton, 2010, Barnett et al., 2008, Mascola et al., 1999) and because neutralising antibodies do 
not require additional immune cells to function as compared to non-neutralising antibodies 
(Forthal et al., 2013) – immune cells which may be more difficult to elicit or control through 
vaccination. However, in the Thai RV144 vaccine trial, non-neutralising IgG antibodies 
targeting the variable 1 and 2 (V1/V2) regions of the HIV-1 envelope correlated with protection 
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from HIV-1 acquisition (Haynes et al., 2012). This has led to increased research on non-
neutralising antibodies to better understand their role in HIV-1 prevention (Haynes et al., 
2012). 
 
1.7 Broadly neutralising antibodies against HIV-1 
 
1.7.1 Immune response to HIV-1 natural infection – is there a role for antibodies? 
 
B cell responses are initiated days after HIV-1 infection and can be detected in the form of 
antibody-antigen complexes (Tomaras et al., 2008). This is followed by the appearance of 
gp41-specific non-neutralising antibodies (Fig 1.6) (McMichael et al., 2010) and anti-gp120 
antibodies targeting the V3 loop a few weeks later (Overbaugh and Morris, 2012). These 
responses, however, are unable to control viral replication (Tomaras et al., 2008). The 
emergence of autologous neutralising antibodies only occurs after approximately 3 months of 
infection, too late to control the initial viral infection (Fig 1.6) (Gray et al., 2011a, McMichael 











Figure 1.6 Immune response to HIV-1. (1) After transmission, the virus replicates rapidly followed 
by (2) dissemination from the site of infection. Viral replication is (3) controlled by cytotoxic CD8+ T 
cells which reduce the viral load to a set point. (4) Binding antibodies specific to gp41 slowly emerge 
during the CD8 T cell response and seroconversion occurs at approximately 3 months after infection. 
Neutralising antibodies only develop in chronic infection. Source: (Immunopaedia, 2016). 
 
Autologous neutralising antibodies are antibodies that neutralise the host’s own virus (Gray et 
al., 2007a, Richman et al., 2003, Wei et al., 2003). These antibodies are detectable months after 
acute HIV-1 infection but are reduced considerably during the AIDS phase of the condition, 
most likely due to the compromised state of the immune system as a whole (Deeks et al., 2006). 
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In natural infection, studies have shown that autologous neutralising antibodies promote viral 
escape from neutralising responses (Bunnik et al., 2008, Moore et al., 2008, Richman et al., 
2003, Wei et al., 2003).  
 
In the first year post-infection, autologous neutralising antibodies are frequently only able to 
bind to one or two variable regions on Env (Moore et al., 2009). The virus escapes autologous 
antibody neutralisation by several mechanisms including substitutions, insertions and deletions 
of single residues (Frost et al., 2005b) and through shifting glycans to block underlying 
epitopes (Moore et al., 2012). It is hypothesised that as escape mutants arise, autologous 
antibodies gain additional specificities towards new immunodominant epitopes and if these 
epitopes are within conserved regions, this may give rise to bnAbs (Moore et al., 2012, Moore 
et al., 2009). The specificities targeted by autologous neutralising antibodies include the V1/V2 
regions across subtypes (Moore et al., 2009) and the C3 region and the α2-helix in subtype C 
infection (Gray et al., 2011b, Rong et al., 2009). 
 
Although eliciting autologous neutralising antibodies is not the goal in vaccine development, 
an understanding of their structure, function and epitopes may be important in delineating how 
bnAbs develop because narrowly neutralising autologous antibodies are likely precursors to 
bnAbs (Doria-Rose et al., 2014, Liao et al., 2013). 
 
1.7.2 Role of broadly neutralising antibodies in natural infection 
 
BnAbs develop in chronic infection in approximately 25% of HIV-1-infected individuals (Gray 
et al., 2009b, Stamatatos et al., 2009, Binley et al., 2008), with approximately 1% developing 
highly potent cross-reactive response (Sather et al., 2012, Simek et al., 2009, Stamatatos et al., 
2009), although the precise proportion depends upon the definition and cut-off used. One study 
has shown that up to 50% of HIV-1-infected individuals develop broadly neutralising responses 
(Hraber et al., 2014b). BnAbs typically only arise in chronic infection (Moore et al., 2015). 
Monoclonal antibodies (mAbs) have been isolated which neutralise more than 95% of HIV-1 
isolates across subtypes (N6 and 10E8 mAbs) (Huang et al., 2016, Huang et al., 2012) and 
therefore elicitation of such antibodies with an HIV-1 immunogen may lead to effective 
protection from the virus. 
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There are opposing views on whether bnAbs are beneficial during natural infection in the 
control of the virus. Studies have shown that having broad anti-HIV-1 neutralising antibody 
responses is not associated with a better prognosis. In fact, neutralisation breadth at 3 years 
post-infection was found to be associated with lower CD4+ T cell counts although this 
association is almost certainly indirect (Gray et al., 2011a, Euler et al., 2010, Piantadosi et al., 
2009).  
 
The study performed by Piantadosi et al., also revealed that the time to start of ART at a CD4+ 
T cell count <200/µl and AIDS-related death were not influenced by the production of bnAbs 
in a cohort of women in Mombasa. Critically, this study found that the time to CD4+ T cell 
count of <200 cells/µl was not associated with bnAb development (Piantadosi et al., 2009).  
Euler et al., presented similar results in their cohort as they showed that time to AIDS or death 
was not significantly different between individuals with strong, moderate or no bnAb responses 
3 years post-seroconversion. This study found that CD4+ T cell counts prior to and after 
infection were significantly lower in people with bnAbs (Euler et al., 2010). The explanation 
of the poor prognosis associated with the development of bnAbs in natural infection may be 
that the production of bnAbs is likely driven by a high antigen burden (high viral load) which 
stimulates B cells but subsequently leads to the reduction of CD4+ T cells which leads to the 
development of AIDS in the absence of ART (Moore et al., 2015, Gray et al., 2011a, Doria-
Rose et al., 2009, Sather et al., 2009).  
 
Neutralising antibodies are unable to eliminate the virus in natural infection partly because the 
selective pressure exerted by these antibodies leads to neutralisation escape of the virus 
(Murphy et al., 2013). As soon as neutralising antibodies towards a viral variant develop, the 
virus mutates to evade the immune response (Liao et al., 2013, Moore et al., 2012, Richman et 
al., 2003, Wei et al., 2003). In most instances, the antibody pressure from bnAbs may be unable 
to efficiently select for less fit or less pathogenic isolates to delay disease progression (Bunnik 
et al., 2010b) leaving bnAbs unable to control viral replication in natural infection.  
 
One way to determine the role of neutralising antibodies in HIV-1 infection is to deplete them 
from the host. B cell depletions have been performed in primate models and one case of B cell 
depletions has been reported in a human subject. Researchers used rhesus macaque models and 
depleted B cells using an anti-CD20 antibody prior to simian immunodeficiency virus (SIV) 
challenge (Gaufin et al., 2009a, Gaufin et al., 2009b, Miller et al., 2007, Schmitz et al., 2003). 
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Two of the studies mentioned showed that the presence of antibody pressure reduced viral load 
(Miller et al., 2007, Schmitz et al., 2003) and one study reported protection from disease 
progression by antibodies (Miller et al., 2007). Another study found that antibodies had limited 
to no influence on disease progression (Gaufin et al., 2009a). However, it is unclear how to 
interpret the lack of effect of the antibodies when comparing the B cell-depleted and control-
depleted groups as neither of them made detectable responses to the challenge virus. 
Complicating the issue further, none of the studies were able to completely deplete B cells in 
the macaques, making interpretation more complex and the conclusions less clear.  
 
A human B cell depletion study provides evidence that bnAbs may play a protective role in 
HIV-1 infection (Huang et al., 2010). Anti-CD20 was used to deplete B cells from a chronically 
HIV-1 infected individual which resulted in an increase in viremia and the emergence of an 
antibody neutralisation sensitive virus (Huang et al., 2010). These data suggest a role for 
antibody in controlling HIV-1 and therefore the field is still divided on the protective role of 
neutralising antibodies in natural infection. 
 
1.7.3 Can individuals with low viral loads produce bnAbs? 
 
Another key research question is whether people on ART and non-progressors – individuals 
who maintain low viral loads and high CD4+ T cell counts without ART – are able to produce 
bnAbs. In one study, only a small percentage of individuals on ART (1.3%) with low or 
undetectable viral loads produced bnAbs (Medina-Ramirez et al., 2011). In this small set of 
individuals who produced bnAbs, ART therapy likely improved functionality of the humoral 
immune response which increased the probability of production of neutralising responses 
(Medina-Ramirez et al., 2011) although the general trend is for antibody production to decrease 
after ART initiation as the viral load decreases (Morris et al., 1998). 
 
Deeks and colleagues (2006) examined antibody responses against both autologous and 
heterologous viruses amongst 65 acute and chronically HIV-1-infected individuals. They found 
that in chronic infection, non-progressors possessed neutralising antibodies targeting 
contemporaneous autologous virus (Deeks et al., 2006). However, these antibody responses 
were detected at a very low level and therefore, it can be assumed they were not major 
contributors to HIV-1 control in those individuals. Studies have suggested that non-progressors 
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possess CD8+ T cells with superior functionality which suppress their viremia (Almeida et al., 
2007, Deeks and Walker, 2007, Betts et al., 2006). 
 
To better understand what determinants were involved in developing broad responses, Rusert 
and colleagues analysed over 4000 HIV-1-infected individuals. They concluded that there is 
an interplay between certain host and viral factors which are associated with the development 
of bnAbs (Rusert et al., 2016). They found that higher viral load, longer time of untreated HIV-
1 infection, higher viral diversity and being of a certain race were associated with bnAb 
production (Rusert et al., 2016). 
 
1.7.4 Can bnAbs protect from superinfection? 
 
Since bnAbs do not necessarily have a protective role once HIV-1 infection is established, this 
raises the question of whether bnAbs can protect against HIV-1 acquisition. One method to 
determine whether bnAbs would protect individuals after vaccination is through the study of 
HIV-1 superinfection. Superinfection occurs when an HIV-1-infected individual gets re-
infected with a different viral isolate (Redd et al., 2013).  
 
Studies have found that individuals who had superinfecting viruses had lower anti-HIV-1 
autologous and broad antibody responses as opposed to controls (Smith et al., 2006), with 
individuals with superinfections having higher IgA responses but lower IgG responses (Basu 
et al., 2012). Further evidence that neutralising antibodies aid in the prevention of 
superinfection is that most intra-subtype superinfections are observed in primary infection (Jost 
et al., 2002), presumably before a robust antibody response has formed. Superinfections also 
occur after treatment interruption (Altfeld et al., 2002) as the immune system becomes 
dysfunctional. 
 
Some studies however, such as the one conducted by Blish and colleagues, show that the 
presence of neutralising antibodies does not prevent superinfection (Blish et al., 2008). In this 
study, the authors found that women who became superinfected possessed antibodies at the 
time of superinfection of similar breadth and potency to controls, however, when tested in vitro, 
the antibodies were able to neutralise the superinfecting virus, but with low ID50 values <100 
(Blish et al., 2008). These data suggest that the antibody titres in superinfected individuals were 
not sufficient to suppress viral entry and a vaccine-induced antibody response would need to 
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be more robust (Blish et al., 2008). With the emergence of next generation sequencing (Chabria 
et al., 2014), superinfections which failed to establish in the host can, in principle, now be 
detected and therefore more knowledge on the titres required for antibodies to prevent 
superinfection can be investigated more robustly. 
 
1.7.5 Can bnAbs protect from infection/challenge in a vaccine setting?  
 
Non-human primate (NHP) models provide compelling data that bnAbs can prevent against 
HIV-1 infection (Overbaugh and Morris, 2012). BnAbs administered to NHPs have been 
shown to protect from SHIV challenge (Mascola, 2002). Early studies used 2F5 (MPER-
specific), 2G12 (N332 glycan-dependent) mAbs and HIV immune globulin. Despite the two 
mAbs antibodies displaying moderate breadth and potency alone, the combination protected 
the NHPs from SHIV infection both vaginally (Mascola et al., 2000) and intravenously 
(Mascola et al., 1999).  
 
The more recently isolated mAbs used alone such as PGT121 (Moldt et al., 2012) and PGT126 
(Moldt et al., 2016) or in combination such as VRC01, VRC01-LS, 3BNC117, and 10-1074 
(Gautam et al., 2016) have been found to prevent infection in NHP models. mAbs such as 
3BNC117 (Scheid et al., 2016, Caskey et al., 2015), 10-1074 (Caskey et al., 2017), VRC01 
(Bar et al., 2016) and N6 (Julg et al., 2017) have been shown to suppress viremia for a 
prolonged period of time in passive immunisation trials in HIV-1-infected individuals (Caskey 
et al., 2017, Bar et al., 2016, Scheid et al., 2016) and NHPs (Julg et al., 2017) but similar to 
previous studies (Mehandru et al., 2007, Trkola et al., 2005), viral escape mutants emerged 
during therapy. 
 
Interestingly, Fc-mediated effector functions have been implicated in bnAb protection 
following passive immunisation. In vivo studies have found that FcγR-mediated effector 
functions are a substantial contributor to the effectiveness of some bnAbs and help in blocking 
viral entry and suppressing viremia (Bournazos et al., 2014). For example, Fc-mediated effector 
functions were important in achieving the full in vivo protective effect of mAb b12 (Hessell et 
al., 2009, Hessell et al., 2007). 
 
HIV-1 viral escape from antibody pressure occurs early in acute infection and continues 
throughout infection with antibodies being major drivers of Env variation (Frost et al., 2005b). 
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Therefore, in principle, bnAbs can protect against HIV-1 infection but cannot protect once 
infection has already been established due to rapid and constant viral escape (Richman et al., 
2003). 
 
1.7.6 Broadly neutralising antibody epitopes as attractive vaccine targets 
 
As of 2010 there has been a rapid increase in the number of isolated and characterised mAbs 
(Fig 1.7) due to the emergence of highly sophisticated isolation techniques including the use 
of recombinant gp120 and trimeric proteins to capture specific B cells (McCoy and Burton, 
2017, van Gils et al., 2016, Mouquet, 2014, Burton et al., 2012, Wu et al., 2010). Identification 
and characterisation of bnAb epitopes has been performed by techniques such as alanine scan 
mutations (Jacob et al., 2015, Moore et al., 2011, Walker et al., 2011), HIV-1/HIV-2 chimeric 
viruses (Gray et al., 2009a, Binley et al., 2008) and co-crystallisation with HIV-1 proteins 
(Derking et al., 2015). Understanding the structure of bnAb epitopes and how these antibodies 
bind their targets may aid in the rational-based design of an effective, global HIV-1 vaccine 
(Derking et al., 2015). 
 
 
1.7.6.1 V2/apex – the highly conformation-dependent epitope 
 
The V2/apex is a quaternary, conformation-dependent bnAb epitope located on the V1/V2 loop 
and is usually stabilised by the glycan at position N160 (Fig 1.7) (Singh et al., 2011, Wu et al., 
2011, Doores and Burton, 2010). The V1/V2 loop is a hypervariable region due to multiple 
polymorphisms, insertions and deletions, however, within this variable region lies a highly 
conserved surface which is targeted by bnAbs and makes up the V2/apex epitope (Moore et 
al., 2017). 
 
The first identified bnAbs which target the V2/apex were PG9, which binds asymmetrically to 
the HIV-1 trimer at a 1:1 ratio (Julien et al., 2013b), and PG16 which binds to the target in a 
less conformation-dependent manner than PG9 but also at a 1:1 ratio (Pancera et al., 2013, 
McLellan et al., 2011). Separately, these two related antibodies neutralise 70-80% of HIV-1 
isolates (Walker et al., 2009) but used together can achieve up to 90% breadth (McLellan et 
al., 2011). Currently, the only published bnAbs targeting this site that are not dependent on the 
presence of the N160 glycan and exhibit decreased potency if the glycan is present are some 
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of the members of the CAP256-VRC26.25 lineage (Doria-Rose et al., 2015). Eliciting such 
antibodies in a vaccine in conjunction with N160-dependent V2/apex antibodies would be 
advantageous in protecting from isolates with and without the glycan at this position. Another 
interesting characteristic of the CAP256 lineage is that these antibodies are able to develop 
breadth and potency very early in infection (Doria-Rose et al., 2014) which is rare for bnAbs. 
Understanding the pathway taken by such antibodies to achieve breadth may provide insight 
into designing an immunogen which can elicit bnAbs soon after vaccination. 
 
In southern African individuals who do produce bnAbs, 1/3 of broadly neutralising sera target 
the V2/apex (Moore et al., 2017). Therefore, with the right stimulation, B cells may be able to 











Figure 1.7 bnAb targets on HIV-1 Env. The HIV-1 Env timer glycoprotein contains six identified 
bnAb epitopes. The V2/apex bound by antibodies such as PG9 and PG16, the V3/glycans bound by 
antibodies such as 10-1074 and PGT121, the CD4-binding site bound by antibodies such as VRC01 and 
b12, the membrane proximal external region bound by antibodies such as 10E8 and 4E10, the gp120-
gp41 interface bound by antibodies such as PGT151 and 8ANC195 and the newly-identified fusion 
peptide (not depicted) bound by antibodies such as ACS202 and VRC34. Adapted from: (Mouquet, 
2014). 
 
1.7.6.2 V3/glycans – “supersite of vulnerability” 
 
As mentioned, the glycans on Env can be recognised by bnAbs (Ward and Wilson, 2017) 
despite their role in shielding the virus from immune responses (Wei et al., 2003). The V3 loop 
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is a target of narrowly neutralising antibodies as evidenced by viruses with exposed V3 loops 
being exceptionally sensitive to antibody neutralisation, such as HIV-1 isolate SF162 
(McCaffrey et al., 2004, Gorny et al., 2002). However, some of the most potent bnAbs isolated 
to date bind to the glycans at the base of the V3 loop, which form the “high mannose patch”, 
centred around the glycans at positions N301 and N332 (Fig 1.7) (Sok et al., 2014, Mouquet et 
al., 2012, Walker et al., 2011, Sanders et al., 2002). This site has been referred to as a “supersite 
of vulnerability” (Kong et al., 2013) due to the numerous bnAbs that have been isolated that 
target this site. 
 
A crucial protein motif required for neutralisation by most N332-dependent V3/glycan-specific 
bnAbs is the 324GDIR327 motif (Sok et al., 2016, Garces et al., 2015, Garces et al., 2014). N332-
dependent antibodies including PGT126, 128, 130 and 131 also bind to the glycan at position 
N301 (Walker et al., 2011) which is adjacent to the N332 glycan at the base of the V3 loop 
(Garces et al., 2014). Intriguingly, V3/glycan-specific antibodies have been shown to have 
“promiscuous” binding as in the absence of a specific target glycan, some of these antibodies 
can bind to a substitute glycan. For example, in the absence of the glycan at N332, PGT128 
can bind to the glycan at position N295 (Sok et al., 2014). This promiscuous binding may need 
to be considered when designing an immunogen based on the V3/glycans as multiple glycans, 
including ones in the V1/V2 loop, may need to be incorporated into an immunogen with the 
relevant glycans held in the correct orientation and position by scaffolding (Sok et al., 2014).  
 
Antibodies towards V3/glycan epitope have demonstrated remarkable efficacy in NHP and 
human trials. 10-1074 transiently controlled viremia in HIV-1 infected individuals who were 
not on ART (Caskey et al., 2017) and PGT121 protected NHPs from viral acquisition at high 
doses of SHIV (Moldt et al., 2012).  
 
1.7.6.3 CD4-binding site – the “common” bnAb target 
 
The CD4-bs (Fig 1.7) is an attractive vaccine target because it is essential in viral fusion and 
entry into the host cell (Didigu and Doms, 2012) and therefore is presumably heavily 
constrained by function. Up to 15% of bnAbs that develop during natural infection target the 
CD4-bs (Walker et al., 2010). The fact that antibodies targeting the CD4-bs are so commonly 
elicited suggests that making these antibodies may be relatively easy upon vaccination (Walker 
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et al., 2010). One of the most potent and well-characterised antibodies that targets this site is 
VRC01 (Wu et al., 2010). This antibody binds to the CD4-bs partially by CD4 receptor 
mimicry (Zhou et al., 2010); however, like other bnAbs, it requires extensive somatic 
hypermutation which may make it difficult to elicit in a vaccine (Wu et al., 2015). Features 
such as mutations at key residues including those at positions 279, 363, 368 and 371 enable 
viruses to escape neutralisation by VRC01-like antibodies (Huang et al., 2016, Li et al., 2011). 
The most broadly neutralising antibody which targets the CD4-bs that has been identified to 
date is N6, which binds using a unique mode of recognition and overcomes the barriers which 
cause VRC01-resistance (Huang et al., 2016). Although N6 did not display autoreactivity, it 
also had undergone extensive somatic hypermutation (Huang et al., 2016). Again, this may 
limit ease of eliciting similar antibodies in a vaccine setting. 
 
1.7.6.4 Membrane proximal external region – the linear epitope 
 
The membrane proximal external region (MPER) is a bnAb epitope located solely in gp41 (Fig 
1.7) (Zwick, 2005). It is an attractive vaccine target for several reasons including the fact that 
it is a conserved, linear epitope (Zwick, 2005). MPER plays a crucial role in fusion and entry 
of the virus into the host cell (Zwick, 2005). For this reason, targeting the MPER may prevent 
viral infection and its variability is heavily constrained by function (Montero et al., 2008). 
Therefore, it seems likely that the MPER would be an easier model to work with in immunogen 
design. The first-generation MPER-specific mAbs, 2F5 and 4E10, have moderate breadth 
and/or potency (Morris et al., 2011, Nelson et al., 2007, Stiegler et al., 2001, Purtscher et al., 
1994) but the isolation of 10E8 mAb revealed that antibodies with greater than 90% breadth 
do target this epitope (Huang et al., 2012).  
 
Access to MPER is restricted in the Env closed conformation (Chakrabarti et al., 2011, 
Dimitrov et al., 2007) and therefore immunisation with closed recombinant Env proteins may 
not efficiently elicit MPER antibodies. One strategy to improve anti-MPER antibody elicitation 
may be through de-glycosylation of Env, which has been shown to increase binding of 
unmutated ancestor antibodies from 2F5 and 4E10 (Ma et al., 2011) or by immunogen 
modelling of MPER scaffolds (Zhou et al., 2014).  
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1.7.6.5 gp120-gp41 interface – the inter-protomer epitope 
 
The use of recombinant HIV-1 proteins to capture specific B cells by flow cytometry in selected 
donors facilitated the discovery of the gp120-gp41 interface epitope, another glycan dependent 
epitope which spans both gp120 and gp41 subunits (Fig 1.7) (Falkowska et al., 2014, Huang 
et al., 2014, Scharf et al., 2014). This site may be difficult to develop into an immunogen as 
the antibodies which have been isolated towards these sites all target distinct glycans. 
8ANC195 is dependent on glycans at positions N234 and N276 (Scharf et al., 2015, Scharf et 
al., 2014) while glycans at N611 and N637 are required for PGT151 binding (Falkowska et al., 
2014). 35O22 targets N88 (Huang et al., 2014) and CAP248-2B targets a distinct but 
overlapping epitope (Wibmer et al., 2017). However, all glycans targeted by these antibodies 
lie at the interface of the gp120-gp41 subunits and this is the underlying factor which groups 
them together (Mouquet, 2014). Strikingly, mutations that mediate viral escape from the 
CAP248-2B mAb led to increased MPER exposure of HIV-1 isolates (Wibmer et al., 2017). 
Exploiting the exposure of the MPER epitope by certain mutations could potentially be useful 
in the development of a vaccine to elicit anti-MPER antibodies 
 
1.7.6.6 Fusion peptide – the novel epitope 
 
Until 2016, MPER was considered the only linear bnAb target in gp41 but now the FP has been 
implicated in bnAb recognition and neutralisation (Kong et al., 2016, van Gils et al., 2016). 
The FP is a glycine-rich, hydrophobic region at the Env N-terminus which is 15-20 amino acids 
long (Chan and Kim, 1998). Its conserved role in viral fusion and entry makes it an attractive 
vaccine target (Didigu and Doms, 2012).  
 
Although the exposure of the FP in the closed spike is not well characterised, two FP-specific 
bnAbs have been isolated to date which bind to the closed trimer spike, ACS202 (van Gils et 
al., 2016) and VRC34 (Kong et al., 2016). Env recognition by both bnAbs is dependent upon 
the amino acids forming the FP and upon the glycan at position N88. Some antibodies targeting 
the gp120-gp41 interface also depend upon the glycan at N88 (Huang et al., 2014), however 
they do not require FP residues for neutralisation. More information on the FP epitope such as 
the frequency of bnAbs targeting this site and their characteristics are needed to determine 
whether an immunogen based on this peptide would elicit desirable responses. 
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1.7.7 Characteristics of broadly neutralising antibodies 
 
BnAbs have several unusual characteristics that raise the question of whether they can be 
elicited easily and quickly after vaccination. One of these characteristics is extensive somatic 
hypermutation of up to 30% in the complementarity-determining regions and frame-work 
variable regions, which promotes specificity to their targets (Borrow and Moody, 2017, 
Georgiev et al., 2014, Klein et al., 2013). Somatic hypermutation is part of the affinity 
maturation process which selects for antibodies with high binding affinity (Allen et al., 2007). 
The fact that this process is so extensive in bnAbs may explain why they often take years to 
develop (Sok et al., 2017). For example, VRC01 is mutated about 30% from its inferred 
germline sequence and the lineage took approximately 15 years to gain breadth (Wu et al., 
2015). Even bnAbs targeting the V2/apex that generally have lower levels of somatic 
hypermutation are 14-19% mutated (e.g. PG9 and PGT-145) (Sok et al., 2013).  
 
A second characteristic of some bnAbs which is believed to limit the ability of individuals to 
produce bnAbs is autoreactivity (Borrow and Moody, 2017, Moore et al., 2017, Liu et al., 2015, 
Verkoczy and Diaz, 2014). Anti-MPER antibodies were the first antibodies to be identified as 
auto-reactive when 4E10 and 2F5 were found to bind to cardiolipin (Haynes et al., 2005). The 
authors hypothesised that HIV-1 may display epitopes such as MPER which mimic 
autoantibody epitopes to escape neutralisation because auto-reactive antibodies are often 
deleted from the B cell repertoire (Haynes et al., 2005).  
 
Some V3/glycan-specific bnAbs including PGT125 and PGT128 are polyreactive, meaning 
that they can bind to various self-proteins with low affinity (Liu et al., 2015). Chuang et al., 
presented data suggesting that one way to prevent polyreactivity is through the addition of 
glycans on Env at positions proximal to sites that mimic self-epitopes (Chuang et al., 2015). 
Immunogens designed with these protective glycans may elicit bnAbs which are less likely to 
be self-reactive.  
 
Despite antibodies such as 2F5, 4E10 and 3BNC117 being reported to be auto- and poly-
reactive (Liu et al., 2015, Mascola and Haynes, 2013, Haynes et al., 2005), these antibodies 
have been used in clinical trials with no immediate adverse effects (Scheid et al., 2016, 
Mehandru et al., 2007, Trkola et al., 2005, Stiegler and Katinger, 2003). Therefore, self-
reactivity seems unlikely to be a problem in terms of vaccine safety. 
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BnAbs are also reported to have unusually long complementarity-determining regions in the 
heavy chain 3  (CDRH3s) (Borrow and Moody, 2017). Long CDRH3s are common in bnAbs, 
especially those which target glycosylated regions as these recognition loops aid in entry of the 
antibody paratope through the dense glycan mesh to the residues below (Moore et al., 2017). 
V2/apex-specific antibodies possess long, anionic CDRH3 regions and this is due to aspartate 
and glutamate residues as well as tyrosine sulphation (Moore et al., 2017). 
 
It was thought that possessing long CDRH3s was a rare phenomenon and therefore may be 
hard to reproduce in a vaccine-setting, however, studies suggest that although long loops are 
naturally found in low frequency, they are a normal feature of the antibody repertoire and 
should not be seen as a restriction to an antibody-based vaccine (Yu and Guan, 2014). 
Additionally, research has shown that long CDRH3s are commonly found in chronic infection 
in a variety of other viral infections (Breden et al., 2011). This study suggests that long 
CHRH3s may just be a consequence of chronic viral infection and that other processes are 
likely contributing to shaping the antibody repertoire during viral persistence and escape which 
leads to development of bnAbs (Breden et al., 2011). 
 
Importantly, a recent study has revealed that V2/apex-specific, moderately broad antibodies 
which contain recognition loops of an average antibody length can develop (Cale et al., 2017). 
This type of antibody may be a more attainable vaccine response for the general population as 
they may develop relatively easily (Cale et al., 2017, Jacob et al., 2015) 
 
Potent bnAbs which lack some of these unusual features have been identified. BnAbs such as 
those in the PGT121 lineage (Sok et al., 2013) and mAb BF520.1 (Simonich et al., 2016) 
developed breadth with relatively modest somatic hypermutation. Interestingly, BF520.1 was 
isolated from an infant at ~1 year of age, a much shorter time than usual for the development 
of bnAbs (Simonich et al., 2016). BF520.1 and the PGT121 lineage target the V3/glycans 
(Simonich et al., 2016) which suggests that antibodies with low somatic hypermutation can be 
elicited towards glycosylated epitopes.  
 
Georgiev and colleagues (2014) found that versions of VRC01 and 10E8 with limited somatic 
hypermutation in their frame-work variable regions still possessed breadth and potency. These 
data reveal that only limited mutations may be needed to achieve breadth. A more detailed 
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understanding of this phenomenon may aid in design of an immunogen capable of eliciting 
bnAbs in a shorter period time than in natural infection (Georgiev et al., 2014). 
 
1.7.8 HIV-1 antibody evasion strategies 
 
HIV-1 has evolved multiple mechanisms to evade the immune response including the shifting 
of glycans (Wei et al., 2003), sequence polymorphism (Mascola and Montefiori, 2010) and 
conformational masking (Kwong et al., 2002). Viruses evade the immune response through the 
addition of Env glycans to form a “glycan shield” (Moore et al., 2012, Pantophlet and Burton, 
2006, Wei et al., 2003, Wyatt et al., 1998). The removal of key glycans such as the glycan at 
position N301 has been shown to expose both underlying and distal epitopes such as the CD4-
bs (Binley et al., 2010, Li et al., 2008, McCaffrey et al., 2004, Koch et al., 2003) highlighting 
the importance of glycans in protection from antibody neutralisation. Knowledge that viruses 
possess potential “holes” in the glycan shield which lead to neutralisation sensitivity has shed 
further light into the role of glycans in the evasion of antibody responses (McCoy et al., 2016). 
 
The ability of the virus to mutate its Env sequence and remain functional is another important 
antibody evasion strategy (Mascola and Montefiori, 2010, Wei et al., 2003). A third mechanism 
used by HIV-1 to evade neutralisation is conformational masking where highly conserved 
bnAb targets such as the CD4-bs and MPER are hidden from antibody neutralisation in the pre-
fusion Env conformation (Peachman et al., 2010, Kwong et al., 2002). Conformational masking 
is most common in highly neutralisation resistant viruses which preferentially remain in a 
relatively closed conformation shielding commonly-elicited neutralising antibody epitopes and 
infrequently fluctuating to an open conformation (Cai et al., 2017, Munro et al., 2014). 
  
Most Env proteins on the surface of the virus are non-functional and do not aid in fusion and 
entry into the cells (Moore et al., 2006, Poignard et al., 2003). Some Env trimers are non-
functional gp120/gp41 monomers or gp41 stumps lacking gp120 (Moore et al., 2006). This 
also serves as a viral escape mechanism from antibody-mediated neutralisation as antibodies 
bind to these non-functional spikes and stumps but cannot neutralise the virus through them 
(Moore et al., 2006, Poignard et al., 2003). 
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Longer V1/V2 and V4 lengths have been associated with HIV-1 resistance to antibody 
neutralisation (Rademeyer et al., 2016, van Gils et al., 2011, Bunnik et al., 2010a). Recently 
transmitted viruses gain neutralisation resistance by the development of longer V1 loops which 
contain more glycans (Bunnik et al., 2010a) and longer V1/V2 loops have been found to protect 
the CD4-bs from neutralisation (van Gils et al., 2011). There is also a relationship between 
V1/V2 net charge and neutralisation resistance, with lower net charge being associated with 
neutralisation resistance (Hraber et al., 2014a).  
It has been found that certain bnAb classes demonstrate subtype-bias. For example, CRF01_AE 
viruses are resistant to a large proportion of antibodies targeting the V3/glycans (Walker et al., 
2011). Subtype A and C viruses have been shown to be more sensitive than subtype B viruses 
to V2/apex-specific antibodies such as CAP256 (Moore et al., 2011).  
1.8 Rational-design of an HIV-1 vaccine: is it really feasible? 
Most HIV-1 vaccine studies focus on the rational-design method, which is the development of 
an immunogen based on a prediction of the type of antibodies that it will elicit (Burton, 2010, 
Ofek et al., 2010). However, previously-identified vaccines, such as the yellow fever vaccine, 
which is extremely successful and protects for 35 years to life (WHO, 2013), were identified 
using the empirical method, which relies on the isolation and attenuation of a pathogen, 
followed by injection into the recipient (Rueckert and Guzman, 2012). 
In whole killed virus vaccines, the virus is grown in culture and chemically deactivated (Chiodi 
and Weiss, 2014). In this way, the structure of the virus is preserved to elicit a robust immune 
response upon immunisation (Chiodi and Weiss, 2014). Vaccines such as the Salk polio 
vaccine work on this principle (Chiodi and Weiss, 2014). A Phase I human clinical trial in 
HIV-1-infected individuals has shown that this type of immunogen may be safe and can 
enhance pre-existing anti-HIV-1 immune responses (Choi et al., 2016), however safety 
concerns have resulted in most research steering away from this method for a preventative 
vaccine. HIV-1 vaccine research now primarily focuses on delivering HIV-1 proteins instead 
of the whole virus (Rueckert and Guzman, 2012). 
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Recombinant gp120 vaccines have failed to elicit robust antibody responses (Esparza, 2013). 
The RV144 trial has been the only trial to show modest efficacy (31.2%) and was made up of 
a canarypox prime with a recombinant gp120 boost (Buchbinder et al., 2008). 31.2% efficacy 
is too low to license this vaccine and therefore more immunogens, building up on this moderate 
success, must be designed to produce sufficient vaccine efficacy (Esparza, 2013). One of the 
focuses of HIV-1 immunogen research has been the use of the HIV-1 trimer as an immunogen 
instead of the gp120 monomer alone (Sanders and Moore, 2017). 
 
1.8.1 Env trimers as immunogens 
 
One of the principles behind using a closed HIV-1 Env trimer as an immunogen is that the 
glycosylated HIV-1 trimer in its closed conformation displays all the known bnAb epitopes 
except the MPER whilst shielding multiple epitopes targeted by narrowly neutralising 
antibodies (Guttman et al., 2015, Sattentau et al., 1995, Sattentau and Moore, 1995) and 
therefore using it as immunogen could bias the immune response towards bnAbs (Sanders and 
Moore, 2017). However, one of the challenges of HIV-1 trimer immunogen design is that the 
transmembrane domain of Env is highly hydrophobic (Freed and Martin, 1995) which 
decreases solubility (Sanders and Moore, 2017). To overcome this, researchers have modified 
the Env in several ways, with varying success (Sanders and Moore, 2017). 
 
The most widely used method of modifying the trimer is through the generation of recombinant 
Env trimers known as SOSIP.664 trimers (Fig 1.8). The “SOS” refers to the addition of a 
disulphide bond between gp120 and gp41 to further stabilise these subunits (Sanders et al., 
2013). The “IP” refers to an isoleucine to proline residue change at position 559 that strengthens 
intra-gp41 bonds (Sanders et al., 2013). SOSIP trimers contain gp120 and only the ectodomain 
of gp41 to eliminate hydrophobicity caused by the MPER and the transmembrane domain 
(Sanders et al., 2013), making them soluble trimers. SOSIP trimers also include the addition of 
a RRRRRR (R6) motif in place of the usual furin REKR cleavage motif to optimise the 
cleavage process (Fig 1.8) (Sanders et al., 2013). 
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Figure 1.8 Schematic of the original fully glycosylated BG505 SOSIP.664 gp140 trimer design and 
subsequent modified BG505 SOSIP trimers. The original BG505 SOSIP.664 gp140 trimer contains 
a single disulphide bond between the gp120 C5 and gp41 regions, an I559P mutation, a modified R6 
furin cleavage site and is truncated before the transmembrane domain at position 664.  The SOSIP.v4 
trimer contains 4 additional stabilising mutations in the C1, V3 and HR1 regions. The DS-SOSIP 
contains an additional disulphide bond between gp120 C2 and C4 regions. The SOSIP.664 E49C-
L555C trimer contains an additional disulphide bond between gp120 C1 and gp41 HR1 regions. The 
SC trimer is similar to the native flexibly linked trimer (Sharma et al., 2015). It contains an additional 
flexible GGGGS (G4S) linker between gp120 and gp41 to eliminate the need for furin-dependent 
cleavage. 
 
The first virus to be successfully engineered into a SOSIP trimer was subtype A, T/F virus 
BG505 (Fig 1.8) (Wu et al., 2006). BG505 SOSIP trimers are highly stable, soluble, fully 
cleaved and predominantly in a closed conformation (Sanders et al., 2013). The trimer can be 
bound by all bnAbs it has been tested with which neutralise the corresponding pseudovirus 
including conformation-dependent bnAbs such as V2/apex-specific (Julien et al., 2013b, 
Sanders et al., 2013) and gp120-gp41 interface antibodies (Scharf et al., 2015, Falkowska et 
al., 2014, Huang et al., 2014). This reveals that the trimer is a good mimic of the BG505 virus 
and has optimal antigenicity (Sanders et al., 2013).  
 
The BG505 SOSIP trimer seemed to be the perfect immunogen to elicit bnAbs and it is still 
the gold-standard in terms of SOSIP trimers to date (Julien et al., 2015). The BG505 trimer 
elicited potent, autologous Tier 2 responses in immunogenicity studies using macaques, guinea 
pigs and rabbits but failed to produce broad responses (Pauthner et al., 2017, Cheng et al., 2015, 
Sanders et al., 2015). This was despite further modifications to increase trimer stability through 
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further mutations (Fig 1.8) (Chuang et al., 2017), reduction of non-neutralising epitope 
exposure (de Taeye et al., 2015) as well as trimer delivery through different methods such as 
nanoparticle presentation (Sliepen et al., 2015) and liposome display (Pauthner et al., 2017). 
The autologous antibodies elicited by the BG505 trimer were mainly directed at epitopes 
located under certain “glycan holes” on the trimer (McCoy et al., 2016). 
 
Recently, the BG505 SOSIP trimer has been used in a cow immunisation study, where the 
trimer induced broad and potent responses in all four cows, with one cow developing bnAbs 
capable of neutralising 96% of isolates in a virus panel at 381 days post-immunisation (Sok et 
al., 2017). However, bovine antibody repertoires frequently contain long CDRH3s (Sok et al., 
2017) and therefore eliciting bnAbs may be substantially easier in these animals as opposed to 
humans.  
 
SOSIP trimers of other subtypes have been engineered including subtype B (Stewart-Jones et 
al., 2016, Verkerke et al., 2016, Pugach et al., 2015), subtype G (Stewart-Jones et al., 2016) 
and the most dominant subtype C (Julien et al., 2015) as well as other subtype A SOSIP trimers 
(Verkerke et al., 2016). However, similarly to BG505, the trimers tested for immunogenicity 
have failed to induce broad responses (de Taeye et al., 2015, Sanders et al., 2015).  
 
SOSIP trimers do not contain the MPER epitope because the sequence does not include 
residues after position 664 to increase the solubility of the trimer (Sanders et al., 2013). This 
comes with the cost of not being able to elicit MPER antibodies or study the position of MPER 
in structures derived from SOSIP trimers. Notably, one of the most broadly and potently 
neutralising bnAbs, 10E8, binds to this epitope (Huang et al., 2012). The additional stabilising 
mutations and the exclusion of the MPER, transmembrane and cytoplasmic domains may alter 
the structure of these trimers which may limit their reliability in Env structural studies. 
 
To overcome many of these limitations, researchers developed a method to obtain membrane-
extracted Env trimers lacking only the cytoplasmic tail (EnvΔCT) (Blattner et al., 2014). These 
Env trimers do not have stabilisation mutations added (Blattner et al., 2014).  One example is 
the Env trimer based on the subtype B virus, JR-FL, whose crystal structure has been solved in 
complex with 10E8, providing further insight into the binding of this bnAb to its epitope (Lee 
et al., 2016). These trimers may, therefore be more biologically related to the HIV-1 Env, 
although the exclusion of the cytoplasmic tail could modify the structure (Blattner et al., 2014). 
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Immunisation of rabbits with JR-FL EnvΔCT did not produce bnAb responses (Crooks et al., 
2015), indicating that these improvements were not sufficient to generate broad responses. 
 
Only one published recombinant Env trimer, the PVO.4 SOSIP trimer, has been engineered 
based on a neutralisation-resistant virus and there is no published data on its immunogenicity 
(Verkerke et al., 2016). However, Townsley et al., used a rabbit model to test a poxvirus prime-
gp120 boost immunisation strategy which used the PVO.4 gp120. Cross-clade neutralising 
antibodies were elicited although their response was modestly potent and broad (Townsley et 
al., 2016). Although not Tier 3, Klasse and colleagues (2016) immunised rabbits with subtype 
A, B and C SOSIP trimers, either in combination or sequentially, but in all circumstances the 
trimers produced cross-neutralising antibodies inconsistently and with very little breadth 
(Klasse et al., 2016). These studies leave open the possibility that the use of one or a 
combination of Tier 3 neutralisation resistant Env trimers could lead to a vaccine which elicits 
potent and highly cross-reactive antibodies. 
 
1.8.2 Epitope scaffolds as immunogens 
 
Recombinant Env trimers pose the problem of displaying both non-neutralising and broadly 
neutralising epitopes. For example, the V3 loop of BG505 SOSIP.664 trimer is exposed more 
than that of the native virus (Ringe et al., 2017, de Taeye et al., 2015). One method to overcome 
this is the epitope-focused rational design of HIV-1 protein scaffolds (Morris et al., 2017). 
HIV-1 protein or epitope scaffolds consist of residues forming bnAb epitopes which are grafted 
onto heterologous protein structures based on computational design (Zhou et al., 2014, Ofek et 
al., 2010). A recent proof of principle study in respiratory syncytial virus showed that 
computationally designed protein scaffold immunogen based on a neutralisation epitope on this 
virus induced potent neutralising antibody responses in macaques (Correia et al., 2014) and 
therefore this method could possibly work in the context of HIV-1. 
 
In early epitope-focused immunogen design, researchers designed scaffold-based immunogens 
based on partial MPER epitopes because the linear nature of the epitope made it easier to design 
as a scaffold (Ofek et al., 2010). The b12 epitope in the CD4 binding loop and the outer domain 
was also designed as a scaffold immunogen (Azoitei et al., 2011). A more recent study by Zhou 
et al., created epitope scaffolds which included the V1/V2 loop (based on the PG9 epitope), 
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the V3/glycan supersite (based on the PGT128 epitope) and the MPER (based on the 10E8 
epitope) (Zhou et al., 2014), however, no in vivo validation was conducted and therefore no 
progress has been made with these particular immunogens (Morris et al., 2017).  
 
Morris et al., constructed scaffolds containing the V3/glycan supersite and the MPER and 
tested their immunogenicity in mouse models using a variety of delivery systems (Morris et 
al., 2017). MPER scaffolds activated B cells and elicited an antibody lineage with long 
CDHR3s; a characteristic associated with bnAbs (Morris et al., 2017). Interestingly, a 
scaffolded gp140.681 trimer, which contained most of the MPER, elicited antibody responses 
targeting the trimer apex but the parent gp140.664 trimer could not elicit such responses which 
suggests scaffolding may result in a superior immunogen (Morris et al., 2017). These data 
suggest that using a combination of the principles of recombinant trimers and scaffolds may 
result in the design of a stabilised immunogen capable of eliciting broad antibody responses 
upon immunisation (Morris et al., 2017). Scaffolds and trimers may also be used at different 
stages of an HIV-1 immunisation regime to promote the elicitation of bnAbs (Morris et al., 
2017) because the correct combination may drive the needed antibody evolution (Doria-Rose 




1.9 Study Objectives 
 
As studies have shown that HIV-1 has progressively become more resistant to neutralising 
responses over the HIV-1 pandemic (Bouvin-Pley et al., 2014, Bouvin-Pley et al., 2013, Bunnik 
et al., 2010a) an understanding of these highly neutralisation resistant viruses may be needed 
to develop a global HIV-1 vaccine capable of protecting against most, if not all, HIV-1 strains.  
 
There were three main objectives of this thesis. The first objective was to identify and study 
the neutralisation characteristics of the Tier 3, CRF02_AG virus, 253-11 (Kulkarni et al., 
2009). The second aim of this thesis was to delineate the mechanism of neutralisation resistance 
of 253-11 and better understand the structural implications of its neutralisation resistance 
phenotype using X-ray crystallography. The last aim was to better understand commonly-
elicited antibodies to HIV-1 that might resemble those elicited by a vaccine and explore their 
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interplay with viral escape. This was achieved by first determining the contribution of 
antibodies targeting the V3/glycans to breadth and potency in a cohort of HIV-1-infected 
individuals and secondly, determining the effects on neutralisation resistance of the removal of 
the conserved V3/glycan at position N301. 
 
Objective 1: Identifying the neutralisation resistance characteristics of virus 253-11 
 
253-11 is a Tier 3, CRF02_AG virus which is poorly recognised by subtype-matched (Jacob et 
al., 2012) and subtype C sera (Jacob et al., 2015). This objective aimed to determine the 
mechanism of the resistance of this virus through investigating the presence of bnAb epitopes 
in the sequence, unusual PNGs and certain Env polymorphisms. Mutational analysis was also 
conducted on 253-11 and a subtype-matched, neutralisation sensitive virus, 928-28, to test key 
hypotheses to explain the resistance phenotype of 253-11. The effects of kinetic MPER 
mutations, L669S and Y681H, on 253-11 and 928-28 were also explored.  
 
Objective 2: Understanding the structural basis behind the resistance phenotype of virus 
253-11 
 
To gain insight into the structure of the 253-11 Env trimer, a 253-11 SOSIP.664 trimer was 
engineered and used to determine the structural and antigenic properties of the Env trimer. The 
253-11 SOSIP trimer was co-crystallised with the antigen-binding fragment (Fab) of the 
V3/glycan-specific antibody, 10-1074. The structure of 253-11 was compared with other 
solved trimer structures to delineate characteristics of the 253-11 structure that were unusual 
compared to other trimer structures, particularly the compactness of the closed Env trimer. 
 
Objective 3: Understanding the contribution of the V3/glycans to the breadth and potency 
of HIV-1 neutralising antibody responses and their potential interplay with antibody 
escape 
 
There is evidence that antibodies with moderately high neutralisation breadth are frequently 
attainable as compared to highly potent and broad antibodies which are found in only a small 
subset of HIV-1 infected individuals (Hraber et al., 2014b). These moderately neutralising 
antibodies may be a more realistic target for a vaccine. Therefore, this objective first examined 
whether the V3/glycans were preferentially targeted by moderately broadly neutralising sera 
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from HIV-1 infected individuals. As the V3/glycans were found to be associated with breadth 
and potency, the second part of this objective investigated how the V3/glycans contribute to 
shielding the virus from antibody responses while also being bnAb targets themselves. 
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Chapter 2: Deciphering the Molecular Basis of Unusually High 




Understanding the mechanisms used by HIV-1 to evade antibody neutralisation may contribute 
to the design of a high-coverage vaccine. We studied 253-11, a highly neutralisation resistant 
(Tier 3) virus, to understand the molecular basis of its neutralisation profile. The 253-11 virus 
is poorly recognized by subtype-matched and subtype C sera, even when compared to other 
Tier 3 viruses. Although sequence polymorphisms in the V3 loop and N-linked glycosylation 
sites may contribute, they do not substantially explain the neutralisation resistance of 253-11. 
We also found that the 253-11 membrane proximal external region (MPER) is rarely 
recognized by sera in the context of the wild-type virus, but is commonly recognized in the 
context of an HIV-2/HIV-1 chimeric virus. Mutating the 253-11 MPER into a subtype-
matched, MPER-sensitive virus, 928-28, revealed that the resistance of 253-11 to anti-MPER 
antibodies was primarily controlled by sequences outside MPER. Mutations in the 253-11 
MPER – which were previously reported to increase the lifetime of the post-CD4 Envelope 
(Env) conformation – increased the sensitivity of 253-11 to antibodies targeting various 
epitopes on HIV-1 Env. Interestingly, PG9, a broadly neutralising antibody recognizing a 
quaternary epitope on the trimer spike, instead showed decreased neutralising ability towards 
the 253-11 MPER mutants. The same MPER mutations in virus 928-28 did not result in a 
decrease in PG9 neutralisation activity. This, along with the fact that PG9 targets the pre-fusion 
trimer spike, suggests that these MPER mutants specifically destabilise an otherwise unusually 
compact, closed 253-11 trimer structure, in addition to or in place of any other effects that the 
MPER mutants have upon the lifetime of the post-CD4-bound Env conformation. Together, 
these findings suggest that the 253-11 Env sequence confers an unusually compact trimer 
structure that contributes to its unusually high neutralisation resistance. 
  
 




The HIV-1 Envelope (Env) is the sole target of HIV-1-specific neutralising antibodies and 
therefore an attractive vaccine target (Wyatt et al., 1998). It has been proposed that HIV-1 has 
progressively become more resistant to neutralising antibodies over the course of the HIV-1 
pandemic (Bouvin-Pley et al., 2014, Bouvin-Pley et al., 2013, Bunnik et al., 2010a). An 
understanding of these highly neutralisation resistant viruses may be needed to develop a global 
HIV-1 vaccine capable of protecting against most HIV-1 strains.  
 
Extensive screening of sera from HIV-1-infected individuals has resulted in the identification 
of relatively rarely-elicited broadly neutralising antibodies (bnAbs) that primarily target six 
epitopes on the HIV-1 Env (Ward and Wilson, 2017, Wibmer et al., 2015): in gp120, the 
V2/apex region (Doores and Burton, 2010, Walker et al., 2009), the V3/glycan supersite (Kong 
et al., 2013, Walker et al., 2011, Sanders et al., 2002, Kunert et al., 1998) and the CD4 binding 
site (CD4-bs) (Wu et al., 2010, Burton et al., 1994); in gp41, the membrane proximal external 
regions (MPER) (Huang et al., 2012, Nelson et al., 2007, Zwick et al., 2001) and recently the 
fusion peptide (FP) (Kong et al., 2016, van Gils et al., 2016); and the gp120-gp41 interface 
(Falkowska et al., 2014, Huang et al., 2014, Scharf et al., 2014).  
 
Neutralisation resistant viruses have evolved numerous mechanisms to evade antibody 
responses. One of the ways HIV-1 evades the immune response is through the formation of a 
“glycan shield”, protecting underlying Env epitopes (Moyo et al., 2017, Moore et al., 2012, 
Pantophlet and Burton, 2006, Wei et al., 2003, Wyatt et al., 1998). The ability of the virus to 
substantially mutate its sequence and remain functional is also a critical component of the viral 
antibody evasion strategy (Mascola and Montefiori, 2010, Wei et al., 2003). Additionally, HIV-
1 expresses non-functional Env spikes (Moore et al., 2006) that may serve as decoys to divert 
the antibody response, and contribute to yet another immune evasion mechanism. 
 
HIV-1 also evades neutralisation through conformational masking (Kwong et al., 2002). 
Conformational masking refers to the phenomenon in which the pre-fusion HIV-1 Env, which 
exists largely as closed trimer spikes, occludes key neutralising antibody targets (Kwong et al., 
2002). As examples, the positioning of the V1/V2 loops aids in the occlusion of the V3 loop 
(Bartesaghi et al., 2013, Kwong et al., 1998, Stamatatos and Cheng-Mayer, 1998); neighboring 
protomers in the trimer spike restrict the angle of approach to the CD4-bs (Stamatatos and 
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Cheng-Mayer, 1998) and the MPER is often partially sunk into the membrane (Montero et al., 
2012, Sun et al., 2008). In this closed state, narrowly neutralising antibodies are generally 
unable to bind and neutralise the virus (Guttman et al., 2015).  
 
It is becoming increasingly clear that the HIV-1 Env spike is dynamic and shifts between closed 
and open conformations in the pre-fusion state (Guttman et al., 2015, Munro et al., 2014). 
During the transition of the Env trimer to the open state, the trimer re-arranges, facilitating a 
shift of the V1/V2 loops to the perimeter of the structure (Bartesaghi et al., 2013, Merk and 
Subramaniam, 2013, Shen et al., 2010). In this transient state in which Env is relatively open, 
narrowly neutralising antibodies generally bind more efficiently to Env because the V3 loop, 
CD4-bs and MPER are better exposed (Guttman et al., 2015, Ward and Wilson, 2015). It is 
thus possible that a virus could be relatively neutralisation resistant if this equilibrium was 
shifted in favor of the more closed state(s). Supporting this idea, only the broadest and most 
potent neutralising antibodies effectively bind to the virus in the closed spike conformation 
(Guttman et al., 2015, Kwong et al., 2002).  
 
Here, we describe the molecular basis of antibody resistance of a highly neutralisation-
resistant, Tier 3 virus, 253-11 (Kulkarni et al., 2009). In order to probe the resistance kinetics 
of 253-11 Env, we utilized changes in specific amino acid residues in Env that have been found 
to alter the lifetime of the CD4-bound open conformation. MPER exposure during viral entry 
can be prolonged by mutations in the MPER such as L669S (Shen et al., 2010) and Y681H 
(Ringe and Bhattacharya, 2012). These mutations have been shown to increase the sensitivity 
of viruses to antibodies targeting the V3 loop, CD4-bs and MPER. Their identified mechanism 
of increasing sensitivity is through delaying fusion of the virus and target cell, which increases 
the lifetime of the post-CD4-bound open conformation(s) (Ringe and Bhattacharya, 2012, Shen 
et al., 2010). However, other explanations cannot easily be ruled out.  
 
Together with other experiments, we provide molecular evidence supporting a model in which 
the unusually high neutralisation resistance of 253-11 is substantially mediated by its unusually 
compact, pre-fusion Env structure. Knowledge of the mechanisms used by HIV-1 to escape 
antibody neutralisation has implications in immunogen design and in improving efficacy of 
candidate HIV-1 vaccines that induce neutralising antibodies.  
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2.2 Materials and Methods 
 
2.2.1 Serum samples and monoclonal antibodies 
 
Study participants were recruited from (i) caregivers of patients at the paediatric HIV clinic at 
Groote Schuur Hospital (n=92) and (ii) attendees of the HIV wellness clinic at the Khayelitsha 
Site B clinic (n=125). Both clinics are located in Cape Town, South Africa. In all, 217 blood 
samples were collected between December 2009 and July 2011 from donors who were >18 
years old, chronically HIV-1 infected (>1 year) and were not exposed to antiretroviral therapy 
(ART), except for ART given for prevention of mother-to-child transmission (>3 months prior 
to sample collection). The median CD4 count of the donors was 425 (interquartile range (IQR) 
305, 545). Viral loads were measured on 50 of the 217 samples; median viral load was 27,000 
(IQR 8150, 100,000). Written informed consent was received from study participants. This 
study was approved by the Human Research Ethics Committee, Faculty of Health Sciences of 
the University of Cape Town. Monoclonal antibodies (mAbs) 2F5, PG9, PG16, Z13e1 were 
obtained from Polymun Scientific, Austria and the National Institute of Health, AIDS Reagent 
Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, USA. mAbs 
PGT128, PGT130, PGT151 and F105 were kind gifts from Dr. P. Moore, National Institute for 
Communicable Diseases, South Africa. All other mAbs were obtained through the National 
Institute of Health, AIDS Reagent Program. 
 
2.2.2 Pseudovirus constructs and cell lines  
 
The pSG3Δenv HIV-1 backbone, TZM-bl cells and 293T cells were obtained from the National 
Institute of Health, AIDS Reagent Program. Cloned HIV-1 envelope constructs including 253-
11 (Kulkarni et al., 2009) were obtained through the National Institute of Health, AIDS Reagent 
Program. The 7312A parent HIV-2 construct and the HIV-2 C1 and C1C chimeric constructs 
(Gray et al., 2007a) were kindly provided by Dr. George Shaw, University of Pennsylvania, 
USA. The HIV-2/253MPER chimeric construct was produced by mutagenesis from the HIV-
2 chimeric construct C1 using the Stratagene QuikChange II XL Site-Directed Mutagenesis 
Kit 121 (Stratagene). L669S (Shen et al., 2009) and Y681H (Ringe and Bhattacharya, 2012) 
mutants of 253-11 and 928-28, as well as 253-11_928MPER and 928-28_253MPER swap 
mutants were generated using the GeneArt® Site-Directed Mutagenesis PLUS Kit 
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(Invitrogen). All mutations and the absence of unrelated PCR errors were confirmed by 
sequencing both strands of the entire env open reading frame.  
 
2.2.3 Generation of pseudoviruses and neutralisation assays 
 
Pseudoviruses were prepared and tested as previously described (Montefiori, 2009). Briefly, 
env DNA was co-transfected with pSG3∆env (Wei et al., 2002) into human embryonic kidney 
293T cells. Pseudovirus-containing supernatant was harvested 48h post-transfection and stored 
in single-use aliquots at -80˚C. Neutralisation was tested using a standard TZM-bl pseudovirus-
based neutralisation assay. Antibody and virus were incubated for one hour at 37˚C. TZM-bl 
cells (104 per well) were added to the antibody-virus combination and incubated at 37˚C for 48 
h. Titers (dilution of serum [ID50] or concentration of mAb [IC50] that inhibits 50% of infection) 
were calculated using curve fit functions in Prism (GraphPad). On log scale axes, undetectable 
neutralisation was plotted with the arbitrary values ID50=25, ID50=10 or IC50=80 µg/ml. For 
clarity, scales on graphs of IC50 values were inverted so that larger bars correspond to greater 
neutralisation activity. 
 
2.2.4 Depletion of MPER-specific antibodies 
 
Sera were tested for their capacity to neutralise HIV-1 isolates or chimeric HIV-2 viruses by 
recognition of the MPER. Antibodies were depleted in two rounds of depletion as previously 
described (Jacob et al., 2015, Tomaras et al., 2011, Gray et al., 2009a) using a biotinylated 
MPER peptide (MPR.03 (Morris et al., 2011): 
KKKNEQELLELDKWASLWNWFDITNWLWYIRKKK-biotin-NH2 (Peptide Synthetics). 
Completeness of depletion was tested by measuring the reduction of neutralising activity 
towards HIV-2/HIV-1 MPER chimeric viruses. Neutralisation sensitive HIV-1 virus SF162 
was used as a negative control because we expect antibodies other than anti-MPER 
antibodies to dominate neutralisation of this virus (Pinter et al., 2004). Control depletions 
were performed as above using a biotinylated control peptide with a scrambled sequence: 
KKKNEKSNNDWERLWLEWLYIWLQDWAFTLIKKK-biotin-NH2. A threshold of a ≥3-








2.3.1 Sequence polymorphisms in the V3 loop and N-linked glycosylation only partially 
explain the neutralisation resistance of 253-11  
 
253-11 is a Tier 3 (Seaman et al., 2010) CRF02_AG virus which is highly resistant to 
neutralisation by both subtype-matched blood plasma (Jacob et al., 2012) and subtype C sera 
(Jacob et al., 2015). The sensitivity of 253-11 to different bnAbs was measured in pseudovirus-
based neutralisation assays. The virus was resistant to neutralisation by a range of bnAbs across 
several of the currently identified bnAb targets (Fig 2.1a), even though the 253-11 amino acid 
sequence possesses most of the key residues that make up the different bnAb epitopes (Fig 
2.1b).  
 
The virus is strikingly resistant to most antibodies tested which target the V3/glycans despite 
possessing key glycans at positions 301 and 332 (Sok et al., 2014, Walker et al., 2011) needed 
for recognition of this class of antibodies (Fig 2.1b). Notably, 253-11 lacks the 324GDIR327 
motif required for the binding of some N332-dependent antibodies (Garces et al., 2015, Garces 
et al., 2014, Walker et al., 2011) (Fig 2.1b), instead possessing a 324GNIR327 sequence at that 
position. This could hinder binding of these antibodies, although PGT124 has been shown to 
bind in the presence of an asparagine at position 325 (Garces et al., 2014). The presence of an 
alanine at position 325 does not affect PGT121/128-like neutralisation either (Krumm et al., 
2016, Sok et al., 2016, Walker et al., 2011). To analyse the effect of this polymorphism, we 
created an N325D mutant of 253-11 that restores the 324GDIR327 motif, and tested its sensitivity 
to PGT121, PGT126, PGT128 and PGT130, to which the 253-11 wild-type (WT) is resistant. 
We found that the introduction of the 324GDIR327 motif modestly increased the sensitivity of 
253-11 to only one of the antibodies tested (PGT121) (Fig 2.1c), indicating that sequence 
polymorphism is not the main contributor to the resistance of the virus to our panel of 
V3/glycan-specific bnAbs tested (Fig 2.1a). 
 
Because loop length has been associated with neutralisation resistance (Hraber et al., 2014a), 
we analysed the length of the 253-11 V1/V2 loops to determine whether it was unusually long. 
253-11 has V1/V2 loops which are 65 residues long (Fig 2.1b). Loop lengths of Tier 3, Tier 2 
and Tier 1 viruses are, on average, 72, 68 and 65 residues long, respectively (LANL, 2017). 
Therefore, 253-11 does not have an unusually long V1/V2 loop but in fact resembles an average 
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Tier 1 virus in this regard, which suggests that loop length is not a key factor in the 
neutralisation resistance phenotype of the virus. 
Figure 2.1 253-11 neutralisation resistance is only partially due to sequence polymorphisms and 
N-linked glycosylation. (a) Depicts IC50 values (µg/ml) obtained from pseudovirus-based 
neutralisation assays of 253-11 against mAbs with different specificities. (b) Amino acid sequence of 
253-11, cytoplasmic domain not included (Accession number: ACC97453.1). N-linked glycosylation 
sites are depicted in blue boxes with key glycans involved in bnAb binding numbered; FP: N88, 
V2/apex: N156 and N160; CD4-binding site: N276, V3/glycans: N301 and N332, gp120-gp41 
interface: N88, N611 and N637. Residues forming bnAb epitopes are annotated. Loop D (which forms 
part of the CD4-binding epitope): residues 273-283 (Li et al., 2011); CD4-binding loop: residues 364-
373 (Li et al., 2011); MPER: residues 660-683 (Zwick, 2005); FP: residues 512-525 (van Gils et al., 
2016); V1 loop: residues 131-155 (Zolla-Pazner and Cardozo, 2010); V2 loop: residues 158-196 (Zolla-
Pazner and Cardozo, 2010). All numbering shown is according to the HXB2 sequence. (c) A 253-11 
N325D mutant was engineered to recreate the V3 loop 324GDIR327 motif. The sensitivity to V3/glycan-
specific antibodies of the WT and N325D mutant was tested in pseudovirus-based neutralisation assays 
and the IC50 values (µg/ml) are shown. (d) Two potential N-linked glycosylation sites, N293 and N363, 
present in 253-11 Env but not neutralisation sensitive viruses, 928-28 and Cot6.15, were removed by 
site-directed mutagenesis. Mutants were tested for sensitivity to serum samples from ART-naïve, HIV-
infected individuals which neutralised 253-11 WT poorly or not at all. For calculations, all resistant 
serum/virus pairs in which the virus was resistant was considered to have an arbitrary ID50 value of 25. 
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To determine whether glycans play a role in the neutralisation resistance of 253-11 by 
occluding key epitopes on the virus, we identified and mutated key potential N-linked 
glycosylation sites (PNGs) which are found in 253-11 but not in a subtype-matched 
neutralisation sensitive virus, 928-28, or in a well-characterized, neutralisation sensitive 
subtype C virus, COT6.15 (Gray et al., 2009a). We mutated PNGs at positions N293 and N363 
and tested the sensitivity of these mutants to sera which poorly neutralised (ID50<100) or did 
not neutralise the 253-11 WT virus. The removal of either of the two PNGs modestly increased 
the neutralisation sensitivity of 253-11 to a small proportion of tested sera (Fig 2.1d), probably 
by exposing underlying epitopes on Env (McCoy et al., 2016). Since the neutralisation 
resistance of 253-11 appears to be largely maintained in these glycosylation mutants, we 
propose that the neutralisation resistance phenotype of 253-11 is only minimally due to 
shielding by these glycans. We therefore, next hypothesized that other modes of escape could 
be critical for the resistance phenotype of the virus, such as conformational masking of 
epitopes.  
 
2.3.2 253-11 resistance to MPER-specific neutralising antibodies is primarily controlled 
by sequences outside MPER 
 
Pseudovirus-based neutralisation assays revealed that 253-11 was sensitive to the most broadly 
neutralising monoclonal antibodies (mAbs) targeting the MPER (Fig 2.1a). We further 
explored whether 253-11 was also sensitive to neutralisation by moderately neutralising anti-
MPER antibodies commonly elicited in natural infection. The antibodies in these serum 
samples may be more representative of the responses that would be predominantly generated 
by an HIV-1 vaccine as compared to bnAbs which occur rarely in natural infection (Borrow 
and Moody, 2017, Simek et al., 2009). We screened 217 unselected serum samples from a 
South African cohort of chronically HIV-1-infected, ART-naïve participants and found that 
253-11 WT was resistant to or poorly neutralised by 90% of the sera (Fig 2.2a).  
To investigate the neutralisation susceptibility of the 253-11 MPER, we constructed a chimeric 
virus containing an HIV-2 backbone with the 253-11 MPER sequence (HIV-2/253MPER) 
(Fig. 2.2a). Interestingly, 19 sera (8.8%) recognized the 253-11 MPER in the HIV-2/253MPER 
chimeric construct, but poorly neutralised the 253-11 WT virus (ID50<100, upper left quadrant, 
Fig 2.2a). A threshold of ID50>1000 was chosen as an identifier of anti-MPER antibodies in 
sera (Jacob et al., 2015, Gray et al., 2009a, Li et al., 2009, Binley et al., 2008, Gray et al., 
2007a). Six of these 19 sera were tested and shown to neutralise other Tier 2/3 HIV-1 viruses 
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by specifically targeting the MPER (Jacob et al., 2015). This strongly suggests that the MPER 
antibodies in these sera are not defective in recognising the MPER in HIV-1 pseudoviruses and 
further emphasises that 253-11 is unusually resistant to anti-MPER antibodies in unselected 
sera compared to other HIV-1 isolates. 
 
 
Figure 2.2 Sensitivity of 253-11 to MPER-directed antibodies. (a) 217 serum samples were tested 
for sensitivity to 253-11 and an HIV-2 virus containing the 253-11 MPER sequence. The HIV-2 
backbone is derived from the 7312A construct. A threshold titer of 1:1000 was used to define significant 
anti-MPER neutralisation (Jacob et al., 2015, Gray et al., 2009a). A threshold titer of 1:100 was used to 
define substantial anti-253-11 neutralisation. Resistant sera were displayed on the graph with an 
arbitrary value of ID50=10. The top panel is a schematic representing how the HIV-2/253MPER was 
constructed; adapted from (Dimitrov et al., 2007). (b) MPER sequences between subtype-matched 
viruses 253-11 and 928-28 were swapped between the viruses by site-directed mutagenesis. 10/19 sera 
from the upper left quadrant of Fig 2.2a were tested for neutralisation sensitivity to 253-11 and 928-28 
MPER-swap mutants. Neutralisation was compared to the wild-type viruses of each. In this panel, 
undetectable neutralisation was displayed with the arbitrary value of ID50=25 (Note: Data in Fig 2.2a 
from (Jacob, 2014)). 
 
To determine whether the resistance of 253-11 WT to anti-MPER antibodies in sera was 
induced by polymorphisms in the MPER itself, we exchanged MPER amino acid sequences 
between 253-11 and 928-28, a subtype-matched virus that is substantially less neutralisation 
resistant (Jacob et al., 2015, Seaman et al., 2010). We tested these MPER swaps for sensitivity 
to 10/19 sera from the upper left quadrant (Fig 2.2a), and observed that the pattern of 
neutralisation generally followed the Env “backbone” and not the MPER sequence (Fig 2.2b) 
suggesting that sequence differences outside of the MPER itself were the cause of 253-11 
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MPER neutralisation resistance. The specificity of 5 of these 10 sera to the 928-28 MPER were 
previously confirmed in anti-MPER-depletion experiments (Jacob et al., 2015).  
 
Two sera were tested in anti-MPER-depletions with the 928_28 chimera containing the 253 
MPER sequence (928-28_253MPER). These two sera were found to contain MPER antibodies 
and neutralised the viruses primarily via recognition of MPER as shown by a lack of 
neutralising ability (ID50<50) after depletion of MPER antibodies from the samples (Fig 2.3). 
Combined, our data thus strongly suggest that 253-11 likely evades neutralisation by common 
MPER-specific antibodies through factors outside the MPER such as conformational masking 














Figure 2.3 Sera neutralise 928-28_253MPER mutant through recognition of its MPER. Two 
samples which did not neutralise 253-11 WT but exhibited high 253MPER neutralising activity (Fig 
2.2a) were used for MPER antibody depletion experiments using the MPR.03 peptide as compared to a 
control scrambled sequence peptide to determine whether MPER specific antibodies were the major 
contributors towards neutralisation of 928-28_253MPER mutants. SF162 was a negative control and 
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2.3.3 MPER mutations alter the exposure of epitopes on the 253-11 trimer to sera 
 
We studied the effect of MPER mutations, L669S (Shen et al., 2010) and Y681H (Ringe and 
Bhattacharya, 2012), on 253-11 neutralisation resistance. These mutations have been described 
as increasing the lifetime of the HIV-1 Env conformation after CD4 has bound (Ringe and 
Bhattacharya, 2012, Shen et al., 2010). We tested the 253-11 MPER mutants for sensitivity to 
12/19 sera which neutralise the 253-11 MPER in the chimeric virus but not in the WT. In all 
cases, the L669S and Y681H mutations increased the sensitivity of 253-11 to these sera, with 
















Figure 2.4 253-11 L669S and Y681H mutants generally have increased sensitivity compared to 
253-11 WT. Neutralisation of the 253-11 WT and L669S/Y681H mutants was assessed by 12/19 of the 
serum samples which recognize the 253-11 MPER in the HIV-2/HIV-1MPER chimera but not in the 
253-11 WT virus. For calculations, all resistant serum/virus pairs in which the virus was resistant was 
considered to have an ID50 value of 25. 
 
 
To test if the L669S and Y681H mutations were not only directly affecting recognition of the 
253-11 MPER but had a more global effect on the structure of 253-11, we depleted MPER 
antibodies from 2/19 sera that have dominant anti-MPER neutralising antibodies. When the 
253-11 L669S and Y681H mutants were tested for sensitivity to MPER-depleted samples, we 
observed substantial residual neutralisation (Fig 2.5), suggesting that antibodies targeting 
epitopes other than the MPER were also responsible for the increase in neutralisation sensitivity 
for the L669S and Y681H mutants. Depletion of MPER-specific antibodies was confirmed by 
testing capacity to neutralise three HIV-2/HIV-1 MPER chimeric viruses, with reductions of 
41-416-fold observed; therefore, it was unlikely that the results were due to incomplete 
 
Chapter 2: Molecular characterisation of virus 253-11 Page 47 
 
depletion. These data indicate that recognition of HIV-1 Env epitopes other than the MPER are 






















Figure 2.5 Neutralisation revealed by L669S and Y681H mutations is only partially due to anti-
MPER antibodies. Two serum samples which neutralised 253-11 poorly (ID50<100) but had exhibited 
high 253MPER neutralising activity (Fig 2a) were used for MPER antibody depletion using the MPR.03 
peptide as compared to a control scrambled sequence peptide to determine whether MPER specific 
antibodies were the major contributors towards the increase in neutralisation observed with the L669S 
and Y681H mutant viruses. SF162 was a negative control and the HIV-2/HIV-1 chimeras using MPER 
sequences from 253-11, C1C and C1 HIV-2/HIV-1 were the positive controls. 
 
We then investigated whether neutralising antibodies in sera which preferentially neutralise the 
L669S and Y681H mutants over the WT also target the V2/apex and V3/glycan regions. We 
introduced N160A and N301A.N332A mutations to the L669S and/or Y681H mutants to map 
antibodies responsible for increased neutralising activity to the V2/apex or V3/glycans, 
respectively (Jacob et al., 2015, Moore et al., 2011, Tomaras et al., 2011). We found that, in 
some sera, V2/apex and V3/glycan-specific antibodies were responsible for the increases in 
neutralisation activity (Fig 2.6). These data suggest that the MPER mutations affect distal 












Figure 2.6 V2/apex and V3/glycan epitopes are affected by 253-11 L669S and Y681H mutations. 
Serum samples whose increased neutralising activity towards the L669S and Y681H mutants was 
mapped to the V2/apex (L669S.N160A and Y681H.N160A mutants) or V3/glycans 
(Y681H.N301A.N332A mutant only; L669S.N301A.N332A did not produce infective virus). Three 
sera (displayed) out of seven tested exhibited dominant V2/apex-directed (N160-dependent) 
neutralisation that was revealed by L669S and/or Y681H. Two sera (displayed) of five tested exhibited 
dominant V3/glycan-dependent neutralisation that was revealed by Y681H. For calculations, all 
resistant serum/virus pairs in which the virus was resistant was considered to have an ID50 value of 25. 
 
2.3.4 MPER mutations increase 253-11 sensitivity to some broadly neutralising 
monoclonal antibodies, but decrease sensitivity to mAb PG9 
 
We further explored how bnAb epitopes across Env are affected by the 253-11 MPER mutants 
by testing the 253-11 L669S and Y681H mutants for sensitivity to mAbs that target five of the 
major sites of vulnerability on the HIV-1 Env (Fig 2.7).  
Figure 2.7 Impact of 253-11 L669S and Y681H mutants on bnAb recognition. Neutralisation of the 
253-11 WT and L669S/Y681H mutants by mAbs targeting most of the broadly neutralising antibody 
epitopes. On the log scale axes, undetectable neutralisation was plotted with the arbitrary values IC50=80 
µg/ml. For clarity, scales of IC50 values were inverted so that higher bars always correspond to greater 
neutralisation activity.  
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Importantly, and in contrast to their effect upon V2-targeted antibodies in sera which neutralise 
the L669S and Y681H mutants better than the WT (Fig 2.4), the MPER mutants decreased 
sensitivity of 253-11 to mAb PG9 (Fig 2.7). PG9 binds to a conformation-dependent epitope 
in the V2/apex that preferentially exists in the pre-CD4-bound Env spike (Walker et al., 2009). 
We hypothesize that the decrease in neutralisation may be due to a destabilization of the PG9 
quaternary epitope at the apex of the pre-fusion trimer. This effect was only seen in 253-11; no 
change in sensitivity to PG9 was observed when the same mutations were introduced into 928-
28 (Fig 2.8a).  
 
Figure 2.8 Effect of L669S and Y681H mutants on sensitivity of 928-28 to bnAbs. (a) 928-28 and 
its corresponding L669s and Y681H mutants were tested for sensitivity to a subset of mAbs. For clarity, 
scales of IC50 values were inverted so that larger bars always correspond to greater neutralisation 
activity. (b) Comparison of IC50 (µg/ml) between 253-11 WT, 928-28 WT and their L669S and Y681H 
mutants. 
 
L669S and Y681H increased 253-11 sensitivity to V2-specific (N160-dependent) antibodies in 
some sera (Fig 2.6), yet decreased sensitivity to the V2/apex-specific antibody PG9 (Fig 2.7) 
in a manner apparently specific for 253-11 (Fig 2.8b). We propose that the V2/apex-specific 




Chapter 2: Molecular characterisation of virus 253-11 Page 50 
 
Unsurprisingly, compared to 253-11 WT, the MPER mutants were more sensitive to anti-
MPER mAbs 4E10, 2F5, Z13e1 and 10E8 (Fig 2.7). Strikingly, the MPER mutants were also 
more sensitive to neutralisation by V3/glycan mAbs 10-1074 and PGT128 but both WT and 
mutants were resistant to PGT121, PGT126 and PGT130 (Fig 2.7). Several bnAbs that target 
other epitopes were also not affected by these mutants, including PGT151 targeting the gp120-
gp41 interface and VRC01, NIH45-46 and 3BNC117 targeting the CD4-bs (Fig 2.7).  
 
As expected, 928-28 and its MPER mutants displayed similar changes in antibody sensitivity 
as 253-11 and its mutants when tested with anti-MPER antibodies 2F5 and 10E8 (Fig 2.8b). 
sCD4 also neutralised the 928-28 mutants better than WT, while the neutralisation of 10-1074 
was not substantially affected by the mutations as it was for 253-11 (Fig 2.8b). Our data 
indicate that L669S and Y681H mutations drastically affect the neutralisation sensitivity of 
253-11 to V2/apex (PG9) and V3/glycan (10-1074) bnAbs compared to subtype-matched virus, 
928-28. We propose that the mutants are likely disrupting the pre-fusion conformation of 253-
11 substantially more than that of the more neutralisation sensitive virus, 928-28. We therefore, 









A global HIV-1 vaccine will likely need to protect against neutralisation resistant viruses to 
effectively reduce HIV-1 incidence. In this report, we studied 253-11, a highly neutralisation 
resistant, Tier 3 (Seaman et al., 2010), CRF02_AG virus whose env gene was obtained from 
Cameroon (Kulkarni et al., 2009). We noted that 253-11 was resistant to bnAbs and sera 
targeting different epitopes on the HIV-1 Envelope (Env). The virus was resistant to 
V3/glycan-specific broadly neutralising antibodies (bnAbs) despite the presence of potential 
N-linked glycosylation sites (PNGs) at positions 301 and 332 which are the primary targets of 
these antibodies (Walker et al., 2011). We considered that this resistance may be explained by 
a polymorphism in the 324GDIR327 motif. However, restoration of this motif by mutagenesis 
did not restore neutralisation sensitivity to the bnAbs. We also tested the role of glycans in the 
neutralisation resistance of 253-11 and found that the deletion of key glycans only marginally 
affected neutralisation. Thus, sequence polymorphisms and N-linked glycans glycosylation of 
Env do not substantially explain the neutralisation resistance of 253-11. The high neutralisation 
resistance of this virus may be more clearly explained by its highly compact trimer spike. 
 
The introduction of L669S (Shen et al., 2010) and Y681H (Ringe and Bhattacharya, 2012) 
mutations in the MPER of viruses have previously been shown to shift viral entry kinetics by 
delaying fusion and thus increase the neutralisation sensitivity of viruses. These mutations 
increased the sensitivity of the 253-11 virus to serum antibodies targeting the V2/apex (N160-
dependent antibodies) and the V3/glycans, soluble CD4 (sCD4) and monoclonal antibodies 
(mAbs), including 2F5, 10E8, 4E10, Z13e1, 10-1074, PGT128 and VRC03. These results 
suggest a change in exposure of a range of epitopes across Env due to these mutations. 
 
Strikingly, the mutations decreased neutralisation sensitivity to PG9, a conformation-
dependent antibody targeting the V2/apex in the Env trimer spike. The mutations did not alter 
the sensitivity of subtype-matched virus 928-28 to the same antibody. Additional Tier 2 and 
Tier 3 viruses should be tested in this manner to determine to what extent compactness is an 
effect that is specific to 253-11. This is the first report to show that the L669S and Y681H 
mutations can affect neutralisation of HIV-1 isolates by antibodies that target the closed, pre-
fusion conformation such as those which bind the V2/apex, mAb PG9 (Julien et al., 2013b) 
and V3/glycans, mAbs 10-1074 (Mouquet et al., 2012) and PGT128 (Lee et al., 2015a). Trimer 
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structures solved in complex with V3/glycan and V2/apex bnAbs are locked in a closed 
conformation (Lee et al., 2017, Gristick et al., 2016, Garces et al., 2015, Lee et al., 2015a, 
Julien et al., 2013a), strongly suggesting that their epitopes are properly displayed in the trimer 
spike.  
 
Nonetheless, many of the bnAbs tested showed no change in neutralising activity between the 
WT and MPER mutants. This may be because many of the most broadly neutralising antibodies 
are broad and potent because they have evolved to bind to both the closed and open 
conformations of Env (Guttman et al., 2015). Together, these data led us to hypothesize that 
the 253-11 trimer is in a stable, unusually compact conformation in its native, pre-fusion form 
and that the L669S and Y681H mutants destabilize and open this structure, leading to a more 
neutralisation sensitive phenotype. We cannot rule out contributions to neutralisation 
sensitivity from other mechanisms, including the delay of fusion (Shen et al., 2010); however, 
the change in sensitivity to PG9 clearly suggests a mechanism associated with the Env spike 
before CD4 binding. One caveat of our conclusions concerning the increased PG9 sensitivity 
of the 253-11 mutants is that we only studied the 253-11 virus.  This makes it difficult to 
generalise the findings to other neutralisation-resistant viruses. We postulate that some but not 
all highly neutralisation-resistant viruses will likely exhibit similar characteristics. Future 
studies should include a larger panel of Tier 3 viruses to determine whether this is a global 
effect. 
 
More generally, it seems plausible that the equilibrium of compact Env spikes, such as those 
of 253-11, strongly favors a closed conformation that is less likely to enter transient open 
conformations as compared to spikes of most other HIV-1 isolates (Cai et al., 2017, Guttman 
et al., 2015). It has been suggested that Tier 3 viruses preferentially remain in their closed 
conformation while Tier 1 viruses tend to remain in a relatively open conformation (Cai et 
al., 2017, Guttman et al., 2015). Our data lean towards the mechanism of neutralisation-
resistance of 253-11 mainly being due to having an unusually compact, closed Env trimer 
structure. An understanding of the mechanisms employed by viruses to gain neutralisation 
resistance is critical because it may aid in the design of immunogens capable of eliciting 
antibodies that have high strain coverage. 
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Chapter 3: Understanding the structural basis behind the 




253-11 is a CRF02_AG virus that is highly resistant to antibody neutralisation as determined 
by several antibody panels. Sequence polymorphisms in the V3 loop and N-linked 
glycosylation sites play a role in viral escape, but only marginally explain its neutralisation 
resistance phenotype. We found that the 253-11 membrane proximal external region (MPER) 
is rarely recognised by sera in the context of the wild-type virus, but is commonly recognised 
in the context of an HIV-2 chimeric virus. Mutations L669S and Y681H in the 253-11 MPER 
– which were previously reported to increase the lifetime of the pre-fusion Envelope (Env) 
conformation – increased the sensitivity of 253-11 to antibodies targeting various epitopes on 
HIV-1 Env. Remarkably, PG9, a broadly neutralising antibody recognising a quaternary 
epitope on the trimer spike, instead showed decreased neutralising ability towards the 253-11 
MPER mutants. This suggests that the MPER mutants destabilise the pre-fusion Env trimer 
spike. Together, these data led us to hypothesize that 253-11 preferentially stays in an unusually 
compact, closed Env conformation that makes it difficult for antibodies to penetrate and 
neutralise the virus. To gain information about the structure of the 253-11 Env trimer, a 
SOSIP.664 trimer based on the 253-11 virus was engineered. We found that the 253-11 SOSIP 
trimer has a high melting temperature, is a good antigenic mimic of the functional Env spikes 
expressed by the corresponding pseudovirus and exhibits a predominantly closed 
conformation. We solved the crystal structure of the 253-11 SOSIP trimer in complex with 
V3/glycan-specific antibody, 10-1074, at a resolution of 6.5 Å. The crystal structure of the 253-
11 trimer revealed that the heptad repeat helices in gp41 are drawn closer to the trimer axis as 
compared to other SOSIP trimer structures, suggesting local compactness in gp41. 253-11 
gp120 protomers also showed a relatively compact disposition around the trimer axis. 
Together, these data suggest that the 253-11 Env sequence confers an unusually compact trimer 
structure, supporting the hypothesis that a robust form of conformational masking is used by 
this virus, and plausibly other Tier 3 viruses, to achieve high neutralisation resistance. 
  
 




In Chapter 2 of this thesis, we hypothesised that the neutralisation resistant phenotype of the 
253-11 virus was mainly a result of the unusually compact and closed conformation of its 
Envelope (Env) protein that masks neutralising antibody (nAb) epitopes. To further investigate 
the compactness of the 253-11 Env and to probe the ability of the 253-11 sequence to 
preferentially adopt a pre-fusion Env structure, we engineered a 253-11 SOSIP.664 Env trimer 
as previously described (Sanders et al., 2013) and we solved its structure by X-ray 
crystallography. 
 
Determining how broadly neutralising antibodies (bnAbs) recognise the HIV-1 Env trimer is 
an important element of rational-vaccine design based on immunogens that elicit bnAb 
responses (Dimitrov et al., 2011, Kwong et al., 2011, Zhou et al., 2007). X-ray crystallography 
has long been the dominant method for deducing high-resolution protein structures (Green et 
al., 1954, Kendrew et al., 1958, Blake et al., 1965). Prior to the design of recombinant HIV-1 
Env trimers such as SOSIP.664 trimers, most antibodies were crystallized with fragments of 
HIV-1 Env (McLellan et al., 2011, Zhou et al., 2007). For example, Zhou and colleagues 
crystallized the CD4-bs antibody b12 complexed with an HIV-1 gp120 monomer and PG16 
was co-crystallized with a V1/V2 gp120 domain (Pancera et al., 2013). Another study used 
monomeric V1/V2 loop Env protein scaffolds in complex with antibodies such as PG9 to 
delineate their epitope binding (McLellan et al., 2011). However, these methods are not able 
to address trimeric structural changes which may be more immunologically relevant, such as 
the compactness that our study suggests may explain the high neutralisation resistance of 253-
11. The development of SOSIP.664 trimers paved the way to a better understanding of Env 
immunogenicity (Sanders et al., 2013) and eventually led to the first high resolution crystal 
structure of HIV-1 Env (Julien et al., 2013a). 
 
The first structure of the HIV-1 Envelope (Env) trimer was solved at 4.7 Å from crystals of the 
BG505 SOSIP.664 trimer (Julien et al., 2013a). The crystal structure of the BG505 trimer shed 
light on the architecture of the HIV-1 trimer at atomic resolution. However, crystallization of 
Env trimers has been a challenge and only four other Env SOSIP.664 trimers have been solved 
by crystallography or cryo-electron microscopy to date: JR-FL (Subtype B), X1193.c1 
(Subtype G) (Stewart-Jones et al., 2016), 16055 (Subtype C) (Guenaga et al., 2017) and most 
recently, B41 (Subtype B) (Ozorowski et al., 2017). Some of the difficulties in crystallizing 
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HIV-1 trimers include instability, protein flexibility especially at the variable loop regions and 
dense gp120 glycosylation (Ward and Wilson, 2017). To overcome this, most Env trimers have 
been crystallized without their native glycans and in complex with the antigen-binding 
fragment (Fab) of an HIV-1-specific antibody (Ward and Wilson, 2017).  
 
As very few HIV-1 strains are amenable to SOSIP design (Sanders and Moore, 2017, Julien et 
al., 2015), little is known about how Tier 3 viruses from chronic infection would perform as 
SOSIP trimer immunogens and if their structures differ from more neutralisation sensitive 
viruses. It is plausible that their structures differ from Tier 1 and 2 viruses as it has been shown 
that unliganded Tier 3 viruses preferentially remain in a closed conformation with fewer 
conformational fluctuations compared to neutralisation sensitive viruses (Cai et al., 2017, 
Munro et al., 2014). Only one neutralisation resistant SOSIP trimer has been described in the 
literature, based on the PVO.4 virus but it is only moderately neutralisation resistant (Tier 2/3) 
(Verkerke et al., 2016, Seaman et al., 2010) and its structure has not been solved to date. 
Therefore, there is a need for more Tier 3 SOSIP trimers because they may induce a robust 
broadly neutralising response when used as immunogens as preferentially remaining in a closed 
conformation may display bnAb epitopes and occlude narrowly-neutralising ones more 
efficiently (Cai et al., 2017).  
 
We engineered a SOSIP trimer based on the 253-11 Env sequence and in preliminary studies 
by our collaborators Ereño-Orbea and Julien, small-angle X-ray scattering (SAXS) 
measurements coupled to size-exclusion chromatography (SEC) (SEC-SAXS) revealed that 
the 253-11 SOSIP.664 trimers were almost entirely free of aggregation and properly folded, 
and the calculated diameter (Dmax) for the 253-11 trimer (152.4 Å) was comparable to BG505 
(146.2 Å) (Fig 3.1). Although the 253-11 and BG505 structures analysed by SAXS contained 
a (His)6x tag at their C-termini, the Dmax of BG505 was almost identical to BG505 without the 
(His)6x tag (147 Å) (Liang et al., 2016). This suggests that the (His)6x tag had little to no effect 
on the measurements. The low-resolution three-dimensional volume obtained from SAXS 
measurements demonstrated that the 253-11 trimer adopts a closed conformation that was of 
similar dimensions to that of the BG505 trimer (Fig 3.1). This led us to hypothesize that the 
compact phenotype of 253-11 may be as a result of discrete features in its secondary structure 
that cannot be observed at this low resolution. 
 
 











Figure 3.1 Low-resolution characterisation of 253-11 SOSIP.664 Env trimers. Three views (side, 
top and bottom) of the SAXS envelope reconstruction obtained for 253-11 (grey) and BG505 (yellow) 
trimers by SEC-SAXS. The crystal structure of the fully glycosylated BG505 SOSIP trimer (PBD 
ID:5FYL) was fitted into the SAXS 3D volume and is shown as a secondary structure cartoon. 
 
In this chapter, the 253-11 SOSIP.664 trimer, initially designed by our collaborators Ereño-
Orbea and Julien, was further analysed. We first investigated its biophysical properties 
including antigenicity and thermostability. Then, to gain further understanding of the discrete 
structural elements of 253-11 resulting in its neutralisation resistant phenotype, we co-
crystallized the 253-11 trimer with 10-1074, a V3/glycan-specific antibody which is highly 
potent and broad (Mouquet et al., 2012), even against the 253-11 virus. Thus, the 253-11 SOSIP 
trimer we designed increases the number of recombinant Env trimers currently available, 
shedding light on the structure of Tier 3 Env trimers and adding to the potential HIV-1 
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3.2 Materials and Methods 
 
3.2.1 253-11 SOSIP, BG505 SOSIP, VRC01, PG9 and 10-1074 Fab construct design 
 
All sequences were codon-optimized for expression in human cells and synthesized by 
GeneArt (Life Technologies). 253-11 and BG505 SOSIP.664 constructs were subcloned into 
the pHLsec vector (Aricescu et al., 2006) using restriction enzymes AgeI and KpnI, such that a 
(His)6x tag was at the C terminus of the constructs to facilitate affinity purification. Addition 
of a stop codon before the (His)6x tag allowed for the removal of the tag and production of an 
untagged 253-11 trimer for crystallization.  The heavy chain and light chains of the 10-1074, 
PG9 and VRC01 Fabs were subcloned into the pHLsec vector (Aricescu et al., 2006) using 
restriction enzymes AgeI and KpnI. 
 
3.2.2 Trimer expression and purification 
 
253-11 SOSIP.664 and BG505 SOSIP.664 plasmids were transiently co-transfected with a 
furin protease plasmid into HEK293F or HEK293 suspension cells (ATCC). Cells were 
passaged in 200 ml cultures at 0.8 x 106 cells per ml. 50 µg of DNA was filtered and mixed in 
a 1:1 ratio with transfection reagent FectoPRO (Polyplus Transfections). The DNA:FectoPro 
solution was incubated with the cells at 37 oC for 6-7 days. Cells were harvested by 
centrifugation and supernatants filtered using a 0.22 µm Steritop filter (EMD Millipore). 
Supernatant containing protein with the (His)6x tag was passed through a HisTrap Ni-NTA 
column (GE Healthcare). The column was washed with 1x Phosphate buffered saline (PBS) 
buffer pH 7.4 with 5 mM imidazole prior to elution with an increasing gradient of imidazole 
up to 500 mM. The untagged 253-11 trimer protein was purified through a Galanthus nivalis 
lectin (GNL) column. The trimer was washed with 1x PBS, then 0.5 M sodium chloride (NaCl) 
in 1x PBS followed by an additional 1x PBS wash. The trimer was eluted with 1 M methyl-α-
D-mannopyranoside (MMP) in 1x PBS. In both cases, the affinity-purified proteins were 
further purified to size homogeneity using two runs of Superdex 200 10/300 increase size-
exclusion chromatography (SEC) (GE Healthcare) in 20 mM Tris pH 9.0, 150 mM NaCl buffer. 
Purity of the SOSIP.664 trimers was assessed by non-reducing and reducing sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) gels stained with 
Quick Coomassie Blue (Regeneron) for visualisation. The Precision Plus ProteinTM Dual Color 
Standards (Bio-rad) molecular weight marker was used to determine the apparent size of the 
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proteins. Protein concentrations were measured using the Nanodrop 2000 spectrophotometer 
(ThermoFisher Scientific).  
 
3.2.3 Fab expression and purification 
 
HEK293F or HEK293S cells were transfected with heavy and light chain plasmids (2:1 ratio) 
in a total DNA amount of 90 ug for each 200 ml culture. FectoPRO reagent was used as a 
transfection reagent in a 1:1 ratio of DNA:FectoPRO. Cells were transfected at a cell density 
of 0.8 x 106 cells per ml and incubated at 37oC for 6-7 days. Cells were harvested and 
supernatants and filtered through a 0.22 M membrane. Supernatants were passed through an 
anti-Kappa affinity column (GE Healthcare) or anti-Lambda affinity column (GE Healthcare) 
using an AKTA Start chromatography system (GE Healthcare) and eluted with 100 mM 
glycine pH 2.2-2.7. Eluted fractions were immediately neutralised with 1 M Tris-HCl pH 9.0. 
Fractions containing protein were buffer exchanged into 20 mM sodium acetate, pH 5.6. Ion 
exchange chromatography was performed using a cation MonoS column (GE Healthcare) and 
eluted with a potassium chloride gradient. Fractions were pooled, concentrated and flowed 
through a Superdex 200 Increase gel filtration column (GE Healthcare) in 20 mM sodium 
acetate pH 5.6 to obtain purified samples. Purity of protein samples was assessed by non-
reducing and reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE 
gels stained with Quick Coomassie Blue (Regeneron) for visualization. The Precision Plus 
ProteinTM Dual Color Standards (Bio-rad) molecular weight marker was used to determine the 
apparent size of the proteins. Protein concentrations were measured using the Nanodrop 2000 
spectrophotometer (ThermoFisher Scientific). 
 
3.2.4 Determination of the SOSIP trimer melting temperatures (Tm) 
 
The conformational stability of the 253-11 trimer and 253-11 (His)6x-tag trimer was assessed 
by measuring the melting temperature (Tm) determined by an intrinsic fluorescence intensity 
ratio (350/330 nm) using the UNit system (Unchained Labs). SEC-purified SOSIP trimer 
samples were concentrated to 1 mg/ml and heated from 20 to 90 °C using 1°C increments, with 
an equilibration time of 60 s before each point measurement. Trimer thermostability was 
measured in three different buffers; 50 mM Tris pH 9, 50 mM HEPES pH 7 and 50 mM sodium 
acetate. All buffers contained 150 mM NaCl. Data was processed using the standard UNit 
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analysis software. Sample measurements were taken in triplicate; values were averaged and 
standard errors were calculated using GraphPad Prism v5.  
 
3.2.5 Fab and antibody binding assay using biolayer interferometry 
 
Binding affinities of VRC01, PG9 and 10-1074 Fabs, and 17b and F240 antibodies to 253-11 
SOSIP trimers were measured by biolayer interferometry (BLI) (Rich and Myszka, 2007) using 
the Octet Red system (Pall FortéBio) (Shah and Duncan, 2014). Anti-human Fab-CH1 or anti-
human IgG biosensors were hydrated in 1x kinetics buffer (1X PBS, pH 7.4, 0.002% Tween, 
0.01% BSA) and loaded with 10 μg/ml Fab for 60 s. Biosensors were then transferred into 
wells containing 1x kinetics buffer to baseline for 60 s before being transferred into wells 
containing serial dilutions of 253-11 SOSIP.664 trimer starting at 1500 nM and decreasing to 
187.5 nM. The 300 s association phase was subsequently followed by a 600 s dissociation step 
in 1x kinetics. For antibody F240, the association phase was 150 s and the dissociation phase 
was 350 s. Analysis was performed using the Octet software, with a 1:1 fit model. Experiments 
were repeated in triplicates. 17b and F240 antibodies were obtained from the National Institute 
of Health, AIDS Reagent Program. 
 
3.2.6 Crystallization of the 253-11 SOSIP trimer in complex with 10-1074 Fab 
 
Molar excess of 10-1074 Fab was added to purified 253-11 SOSIP trimer expressed in HEK293 
GnT I-/- cells. To obtain deglycosylated samples, the complex was then treated with the enzyme 
Endoglycosidase H (Endo H) (New England Biolabs) for 1 h at 37 oC. Deglycosylated 253-11 
SOSIP trimer in complex with 10-1074 Fab was purified by SEC using a Superose 6 SEC 
column (GE Healthcare). The purified 253-11 SOSIP trimer with 10-1074 Fab complex was 
concentrated to 5 mg/ml in a buffer containing 20 mM Tris pH 9.0 and 150 mM NaCl. Crystals 
were obtained by hanging drop vapor-diffusion in 0.5 M sodium chloride, 1.9 M ammonium 
sulphate and 0.1 M sodium cacodylate, pH 6.5. Crystals were improved by micro-seeding after 
mixing 0.6 μl of protein, 0.4 μl solution and 0.2 μl crystal seeds. Crystals were cryo-protected 
by soaking in mother liquor solution containing 20% glycerol and flash cooled in liquid 
nitrogen. X-ray diffraction data were collected at the 23-ID-D beamline at the Argonne Photon 
Source, USA. A unique dataset for the 253-11 SOSIP trimer + 10-1074 Fab complex was 
processed using XDS (Kabsch, 2010). Based on the R3:H space group and Matthews volume 
calculation (Weichenberger and Rupp, 2014, Matthews, 1968, Kantardjieff and Rupp, 2003) 
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we estimated that there were two molecules of the 253-11 SOSIP protomer + 10-1074 Fab 
complex in the asymmetric unit. The crystal structure was solved by molecular replacement 
using one protomer of BG505 SOSIP in complex with 10-1074 Fab (PDB ID: 5T3X) (Gristick 
et al., 2016) as a search model in Phaser (McCoy et al., 2007). The structure was refined by 
manual building in Coot (Emsley et al., 2010)  and using phenix.refine (Adams et al., 2002) 
with strict reference model and secondary structure restraints given the resolution. The 
structure of BG505 SOSIP in complex with a PGT121-family precursor (PDB ID: 5CEZ) 
(Garces et al., 2015) was used to manually build the fusion peptide of 253-11 in Coot. Protein 
structure superimpositions and center of mass analyses were conducted using Pymol v1.8.6.0 
(Schrodinger, 2015). The centre of mass of individual gp120 protomers (residues 32-504) and 
distances between the three gp120 centers of mass were calculated using the “centreofmass” 
and “measurement” commands in Pymol, respectively. Software were accessed through 
SBGrid (Morin et al., 2013). 
  
 




3.3.1 SOSIP.664 trimer expression and purification 
 
The 253-11 SOSIP.664 was designed as described previously (Sanders et al., 2013) with a 
disulphide bond linking gp120 and gp41 subunits and an isoleucine to proline mutation at 
position 559 to increase trimer stability (Fig 1A). The sequence was truncated at position 664 
before the membrane proximal external region (MPER) to increase the solubility of the trimer 
(Fig 1A).  
 
The 253-11 Env is a heavily glycosylated glycoprotein (Fig 1A) (Ward and Wilson, 2017). For 
this reason, the 253-11 trimer constructs were expressed in HEK293F or 293S mammalian cell 
lines. A (His)6x-tag was added to 253-11 and BG505 trimers to allow affinity purification using 
nickel chromatography (Bornhorst and Falke, 2000). However, because of the flexibility and 
charge caused by the C-terminal (His)6x-tag, it was removed from the 253-11 trimer for 
crystallization.  
 
HEK293F cells are fast growing, highly transfectable cells that contain a mutant version of the 
SV40 large T antigen (Rio et al., 1985). These cells express proteins with wild-type (WT) N-
linked glycans and are therefore useful in biophysical analysis of proteins as they are 
representative of HIV-1 Env in its native state. However, complex and hybrid N-linked glycans 
increase the chemical and conformational heterogeneity of proteins, which dampens the 
chances of getting good diffracting crystals. This is one of the major challenges in 
crystallization of the HIV-1 trimer as it is densely covered by glycans (Ward and Wilson, 
2017). To overcome this, for crystallization trials, the 253-11 trimer and glycosylated Fabs 
were expressed in HEK293S cells. HEK293S cells are also highly transfectable but are 
deficient in the GnT I enzyme which limits the heterogeneity of N-linked glycans as they enrich 
for high mannose glycans only (Chaudhary et al., 2012). 
 
After 6-7 days of expression, protein was harvested from the supernatant and purified until 
homogeneity using two chromatography steps; a first step of affinity chromatography followed 
by size-exclusion chromatography (SEC). While 253-11 trimers (253-11_histag trimer) and 
BG505 trimers containing the (His)6x-tag were affinity purified using nickel-coated columns 
(Fig. 3.2b), the 253-11 trimers lacking the (His)6x tag were purified by a lectin column through 
binding of the HIV-1 Env glycans to D-mannose subunits (Barre et al., 2001) (Fig. 3.2c).  
 





















Figure 3.2 Representative affinity chromatography purification profiles and SDS-PAGE gels of 
253-11 trimers. (a) Schematic linear representation of the glycosylated 253-11 SOSIP.664 trimer 
design highlighting the features which constitute a SOSIP trimer. (b) After expression in either 
HEK293F or HEK293S cells, the proteins first underwent affinity chromatography as an initial 
purification step. 400 ml 253-11_histag trimer was purified through a nickel column and eluted with 
500 mM imidazole in 1x PBS. (c) 600 ml 253-11 trimer was purified through a GNL column and eluted 
with 1M MMP in 1x PBS. The proteins were run on a SDS-PAGE either with β-mercaptoethanol 
(reducing) or without (non-reducing). Before: protein before affinity purification; After: protein after 
affinity purification. FT: flow-through from affinity column. Blue line: UV absorbance corresponding 
to protein elution; red line: elution buffer conductivity. 
 
Protein purity was assessed by running the eluted peak on an SDS-PAGE in either reducing 
(by adding 5% β-mercaptoethanol) or non-reducing conditions. Under non-reducing conditions 
trimers of above 250 kDa molecular weight and gp120-gp41 protomers of approximately ~140 
kDa were obtained. Addition of β -mercaptoethanol reduced the disulphide linkage between 
the gp120 (band at 120 kDa) and gp41 (band around 37 kDa). Multiple bands for gp41 are 















Figure 3.3 Representative size-exclusion chromatography profiles for purification of 253-11 
SOSIP trimers. After affinity chromatography, the 253-11 trimers (both with and without a (His)6x-
tag) underwent SEC in a Superdex 200 column to further remove aggregates, dimers and monomers. 
Protein from the first SEC was eluted at 0.1 ml/min to ensure good separation. The area between the 
dotted lines represents the fractions from the 1st SEC used to run the 2nd SEC. The second SEC was 
conducted at 0.5 ml/min on a Superdex 200 Increase column. The second 253-11 trimer chromatogram 
was superposed with one for the BG505 SOSIP trimer as a comparison and an SDS-PAGE gel of the 
two trimers in both reducing (R) and non-reducing (NR) conditions is shown.  
 
To separate 253-11 SOSIP.664 trimers to size homogeneity from aggregates, monomers and 
dimers, we further purified the protein by SEC using a Superdex 200 Increase column (GE 
Healthcare) (Fig 3.3). To further polish purification, a second SEC was conducted. 253-11 
SOSIP trimers eluted as a single peak at the same volume (~10 ml) as BG505 SOSIP trimers 
and expressed in slightly higher yields compared to BG505 SOSIP trimers. The trimers were 
efficiently cleaved into gp120-gp41 subunits during processing in the Golgi as observed in 
SDS-PAGE under reducing conditions (Fig 3.3). In summary, we successfully expressed the 
253-11 SOSIP.664 trimer and produced the yields and purity needed for subsequent 
biophysical and structural experimentation.  
 
3.3.2 Evaluation of trimer stability reveals (His)6x-tag on 253-11 trimer affects 
thermostability 
 
Thermostability is an important characteristic of SOSIP trimers (Sanders et al., 2013, Ward 
and Wilson, 2017) and may give some insight into their overall stability. We analysed the 
thermostability of 253-11 trimers with and without a His(6x)-tag using the UNit system 



















Figure 3.4 Comparison of thermostability between 253-11 trimers, 253-11_His-tag trimers and 
BG505 trimers at different pH values. The conformational thermostability of the 253-11 trimers was 
measured using an intrinsic fluorescence measurement carried out using the UNit (Avacta). The trimers 
were in buffers of different pH values and their Tm were measured by exposing the proteins to increasing 
temperatures and measuring the changes in fluorescence over time. Measurements were conducted in 
triplicate. BG505 trimers were used as a comparison of trimer stability. Thermostability was measured 
in different pH conditions: 50 mM Tris pH 9.0, 50 mM HEPES pH 7.0 and 50 mM sodium acetate pH 
5.6. All buffers contained 150 mM NaCl.  
 
The UNit system can simultaneously measure intrinsic fluorescence spectroscopy and static 
light scattering to provide information on changes in tertiary structure and aggregation, 
respectively (He et al., 2013). The trimer contains aromatic residues that are folded into the 
centre of the protein structure. These aromatic residues fluoresce when excited with UV light. 
As the protein denatures when exposed to increasing temperature from 20 to 90 °C, these core 
aromatic residues are increasingly exposed to UV light. The changes in fluorescence emission 
intensity (350/330 nm) of the protein are measured and a Tm  is determined. (He et al., 2013).  
 
The 253-11 trimers appear to be more stable at higher pH values, with the greatest stability at 
pH 9 (Fig 3.4). Interestingly, the 253-11_histag trimer had higher thermostability overall 
compared to the 253-11 trimer.  In comparison, the BG505 trimer (with a (His)6x tag) was 
consistently more thermostable than both 253-11 trimers and BG505 thermostability appears 
to be largely independent of pH. Despite the 253-11 trimer having a slightly lower Tm compared 
to the gold-standard BG505 trimer, it is one of the most thermostable SOSIP trimers that has 
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3.3.3 Expression and purification of 10-1074, VRC01 and PG9 Fabs 
 
For our studies, we chose PG9, 10-1074 and VRC01 Fabs because the corresponding antibodies 
neutralised the 253-11 trimer potently (Fig 2.1) and therefore would be good markers for 
testing trimer antigenicity. These antibodies are also known to bind to the closed, pre-fusion 
conformation of the HIV-1 Env (Guttman et al., 2015, Julien et al., 2013b, Mouquet et al., 
2012, Li et al., 2011) and therefore were good candidates for use in 253-11 trimer co-
crystallization. Fabs were initially purified using anti-lambda or anti-kappa affinity columns 
depending on their light chains (Fig 3.5). PG9 and 10-1074 have lambda light chains while 
VRC01 has kappa light chains. PG9 and VRC01 both expressed very well and only 200 ml of 
culture was required to produced high yields of protein. 10-1074 expressed poorly and to obtain 
approximately the same amount of protein as the other Fabs, 800 ml of culture supernatant was 

















Figure 3.5 Representative affinity chromatography purification profiles and SDS-PAGE gels of 
10-1074, VRC01 and PG9 Fabs. After expression in either 293F or 293S cells, the proteins underwent 
affinity chromatography as an initial purification step. Blue line: UV absorbance corresponding to 
protein elution; red line: elution buffer conductivity (a) 800 ml of 10-1074 Fab was purified through 
an anti-lambda column and eluted with 100 mM glycine, pH 2.7 (b) 200 ml VRC01 Fab was purified 
through an anti-kappa column and eluted with 100 mM glycine, pH 2.2 (c) 200 ml PG9 was purified 
through an anti-lambda column and eluted with 100 mM glycine, pH 2.7. The proteins were run on a 
SDS-PAGE either with β-mercaptoethanol (Reducing) or without (Non-reducing). Before: protein 
before affinity purification; After: protein after affinity purification. FT: flow-through from affinity 
column. 
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All the Fabs ran to a distinct band at ~50 kDa as expected in non-reducing conditions and 
reduced to two bands ~25 kDa as the light and heavy chain separated. Fabs then underwent 
ion-exchange chromatography to purify the proteins based on charge (Fig 3.6). The theoretical 
isoelectric point (pI) values of the Fabs are 8.4 for 10-1074, 8.0 for VRC01 and 7.9 for PG9. 
The pI is the pH value at which the protein carries no charge (Bjellqvist et al., 1993). Because 
of their pI values, we buffer exchanged the Fabs into a 20 mM sodium acetate buffer, pH 5.6 
to ensure they had a positive charge to purify them on a cation exchange resin. A cation 
exchange resin is negatively charged and therefore binds positively charged proteins 
(Jungbauer and Hahn, 2009). 
Figure 3.6 Representative ion exchange and size-exclusion chromatograms for 10-1074, VRC01 
and PG9 Fabs. (a) 10-1074, (b) VRCO1 and (c) PG9 were run through a cation ion exchange resin to 
separate Fabs from impurities based on charge, followed by a Superdex 200 Increase 10/300 resin as a 
final purification step based on size. The purity throughout the steps was validated by SDS-PAGE in 
both reducing and non-reducing conditions. Numbers correspond to individual peaks and fractions of 
each of these peaks were tested on SDS-PAGE. Blue line: UV absorbance corresponding to protein 
elution; red line in ion exchange chromatograms: elution salt conductivity. 
 
Fabs eluted out in multiple peaks with 10-1074 and VRC01 Fabs having separable peaks, likely 
as a result of glycan heterogeneity. This is likely because both Fabs contain one potential N-
linked glycosylation site (PNG). Differences in the peaks were difficult to distinguish on the 
gels as the molecular weight of a glycan is only ~2 kD, which may be too small to differentiate 
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on SDS-PAGE. PG9 had multiple, overlapping peaks that were difficult to separate. The reason 
for the multiple peaks is likely caused by the presence of a variable number of sulphated 
tyrosine residues (McLellan et al., 2011). Tyrosine sulphation is a post-translational 
modification which occurs in the Golgi apparatus (Huttner, 1982). Since the process is variable, 
distinct PG9 proteins will have different charges which likely led to closely overlapping peaks 
on the chromatogram. 
 
Fabs then underwent SEC for purification based on their molecular weight (Fig 3.6). For 
VRC01, both peaks from the ion-exchange were run separately through the SEC 
(chromatogram for peak 1 shown in Fig 3.6b) yielding one well separated peak. For PG9, 
however, pooled fractions from peaks 1-3 were run on SEC which produced 4 distinct peaks. 
On the PG9 SDS-PAGE gel after SEC, all four peaks corresponding to the expected size of the 
Fab were observed, highlighting micro-heterogeneity. The 10-1074 peak 3 from ion-exchange 
chromatography yielded a single pure peak after SEC. Once purified, Fabs were used for Fab-
trimer binding studies. 10-1074 Fab was also used in crystallization trials. 
 
3.3.4 The 253-11 trimer is a good antigenic mimic of its corresponding pseudovirus 
 
To probe whether the 253-11 SOSIP trimer is a good antigenic mimic of the corresponding 
253-11 pseudovirus, we tested binding of the three Fabs and two non-neutralising antibodies, 
17b and F240, to the 253-11 trimer by biolayer interferometry (BLI) using the Octet RED96 
system (Pall FortéBio). BLI is a label-free technology which measures intermolecular 
interactions through the interference of white light that is reflected from two surfaces: (i) a 
layer of immobilized protein (Fab or antibody) on an anti-Fab/antibody biosensor tip, and (ii) 
an internal reference layer (Shah and Duncan, 2014). Any change in the number of molecules 
bound to the sensors will cause an optical interference between the light reflected (Shah and 
Duncan, 2014). Binding between the immobilized Fab/antibody on the biosensor and the Env 
trimer in solution produces an increase in optical thickness at the biosensor tip, which results 
in a wavelength shift (Shah and Duncan, 2014). Dissociation of the two proteins when the 
biosensor is moved from the wells with trimer to wells containing buffer will lead to a further 
shift (decrease) in the interference pattern (Shah and Duncan, 2014) (Fig 3.7a) This 
information is then processed and the binding kinetics analysed (Shah and Duncan, 2014). 
Using BLI, we tested the binding of 10-1074, VRC01, PG9, 17b and F240 with four 2-fold 
dilutions of the 253-11 trimer (Fig 3.7b). 
 




























Figure 3.7 Determination of Fab-trimer binding by biolayer interferometry. a) Principle of 
biolayer interferometry. Biosensors are dipped into kinetics buffer, followed by loading with Protein 1 
(Fab/antibody). The Fab/antibody-covered biosensor is then dipped into a second baseline of buffer 
then transferred to Protein 2 (trimer) where association is measured. The biosensors are then moved to 
the buffer from the second baseline to measure the dissociation. (b) Representative plots for the 
association and dissociation between the VRC01, PG9 and 10-1074 Fabs and 17b and F240 antibodies. 
The dissociation constant (KD) values are shown in nM and compared to the IC50 values from 
neutralisation assays shown in µg/ml. (c) On-rate (Kon) (1/Ms) and off-rate (Koff) (1/s) values for each 
of the three Fabs.  
 
We found that the VRC01, 10-1074 and PG9 Fabs bound well to the trimer with KD values of 
11.8, 25 and 137 nM, respectively (Fig 3.7b), suggesting that the 253-11 trimers are well folded 
and correctly display broadly neutralising antibody (bnAb) epitopes including the V2/apex 
conformational epitope bound by PG9. The 253-11 trimer was not bound by antibodies 17b 
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and F240, which do not neutralise the 253-11 pseudovirus (Fig 3.7b). This strongly suggests 
that the trimer efficiently occludes the corresponding epitopes that are occluded on the 
pseudovirus. 
 
The Fabs associated (Kon) and dissociated (Koff) very slowly to the Env trimers (Fig 3.7c). The 
on-rate (Kon) refers to the rate at which the Fab binds to the trimer (association) and the off-
rate (Koff) refers to the rate of dissociation. The slow on-rates are likely partly attributable to 
the dense glycan shield of the HIV-1 Env which they need to penetrate to reach their epitopes. 
Once bound, the Fabs dissociated slowly and this is a characteristic which makes bnAbs more 
effective in neutralising HIV-1 as they remain bound to their target for longer periods of time 
(Klasse, 2014, Yasmeen et al., 2014)  
 
3.3.5 Crystallization of the 253-11 SOSIP trimer in complex with 10-1074 
 
To gain a further understanding of how Env compactness contributes to the neutralisation 
resistant phenotype of the 253-11 virus, we crystallized the 253-11 SOSIP trimer. HIV-1 
trimers are generally extremely dynamic proteins (Guttman et al., 2015) which makes 
crystallization difficult and therefore we co-crystallized the 253-11 trimer with Fabs to stabilise 
it in its closed conformation as others have done previously (Stewart-Jones et al., 2016, Scharf 
et al., 2014, Julien et al., 2013a).  
 
Although we set up crystallization trials with all three Fabs, we focused our efforts mainly on 
10-1074. This was because the PGT121-family Fabs (which include 10-1074) have been the 
most successful in obtaining crystals for other SOSIP trimers (Gristick et al., 2016, Garces et 
al., 2015). 
 
To increase our chances of crystallization we expressed 253-11 SOSIP.664 and 10-1074 in 
HEK293S cells, which enrich for more homogeneous, high-mannose type of N-linked glycans 
(Chaudhary et al., 2012). 10-1074 contains one PNG (glycosylation motif: N-P-S) in the heavy 
chain region of the sequence as predicted by NetNGlyc 1.0 Server (Gupta and Brunak, 2002). 
The presence of a proline between the asparagine and serine residues makes the probability of 
the addition of an N-linked glycan very low at this site (Kornfeld and Kornfeld, 1985), 
however, we still decided to treat the Fab with Endo H glycosidase to truncate the potential 
high mannose glycan (Trimble and Maley, 1984). We treated the Fab with Endo H prior to ion 
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exchange chromatography because separation by SEC would be difficult as deglycosylated Fab 
(~50 kDa) and glycosylated Fab (~52 kDa) are similar in size. 
 
The purified 253-11 SOSIP.664 trimer was complexed with 10-1074 by adding a 6-fold molar 
excess of purified Fab. The complex was Endo H-treated to cleave the 253-11 SOSIP N-linked 
glycans unprotected by Fab binding to single N-acetylglucosamine (GlcNAc) moieties. Trimer 
deglycosylation was performed after 10-1074 bound to the trimer because 10-1074 binding is 
dependent on glycans at the base of the V3 loop, particularly the glycan at position N332 
(Mouquet et al., 2012). Once deglycosylated, the trimer-Fab complex was run through a 
Superose 6 Increase (GE Healthcare) SEC column. This column was specifically chosen to 
efficiently separate a complex of larger size (~400 kDa) from unliganded Fab (~50 kDa). Once 
purified, there was a clear peak corresponding to the purified trimer-Fab complex and a peak 
corresponding to excess Fab (Fig 3.8). The trimer-Fab complex was extremely pure as shown 
by SDS-PAGE (Fig 3.8). Fractions corresponding to the trimer-Fab were pooled together and 




Figure 3.8 Representative chromatogram and SDS-PAGE for purification of 253-11 SOSIP 
trimer-10-1074 Fab complex. The 253-11-Fab complex was run through a Superose 6 Increase SEC 
resin as a final purification step. The trimer-Fab complex eluted out first followed by the excess 
unbound Fab. The purity of the proteins was assessed throughout the purification process by SDS-
PAGE in both reducing and non-reducing conditions. 
 
Crystallization screens, JCSG Top96 (Rigaku), Top96 Cryo (Rigaku) and MCSG 1, 2, 3 and 4 
(Anatrace), were initially used, which are designed for high-throughput initial screening of 
crystallization and solubility conditions for biological macromolecules. These screens are 
formulated to maximize the coverage of crystallization parameters (buffers, salts, precipitant 
and pH) and eliminate redundancy. The crystallization method used was the vapour-diffusion 
method (Rhodes, 2006) where 0.1 µl 253-11 trimer-Fab complex was added to 0.1 µl 
precipitant from various crystallization screens in 96-well plates using an Oryx4 crystallization 
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robot (Douglas Instruments). In the vapour-diffusion method, the trimer and precipitant 
equilibrate with a larger volume of the same precipitant conditions (Rhodes, 2006). As 
equilibration occurs, the protein concentration increases and solutes move randomly in solution 
until they interact and form intermolecular forces (Rhodes, 2006). Under the right conditions, 
nucleation occurs. Nucleation is the process whereby solutes in a saturated solution transition 
into a crystal lattice (Rhodes, 2006). 
 
Seven small and poorly diffracting crystals - best diffraction at 12 Å resolution - were obtained 
using synchrotron radiation at the Canadian Light Source. To optimise diffraction, we 
employed the microseeding method to increase the quality of initial crystals. The microseeding 
technique consists of transferring crushed crystal fragments (crystal seeds) generated from 
initial small crystals from one condition to a similar condition (Rhodes, 2006). As crystal seeds 
are already arranged in an ordered lattice, their presence eliminates the process of random 
collisions to form bonds as the solute will be drawn to the ordered lattice and start forming 
crystals around it (Rhodes, 2006). The newly formed crystals will then detach from the seeds 
after they reach an adequate size (Allahyarov et al., 2015). In our experiments, we performed 
three rounds of microseeding optimisation; each time using crystal seeds obtained from the 
previous crystallization trial. Upon microseeding, crystals grew within 3 days and much more 
crystals were obtained compared to without seeding.  
To further optimize crystal diffraction, we dehydrated some of the crystals we obtained to 
remove excess solution, thereby improving crystal packing and diffraction (Russo Krauss et 
al., 2012). Prior to freezing, some crystals were dehydrated by the addition of 1 M NaCl for 4-
6 hours or 48 hours or by air-drying for 2 minutes immediately prior to cryo-protection. X-ray 
diffraction data were collected at the 23-ID-D beamline at the Argonne Photon Source and the 
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Table 3.1. Crystallographic data collection and refinement statistics. 
 253-11 SOSIP trimer + 10-1074 Fab 
Wavelength (Å) 1.03327 
Resolution range (Å) 39.54-6.50 (6.74-6.50) 
Space group R3: H 
Unit cell a, b, c (Å) 
α, β, γ (°) 
237.3, 237.3, 284.3 
90, 90, 120 
Total reflections 33 659 
Unique reflections 11600 (1224) 
Multiplicity 2.9 (2.8) 
Completeness (%) 99.2 (99.9) 
Mean I/σI 11.9 (1.5) 
Wilson B-factor (Å2) 409.15 
Rmerge 0.07 (0.56) 
Rpim 0.05 (0.40) 
CC1/2 99.6 (49.1) 
Reflections used in refinement 11556 (1178) 
Reflections used for Rfree 1174 (118) 
Rwork 0.299 (0.417) 
Rfree 0.383 (0.462) 
















Rotamer outliers (%) 2.6 






 Clashscore  11.4 
PDB ID upon publication 
Values in parentheses correspond to the highest resolution shell 
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Data for the 253-11 trimer in complex with 10-1074 Fab was processed in the space group 
R3:H (Table 3.1). The space group describes the symmetry of the structure (Rhodes, 2006) 
and an R3:H space group means that the structure has a 3-fold symmetry across the axis. Based 
on the space group and unit cell parameters (a=237.3 Å, b=237.3 Å, c=284.3 Å; alpha=90°, 
beta=90° and gamma=120°), the Matthews Coefficient (Matthews, 1968) estimated that the 
asymmetric unit consisted of two molecules of the 253-11 trimer + 10-1074 Fab complex (Fig 
3.9).  The asymmetric unit is the smallest unit of a crystal that can be used to build the complete 
protein structure by application of symmetry (Rhodes, 2006). A unit cell is the smallest unit 
which makes up the complete structure of the protein (Rhodes, 2006). As expected, the 
biological assembly obtained after applying crystallographic symmetry consists of the 253-11 
trimer bound by three 10-1074 Fabs (Fig 3.9). BG505 SOSIP.664 complexed with 10-1074 
and IOMA (PDB ID: 53TX) was used to build the 253-11 structure by molecular replacement, 
as it is the only deposited trimer crystal structure in complex with 10-1074 (Gristick et al., 
2016).  
Figure 3.9 Crystal diffraction and model building. A single crystal diffracted at 6.5 Å and a unique 
dataset for the protein complex was processed using XDS (Kabsch, 2010). The structure was built by 
molecular replacement with the BG505 SOSIP.664 trimer (PDB: 53TX). The asymmetric unit was 
made of two 253-11 + 10-1074 protomers. Once the symmetry mates were added, the complete trimer 
in complex with the three 10-1074 Fabs bound at the V3/glycan epitope could be visualized. Gp120-
gp41 protomers colored in yellow and cyan, respectively, and represented as cartoon. 10-1074 Fab is 
represented as cartoon in grey. Glycans are represented as spheres. 
 
3.3.5.1 Local gp41 compactness identified in heptad repeat helices of 253-11 
 
As expected, the 253-11 SOSIP.664 trimer adopted a closed, pre-fusion conformation with 
three 10-1074 Fabs protruding from the membrane distal gp120 subunits, contacting glycans 
at the base of the V3 loop (Fig 3.9 and Fig 3.10a). Prior to refinement, electron density maps 
revealed distinct density for gp41 heptad repeat (HR) 1 and 2 helices (Fig 3.10b and c). 
Compared to the BG505 SOSIP.664 trimer that was used as the search model in molecular 
replacement (PDB ID: 5T3X), the HR1 helices are slightly shifted inwards towards the trimer 
axis in 253-11 (Fig 3.10b). We note that the HR2 helices in gp41 are also displaced towards 
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the trimer axis in 253-11 (Fig 3.10c), however, as has previously been reported (Guttman et 
al., 2014, Julien et al., 2013a, Lyumkis et al., 2013), this region is flexible in SOSIP constructs 
terminating at position 664 and is involved in crystal packing here. As such, we cannot 
conclude whether this observation highlights a specific attribute of the 253-11 Env or more 
likely, is induced by the arrangement of 253-11 SOSIP.664 trimers in the crystal lattice. As an 
internal reference, such differences in the disposition of helices between 253-11 and the BG505 
trimer were not observed in gp120; all structural elements aligned well in this subunit (e.g. 
gp120 1, Fig 3.10d). 
Figure 3.10 Crystal structure of 253-11 SOSIP trimer in complex with 10-1074 Fab. (a) Side view 
of the crystal structure of 253-11 SOSIP trimer in complex with 10-1074 Fab. One of the protomers is 
highlighted. gp120 and gp41 are colored in yellow and cyan, respectively, and represented as surface 
and cartoon. The heavy chain (in black) and the light chain (in grey) of the 10-1074 Fab are represented 
as cartoon and are binding to the V3 base, specifically to the N332 glycan (represented as maroon 
spheres). Glycans for gp120 and gp41 are represented as spheres in yellow and cyan, respectively. (b 
and c) Bottom view of the 253-11 SOSIP.664 trimer crystal structure showing the Fo-Fc electron 
density map (green mesh) obtained after molecular replacement for (b) HR1 and (c) HR2. (d) Top vew 
of the 253-11 SOSIP trimer showing the 2Fo-Fc electron density map (blue mesh) for the gp120 α1 
helices. (e) A single 253-11 SOSIP.664 protomer represented as cartoon with gp120 (yellow) and gp41 
(cyan) represented along the trimer axis (dashed black line). 253-11 is superimposed with the HR1 and 
HR2 helices of BG505 (PDB IDs: PDBs: 5T3X, 5CEZ, 4ZMJ, 5ACO, 5C7K, 5FYL, 5I8H, 5D9Q, 
5THR, 5U1F, 5UTY, 5UTF, 5V8L and 5V8M); JR-FL (PDB: 5FYK); X1193.c1 (PDB: 5FYJ) and 
16055 (PDB:5UM8) trimers (all shown as cartoon in grey color). 
 
Comparison of the refined crystal structure of 253-11 with other Env trimer structures (PDBs: 
5T3X, 5CEZ, 5FYK, 5FYJ, 4ZMJ, 5ACO, 5C7K, 5FYL, 5I8H, 5D9Q, 5THR, 5U1F, 5UTY, 
5UTF, 5V8L, 5V8M and 5UM8) revealed that the 253-11 trimer complexed with 10-1074 Fab 
had HR helices that are more tightly positioned towards the trimer axis than all other solved 
HIV-1 trimer structures, except for BG505 SOSIP complexed with PGT128 and 8ANC195 
Fabs (PDB: 5C7K) (Fig. 3.10e). 
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3.3.5.2 253-11 had smaller gp120 inter-protomer distances than other trimers 
 
After molecular replacement, we also noted a clear difference in the disposition of the 253-11 
gp120 protomers along the trimer axis. Rigid body refinement slightly re-positioned the gp120 
protomers in closer proximity to the trimer axis. To investigate how compact gp120 protomers 
are within the 253-11 SOSIP.664 trimer compared to trimers of other sequence backbones, we 
calculated distances between the centre of masses of each of the three 253-11 gp120 protomers 
and compared the inter-protomer distances with other trimers for which the structures have 
been solved to date by X-ray crystallography and cryo-EM (Fig 3.11). Specifically, we 
compared gp120 inter-protomer distances for 253-11 and ligand-free BG505 trimer (PDB: 
4ZMJ), BG505 complexed with Fabs (PDBs: 5T3X, 5CEZ, 4NCO, 3J5M, 4TVP, 5ACO, 
5C7K, 5FYL, 5I8H, 5D9Q, 5THR, 5U1F, 5JSA, 5JS9, 5UTY, 5UTF 5V8L, 5V8M and 5UM8) 
and trimers derived from JR-FL (clade B) (PDB: 5FYK), X1193.c1 (clade G) (PBD: 5FYJ) 

















Figure 3.11 gp120 compactness of 253-11 SOSIP.664 trimer. (a) Top view of 253-11 SOSIP trimer 
showing the three gp120 protomers (yellow). The centre of mass (blue spheres) for each gp120 protomer 
was calculated using Pymol v1.8.6.0. The calculated distances between the protomers are represented 
as a blue line with the corresponding values. (b) Superposition of the centre of mass of each of the 
gp120 protomers for the 253-11 trimer (blue spheres) with 19 other SOSIP trimers. Yellow: X1193.c1; 
green: BG505 open trimer (PDB: 5THR); orange: JR-FL (PDB: 5FYK); pink: 16055 (PBD: 5UM8); 
grey: BG505 trimers (PBD IDs: 4ZMJ, 5T3X, 5CEZ, 4NCO, 3J5M, 4TVP, 5ACO, 5C7K, 5FYL, 5I8H, 
5D9Q, 5U1F, 5JSA, 5JS9, 5UTY, 5UTF, 5V8L and 5V8M) (c) Individual gp120 inter-protomer 
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distances are shown for the different trimers from the smallest to the largest. 253-11 trimer is highlighted 
in blue. The 253-11 trimer PDB ID will be deposited into the Protein Data Bank upon publication. 
 
253-11 had smaller gp120 inter-protomer distances compared to the clade B, C and G SOSIP 
trimers and had smaller or comparable gp120 inter-protomer distances as 13 of the BG505 
structures (PDB IDs: 5ACO, 5CEZ, 5JSA, 5JS9, 5C7K, 3J5M, 5U1F, 4TVP, 4NCO, 5T3X, 
5V8L, 5V8M). As an internal validation of our analysis, the CD4/17b/8ANC195-bound open 
structure of BG505 (PDB: 5THR) had the highest inter-protomer distances out of the trimers 
analysed (Fig 3.11c). Interestingly, engineered stabilisations in BG505 trimers (PDB: 5U1F, 
5UTY, 5UTF)  (Chuang et al., 2017, Liu et al., 2017) did not substantially affect distances 
between the three gp120 protomers. Taken together, our structural data support the hypothesis 
that the 253-11 Env sequence encodes for a generally compact structure that is linked to a 
highly neutralisation resistant phenotype for this virus. 
  
 




A global HIV-1 vaccine will likely need to protect against antibody neutralisation resistant 
viruses to effectively reduce HIV-1 incidence. Therefore, an understanding of the mechanisms 
employed by viruses to gain neutralisation resistance is critical. Most HIV-1 immunogen 
research focuses on closed, pre-fusion Env trimers to elicit bnAbs, however, immunisation 
studies with BG505 and other Tier 2 SOSIP trimers have largely yielded autologous responses 
(Sanders et al., 2015, de Taeye et al., 2015, Klasse et al., 2016) despite further modifications 
to increase trimer stability (Chuang et al., 2017, de Taeye et al., 2015) and trimer delivery 
through different methods such as nanoparticle presentation (Sliepen et al., 2015). Therefore, 
a further understanding of the mechanisms used by Tier 3 HIV-1 isolates to evade neutralising 
responses and the development of trimers based on these Tier 3 viruses may aid in the design 
of immunogens capable of eliciting bnAbs. 
 
To gain insight into the structure of 253-11 Env, we constructed a 253-11 SOSIP.664 
recombinant trimer. 253-11 SOSIP trimers predominantly adopt a closed, pre-fusion 
conformation that is comparable to BG505 SOSIP trimers. This indicates that the compactness 
phenotype we hypothesize for 253-11 is not a global structural characteristic but likely caused 
by local, discrete changes in secondary structure elements.  
 
253-11 SOSIP trimers were thermostable and strikingly, addition of a (His)6x-tag at the C 
terminus increased the thermostability of the trimer. The (His)6x-tag has been used to 
incorporate trimers into liposomes and resulted in well-ordered, highly stable trimers which 
remain in a tight trimeric conformation over extended periods of time (Ingale et al., 2016). 
More studies focusing on the role of the (His)6x-tag in trimer stability should be performed 
because its addition to SOSIP trimers is likely useful in increasing thermostability.  
 
The 253-11 SOSIP trimers were bound well by Fabs derived from antibodies which potently 
neutralise the virus and not by antibodies that don’t neutralise the virus. This indicates that the 
trimers likely resemble functional trimer spikes on the 253-11 pseudovirus. More antibodies 
may need to be tested to further ascertain that the 253-11 SOSIP trimer correctly displays the 
gp120-gp41 interface bnAb quaternary epitope and the fusion peptide bnAb epitope while 
occluding other narrowly- and non-neutralising epitopes. 
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Unlike the crystallization of small, homogenous and less complex proteins, HIV-1 Env trimer 
crystallization is generally challenging (Ward and Wilson, 2017). This is because of dense 
glycosylation, protein flexibility and the overall size of the trimer (~250 kDa) (Ward and 
Wilson, 2017). Therefore, 253-11 trimer crystallization required numerous preparatory and 
optimisation steps. The trimer needed to be expressed in HEK293S cells to ensure it contained 
high-mannose glycans, which were subsequently cleaved by the Endo H glycosidase. 
Crystallization of unliganded trimers is also challenging and therefore the 253-11 trimer was 
complexed with a Fab in the hope that it would increase the stability of the closed, pre-fusion 
conformation. To further improve crystal diffraction, microseeding and dehydration techniques 
were also used.  
 
We crystallized the trimer in complex with 10-1074 Fab. This antibody is of particular interest 
in HIV-1 research because in a recent human trial to determine whether it can therapeutically 
control the virus in HIV-1-infected individuals, 10-1074 suppressed viremia in participants for 
an extended period of time (Caskey et al., 2017) and therefore is likely a good therapeutic 
vaccine candidate. The crystal structure of the 253-11 trimer in complex with 10-1074 Fab 
indicated that the gp41 HR1 and HR2 helices are in a more compact disposition relative to the 
trimer axis than most trimer structures solved to date. In addition, our data support a molecular 
mechanism of interconnectedness between inward movements in gp41 HR helices and 
relatively small distances between gp120 protomers for 253-11. Together, this suggests a 
compact phenotype that co-exists with the high neutralisation resistance of this virus. We 
hypothesize that the 253-11 MPER may be less accessible because of the inward disposition 
of the gp41 HR helices and may in part explain why 253-11 is so resistant to anti-MPER 
antibodies prevalent in sera. We cannot address this point directly because the MPER is not 
present in SOSIP constructs. 
 
One of the limitations of the study was the medium-resolution obtained from the 253-11 SOSIP 
trimer crystals. A high-resolution structure would have allowed us to observe the trimer at an 
atomic level. Since we were limited to secondary structure analysis, we may be missing key 
atomic information which could be contributing to the neutralisation resistance phenotype of 
the 253-11 virus. 
 
To date, few published SOSIP trimers based on neutralisation resistant viruses have been 
engineered. One example is PVO.4 (Verkerke et al., 2016), which is more neutralisation 
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sensitive than 253-11 when tested for sensitivity to a panel of Subtype C sera (Jacob et al., 
2015). The development of a SOSIP trimer which contains the neutralisation resistance and 
Env compactness properties of the 253-11 virus thus enables future studies of Tier 3 Env 
structure and immunogenicity. The use of trimers has so far proven ineffective in producing 
broad responses (Klasse et al., 2016) but a compact Tier 3 trimer may overcome this problem 
(Cai et al., 2017). 
 
Most of the SOSIP trimers which have been engineered are derived from transmitter/founder 
(TF) viruses (Julien et al., 2015, Verkerke et al., 2016, deCamp et al., 2014, Sanders et al., 
2013). The 253-11 virus was isolated in chronic infection at Fiebig Stage VI (Seaman et al., 
2010). SOSIP trimers based on chronic viruses, CAP45 and CH505, failed to produce good 
quality trimers (Julien et al., 2015) which further illustrates that producing SOSIPs from 
chronic infection is challenging. The 253-11 SOSIP trimer, being one of a few based on a virus 
from chronic infection, can therefore also shed light on the structure of chronic viruses and 
may be an invaluable tool in HIV-1 pathogenesis studies. 
 
In summary, we present evidence that 253-11 is particularly resistant to antibody neutralisation, 
which coincides with an unusually compact, closed Env structure. The ability of a virus to 
escape from all but the most broad antibody responses through relatively discrete structural 
characteristic has strong implications for understanding how viruses might circulate in a 
population of individuals who have moderate antibody responses induced by a future vaccine.
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Chapter 4: Role of HIV-1 V3/glycans in breadth, potency and 




The HIV-1 Envelope (Env) V3/glycans form a protective “glycan shield, protecting the V3 
loop and CD4-binding site (CD4-bs) from antibody neutralisation. However, some broadly 
neutralising antibodies (bnAbs) have evolved to target this region making it an attractive 
vaccine target. Understanding the role of the V3/glycans in shielding antibody epitopes in 
natural infection and how some viruses have evolved to maintain their neutralisation resistant 
phenotypes in the absence of certain glycans may provide insight into HIV-1 evolution and 
pathogenesis and may be important in the design of a glycan-based immunogen.  
 
We, therefore, investigated two aspects of the V3/glycan epitope. The first aspect explored 
whether there is an association between antibody breadth and potency and the presence of 
V3/glycan-specific antibodies in sera. There were no previously published systematic studies 
of specific epitopes being preferentially targeted by commonly-occurring, moderately 
neutralising antibodies found in sera. Therefore, we measured the relationship between the 
presence of V3/glycan-specific antibodies and neutralisation breadth and potency, and 
compared this to V2/apex-specific antibodies. We screened 177 sera samples from chronically 
HIV-1-infected individuals to assess their breadth and potency. We then explored which sera 
recognised the V3/glycan-site using N301A.N332A mutations and the V2/apex using 
N160A/K and I/K169E mutants in three viral isolates. We found that recognition of the 
V3/glycans was independently associated with breadth and potency, while recognition of the 
V2/apex was not.  
 
Secondly, upon observing this important association, we investigated how the V3/glycans may 
be contributing to antibody neutralisation resistance in HIV-1 isolates. We examined the role 
of key glycans at the base of the V3 loop (N301, N332 and N334) in maintaining the integrity 
of the glycan shields of two subtype C viruses, CAP45.2.00.G3 (CAP45.G3) and Du156.12. 
We considered that these glycans are themselves targets of neutralising antibodies and that may 
select for their loss, while simultaneously antibodies targeting epitopes blocked by the 
V3/glycans may select for their retention. The removal of the N301 glycan from Du156.12 
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exposed epitopes recognised by neutralising antibodies in 28% of sera tested, whilst removal 
of the same glycan from CAP45.G3 resulted in exposure of epitopes recognised by neutralising 
antibodies in only 5% of the sera tested. This suggests that removal of the N301 glycan did not 
substantially affect the integrity of the glycan shield in CAP45.G3 but did in Du156.12. The 
different roles of the N301 glycan in the preservation of the glycan shields of CAP45.G3 and 
Du156.12 were further observed with differences in susceptibility to anti-CD4-binding site 
monoclonal antibodies upon removal of the glycan in Du156.12 compared to CAP45.G3.  
 
Together, these data show that differences in the contribution of the glycan at N301 in overall 
resistance to antibodies commonly elicited in HIV-1-infected individuals differs between 
viruses. While V3/glycan-specific antibodies may select for loss of the N301 glycan, the cost 
in neutralisation sensitivity of this selection may be very low in some viruses, as we observed 
for CAP45.G3, yet substantially higher in others, as we observed for Du156.12. The efficacy 
of passively-infused antibody therapies or a vaccine based on the V3/glycan target may be 
affected by this phenomenon. 
  
 




The V3/glycans and the V2/apex are amongst the targets of broadly neutralising antibodies 
(bnAbs) (Moore et al., 2017, Doores, 2015, Mouquet, 2014, Burton et al., 2012). These sites 
are attractive vaccine targets and efforts to elicit antibodies towards them is ongoing (Moore et 
al., 2017, Sanders and Moore, 2017, Zhou et al., 2014, Alam et al., 2017). The V2/apex is a 
quaternary epitope which usually (Moore et al., 2017, Doores and Burton, 2010) but not always 
(Doria-Rose et al., 2015) relies heavily on stabilisation by the glycan at N160. Antibodies 
which target the V3/glycan epitope depend heavily on the presence of the N301 and/or N332 
glycans (Walker et al., 2011, Doores, 2015), although some of this class of antibodies are able 
to recognise other glycans, particularly PGT121 (Sok et al., 2014). Most N332-dependent 
antibodies also rely on the underlying V3 loop 324GDIR327 motif for binding (Garces et al., 
2015, Garces et al., 2014, Sok et al., 2016). 
 
Some bnAbs targeting the V3/glycans and membrane proximal external region (MPER) – 
another bnAb target - have been found to be self-reactive (Haynes et al., 2005, Liu et al., 2015, 
Verkoczy and Diaz, 2014). V3/glycan-specific antibodies such as PGT125 and PGT128 were 
shown to be polyreactive – recognising multiple self-proteins with low affinity (Liu et al., 
2015) whilst MPER antibodies such as 2F5, 4E10 and 10E8 are autoreactive – binding to a 
discrete number of self-proteins with high affinity (Liu et al., 2015, Haynes et al., 2005). Liu 
et al. characterised 4E10 as polyreactive although Haynes et al., characterised it as 
autoreactive. Very few bnAbs which target the V2/apex have been shown to be autoreactive. 
In the study by Liu et al., only 1 out of 5 V2/apex-specific antibodies tested showed evidence 
of polyreactivity (Liu et al., 2015). 
 
Self-reactivity may be a barrier in the production of bnAbs, as self-reactive B cells are thought 
to be frequently deleted from the repertoire (Haynes et al., 2005, Verkoczy and Diaz, 2014). 
However, despite the autoreactivity of particular MPER-specific antibodies, the presence of 
antibodies recognising the MPER in natural infection is associated with higher neutralisation 
breadth and potency (Jacob et al., 2015). Therefore, an investigation of an association between 
breadth and potency and targeting other sites such as the V3/glycans (with known 
polyreactivity) and the V2/apex (with very little polyreactivity) is of interest. 
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Although the glycans at the base of the V3 loop (N301, N332, N334) are targets of bnAbs 
(Walker et al., 2011), they also block underlying and distal epitopes, contributing to the HIV-
1 Env “glycan shield” (Wei et al., 2003, Pantophlet and Burton, 2006, Zolla-Pazner et al., 
2015). The N301 glycan at the base of the V3 loop protects distal epitopes from antibody-
mediated neutralisation such as the CD4-binding site (CD4-bs) and protects underlying, highly 
neutralisation sensitive, V3 loop epitopes (Binley et al., 2010, Koch et al., 2003, Zolla-Pazner 
et al., 2015).  
 
Glycans at positions N332 and N334 are mutually exclusive due to the overlapping N-X-T/S 
(where X ≠ P) motif (Marshall, 1972). The N332 glycan is recognised by anti-V3/glycan bnAbs 
including the PGT-family of antibodies (Walker et al., 2011), 10-1074 (Mouquet et al., 2012) 
and 2G12 which binds this site distinctly from the rest and is almost exclusively dependent 
upon direct binding to the glycan (Trkola et al., 1996, Sanders et al., 2002). Some moderately-
neutralising precursors of PGT121-123 bnAb lineages depend on both glycans at positions 
N301 and N332 for binding, while the mature bnAbs gain higher affinity for the N332 glycan 
(Sok et al., 2013). This suggests that antibody dependence on glycans is a dynamic process, 
changing with the evolution of those antibodies. N332-dependent antibodies are sometimes 
able to bind to other glycans in the absence on the N332 glycan, including the N334 glycan 
(Sok et al., 2014).  
 
Antibodies which recognise epitopes shielded by the V3/glycans may select for viruses which 
express the shielding glycans whilst V3/glycan-specific bnAbs may select for viruses which 
lack these glycans. There is little known about how glycan shield construction affects 
contemporaneous antibody-mediated selection against or for the glycans on the V3 loop. 
Therefore, in this chapter we first investigated whether there is an association between breadth 
and potency and the targeting of the V3/glycans and the V2/apex in sera from a cohort of 
antiretroviral therapy (ART)-naïve, chronically HIV-1-infected individuals. This study sheds 
light on whether polyreactivity would limit the breadth and potency of antibody responses 
towards the V3/glycans as opposed to the V2/apex. Previously, targeting the V2/apex was not 
found to be associated with breadth and potency, however, that study only mapped V2/apex 
responses using a single virus (Jacob, 2014) and therefore we aimed to perform a more robust 
analysis by using 3 viruses altogether to map V2/apex-specific responses. Using 3 viruses 
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increased the proportion of sera that could be mapped. Sera can only be mapped if they 
neutralise the parent virus because a reduction in neutralisation after mutating out the epitope 
is what must be observed to map sera to the epitope. We, then investigated the role of the 
V3/glycans at positions N301, N332 and N334 on antibody neutralisation resistance to 





Chapter 4: V3/glycans and antibody responses  Page 85 
 
4.2 Materials and Methods 
 
4.2.1 Sera samples 
 
Sera samples from chronically (>1-year) HIV-1-infected participants, >18 years of age from 
Cape Town were collected from December 2009 to July 2011. Participants were ART naive, 
except for ART given transiently to participants for prevention of mother-to-child transmission 
>3 months before recruitment. Participants who were recruited were either (i) caregivers at the 
paediatric HIV Clinic in Groote Schuur Hospital, Cape Town or (ii) patients at the HIV 
Wellness Clinic in Site B clinic, Khayelitsha, Cape Town. Written, informed consent was 
obtained from the participants and the study was approved by the Human Research Ethics 
Committee, University of Cape Town. 
 
4.2.2 Pseudovirus constructs, monoclonal antibodies and cell lines 
 
Cloned HIV-1 envelope constructs were obtained through the National Institute of Health, 
AIDS Reagent Program, except for Du156.12 wild type (WT), N301A, N160K, K169A and 
CAP45.2.00.G3 WT (herein CAP45.G3), N160A and K169E, which were provided by Drs. E. 
Gray, P.L. Moore and L. Morris, South Africa. Mutants of QH343.21M.ENV.A10 (herein 
QH343.A10) (N301A, N301A.N332A, N160A, I169E), of CAP45.2 (N301A), of Du156.12 
(N301A.N332A) and of 253-11 (N301A) were generated using the GeneArt® Site-Directed 
Mutagenesis PLUS Kit (Invitrogen). V3/glycan mutants of CAP45.G3 and Du156.12 
expressing different combinations of potential N-linked glycosylation sites (PNGs) at N301, 
N332 and N334 were similarly produced by site-directed mutagenesis. Amino acids were 
mutated as follows: PNG 301 removal: N301A; PNG 332 removal, N332A; PNG 334 removal: 
N334A; PNG 334 shift to PNG 332 for CAP45.G3: N334T; PNG 332 shift to PNG 334 for 
Du156.12: S334N.N336T. Successful mutagenesis and the absence of unintended mutations 
during PCR were confirmed by sequencing both strands of the entire env open reading frame. 
Monoclonal antibodies (mAbs) PG9 and 10E8 were obtained from Polymun Scientific, Austria 
and from the National Institute of Health, AIDS Reagent Program. mAbs NIH45-46G54W 
(herein NIH45-46), 3BNC117, VRC01, b12, soluble CD4 (sCD4), 2219, 3869 and 3074, as 
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well as the pSG3Δenv HIV-1 backbone plasmid, human embryonic kidney (HEK) 293T and 
TZM-bl cells were obtained from the National Institute of Health, AIDS Reagent Program.  
 
4.2.3 Pseudovirus generation and antibody-based neutralisation assays 
 
HIV-1 pseudoviruses were made by co-transfection of HIV-1 env  and pSG3Δenv plasmids in 
HEK 293T cells as previously described (Montefiori, 2005). After 48 hours, supernatant 
containing pseudovirus was harvested and frozen at -80°C in single use aliquots. Antibody 
neutralisation assays were performed as previously described (Montefiori, 2005). Briefly, 
antibody and virus were incubated for one hour at 37˚C, and then 104 TZM-bl cells were added 
per well to the antibody-virus combination and incubated at 37˚C for 48 h. Titers (dilution of 
serum [ID50] or concentration of mAb [IC50] that inhibits 50% of infection) were calculated 
using curve fit functions in Prism 5 (GraphPad). The Chi-square (χ2) test was used to test the 
statistical significance of differences in proportions between sera in particular groups.  
 
4.2.3 Neutralisation breadth and potency comparison between sera targeting HIV-1 
Envelope epitopes 
 
Breadth and potency of 177 sera from our cohort was determined using a 24-virus panel (Jacob 
et al., 2015) consisting of Tier 2 and neutralisation resistant Tier 3 viruses (Seaman et al., 2010, 
Blish et al., 2009).  A broadly neutralising sample was defined as such if it neutralised ≥18/24 
viruses at ID50≥100 and a potently neutralising sample was defined by a geometric mean 
ID50≥220 for the 24-virus panel (Jacob et al., 2015). Aggregated breadth and potency values 
for sera which targeted the three epitopes (V3/glycans, V2/apex or MPER) was calculated and 
summarised by means of ratios (for potency) and differences (for breadth) and was compared 
to sera that did not map to those sites. Wilcoxon rank sum analysis was used to determine 
distribution differences between breadth and potency. Bootstrap estimation (Hastie et al., 2002) 
was used for estimation of the confidence intervals between the differences and ratios 
calculated; an estimation of the error in the determination of each serum’s neutralisation 
breadth and potency was included. Multivariate analysis was conducted using a linear 
regression model on Stata/IC v13.1 (StataCorp). 
 
Chapter 4: V3/glycans and antibody responses Page 87 
4.3 Results 
4.3.1 Determination of the frequency of sera targeting the V3/glycans and V2/apex 
epitopes 
In a previous study from our research group, the frequency of anti-MPER antibodies in our 
cohort was determined by mapping 177 sera with HIV-2/HIV-1 chimeric viruses (Jacob et al., 
2015). The constructs used were made with a 7312A HIV-2 backbone and an HIV-1 MPER 
from either the consensus C sequence, C1C (Gray et al., 2007a), Yu2 MPER sequence, C1 
(Gray et al., 2007a, Binley et al., 2008) or the MPER from a CRF02_AG virus, 253-11 (Jacob, 
2014) (Fig 4.1a). Previous studies have shown that an ID50>1000 obtained when sera are tested 
with these constructs is associated with the presence of anti-MPER activity in the samples 
(Gray et al., 2007a, Binley et al., 2008, Gray et al., 2009a, Jacob et al., 2015). Nineteen percent 
(33/177) of serum samples recognised one or more of the 3 chimeric viruses (Jacob et al., 2015) 
(Fig 4.1b, Table 4.1). 
We investigated the frequency of antibodies which recognise the V2/apex and the V3/glycans. 
To map antibodies targeting the V3/glycans and V2/apex, we introduced mutations to residues 
critical for formation of these epitopes. These mutations abrogate antibody binding to these 
sites. Mutational mapping determines which epitope is targeted by the dominant antibodies 
present in a serum sample by detecting a substantial drop in neutralisation in the mutant virus 
compared to its unmutated parent. For the V2/apex, we introduced N160A/K mutations to 
prevent addition of the key, stabilising glycan at N160 (Doores and Burton, 2010) and also 
introduced I/K169E mutations (Tomaras et al., 2008, Moore et al., 2011) (Fig 4.1a). These 
mutations were introduced into three viruses: subtype C, Tier 2 viruses CAP45.G3 (tested in 
(Jacob, 2014), Du156.12 and subtype A virus, QH343.A10. QH343.A10 has not been 
categorised into a tier, however, studies from our laboratory (Moyo, 2014) and others (Blish et 
al., 2009) have shown that it is highly neutralisation resistant to subtype C and other serum 
panels.  
The effect of mutations in one site upon neutralising epitopes in distal sites has been somewhat 
well studied for anti-HIV neutralisation. For example, an N160A mutation in the V2/apex 
marginally reduces neutralisation (2-3-fold difference) of some anti-V3/glycan monoclonal 
antibodies (Walker et al., 2011). In another report, Wang and colleagues found that an N301Q 
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mutation in the V3/glycan region induced only marginal drops (up to 2-fold) in neutralisation 
by a series of bnAbs, including PG9 and PG16 which target the V2/apex (Wang et al., 2013). 
Another study found that antibodies that recognise the V2/apex were unaffected by N332A 
mutants (Tomaras et al., 2011). Because drops in neutralisation due to mutations outside of the 
antibody’s epitope were mostly <3-fold in these studies, we chose a >3-fold threshold in our 
study. 
Figure 4.1 Mapping responses to the MPER, V2/apex and V3/glycans. (a) Schematic of approach 
used to map sera to the three bnAb sites. C1, C2, C3: constant region 1,2, 3; V1, V2, V3: Variable loop 
regions 1, 2, 3; HR2: Heptad Repeat 2; TM, transmembrane domain; CT, cytoplasmic tail. (b) 
Distribution of MPER-specific responses towards the three MPER chimeric viruses. Gray shading 
indicates MPER-positive samples (log scale). (c, d, e) Distribution of fold drops in neutralisation from 
WT to (c) N160A/K mutants (d) K/I169E mutants (e) N301A or N301A.N332 mutants. Gray shading 
indicates (c, d) V2/apex-specific and (e) V3/glycan-specific hits. (Note: MPER data from (Jacob et 
al., 2015)). 
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Twenty-nine percent (34/118) of sera were mapped to the V2/apex epitope (recognized ≥1 
mapping virus) (Fig 4.1c and d, Table 4.1). Interestingly, 10 samples neutralised the samples 
better on removal of the N160 PNG (i.e. fold drop ≤ 0.33) (Fig 4.1c). It is likely that the removal 
of the N160 glycan exposed underlying epitopes recognised by antibodies present in these 
samples. 
To map for V3/glycan-specific antibodies, we constructed double mutants of N301A.N332A 
to prevent the addition of these two key glycans; one or both of which is necessary for 
neutralisation by every characterised V3/glycan-specific mAb (Walker et al., 2011, Mouquet 
et al., 2012, Sanders et al., 2002) (Fig 4.1a). These mutations were introduced into the same 
WT viruses as for V2/apex mapping. CAP45.G3 does not possess a PNG at N332 and therefore 
a single N301A mutant was engineered. Nineteen percent (21/113) of sera samples from our 
cohort recognised at least one of the three viruses through targeting the V3/glycans (Fig 4.1e, 
Table 4.1). 
Table 4.1 Comparison of the likelihood of being a broadly or potently neutralising 
antibody depending upon target recognition of neutralising antibodies 
(Note: MPER data from (Jacob et al., 2015)). 
A ≥3-fold drop in neutralisation from WT to mapping mutant was used as the threshold to 
determine whether a serum sample contained dominant antibodies towards that site, similar to 
the threshold used by others (Gray et al., 2011a). Therefore, since the sera had to initially 
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neutralise the WT virus to be mapped, only the subset of the 177 samples which neutralised at 
least one of the 3 WT viruses with ID50≥100 were analysed.  
 
 
4.3.2 Assessment of the association between breadth and potency and targeting the 
V3/glycans and V2/apex  
 
The 177 sera samples from our cohort were tested for breadth and potency. 18% were found to 
be broad (neutralised ≥18/24 viruses) and 16% were potent (geometric mean ID50 ≥220) with 
a strong correlation between breadth and potency (Jacob et al., 2015). Using these samples, the 
presence of anti-MPER antibodies was found to be associated with breadth and potency (Jacob 
et al., 2015, Jacob, 2014).  We therefore, investigated whether there was any association 
between the presence of anti-V3/glycan or anti-V2/apex antibodies and breadth and potency 












Figure 4.2 Neutralisation breadth and potency differences between sera targeting particular 
epitopes. Comparisons of the distribution of neutralisation (a, c, e) breadth and (b, d, f) potency are 
shown for (a, b) MPER positive and negative sera, (c, d) anti-V3/glycan positive and negative sera and 
(e, f) V2/apex positive and negative sera. p values obtained from Wilcoxon rank sum tests. (Note: 
MPER data from (Jacob et al., 2015)). 
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Sera with dominant V3/glycan-specific antibodies were broader and more potent than sera 
which were not demonstrably V3/glycan-specific (Fig 4.2 c, d). Using a bootstrap-based 
method to include an estimate of the error in determining the breadth and potency of individual 
sera, we found that sera with dominant anti-V3/glycan antibodies on average neutralised 3.24 
more viruses and were on average 1.68-fold more potent (Fig 4.3) than sera without V3/glycan 
antibodies. They were twice as likely to be highly broadly neutralising and 2.32 times more 




















Figure 4.3 Neutralisation breath and potency changes between the three epitopes. Changes in (a) 
breadth and (b) potency were investigated for positive and negative samples within one epitope and 
between different epitopes. Differences in breath were calculated by subtraction of viruses neutralised 
while differences in potency were calculated by ratios of geometric mean ID50 values. No difference 
between number of viruses neutralised (breadth) = 0; no difference between geometric mean ID50 values 
(potency) =1. A 95% prediction interval was calculated for all the values by bootstrap-based error 
estimation. (Note: MPER data from (Jacob et al., 2015)). 
 
In contrast, we did not observe an association between the presence of V2/apex-specific 
antibodies in sera and neutralisation breadth and potency. Sera containing dominant V2/apex 
antibodies were not more broad or potent than sera which did not contain these antibodies (Fig 
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4.2e, f). V2/apex-positive samples only neutralised a negligible number of panel viruses (0.38 
more viruses) as compared to V2/apex negative samples (Fig 4.3). V2/apex-specific samples 
were not more potent that negative samples either (0.98-fold difference) (Fig 4.3).  
 
A multivariate analysis was conducted to investigate which of the three epitopes was 
independently associated with breadth and potency (Table 4.4). For breadth, the regression 
coefficients represent how many more viruses are neutralised by antibodies targeting either the 
V3/glycans, V2/apex or MPER compared to antibodies that do not target these sites (without 
the bootstrapping or error estimation that was included in the values in Fig 4.3). For potency, 
the regression coefficients represent how much more potent (defined by geometric mean ID50 
values for neutralisation of the 24-virus panel) a sample is if it targets one of the 3 epitopes as 
compared to antibodies that do not. If the 95% confidence interval crosses over zero, it means 
there is no significant difference in breadth and potency between the antibodies targeting that 
site and those which do not. Strikingly, of the three targets tested, only the V3/glycans were 
independently associated with neutralisation breadth and potency in the multivariate analysis 
(Table 4.2). 
 
Table 4.2 Multivariate analysis of association of breadth and potency with targeting the  
 V3/glycans, V2/apex and MPER 
 
 
As our results show, targeting the V3/glycans, and not the V2/apex, is associated with breadth 
and potency in natural infection. In addition to being targeted by bnAbs (Walker et al., 2011) 
and being amenable to scaffold immunogen design (Zhou et al., 2014), our data further suggests 
that the V3/glycans are an achievable vaccine target. The fact that targeting the V3/glycans is 
associated with breadth and potency, suggests that these antibodies are commonly broad and 
potent in unselected sera and that it may be easier to elicit broad and potent antibodies to the 
V3/glycans after vaccination.  
 
 Regression Coefficient (95% confidence interval) 
 V3/glycans P value V2/apex P value MPER P value 
Breadth 3.13 (0.46 - 5.79) 0.022 0.05 (-2.22 - 2.32) 0.965 1.18 (-1.32 - 3.68) 0.35 
Potency 70.1 (1.01 - 139) 0.047 -27.9 (-86.6 - 30.8) 0.349 15.4 (-49.3 - 80.2) 0.47 
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However, this epitope is not only recognised by bnAbs but also serves to protect HIV-1 Env 
from neutralisation, forming a “glycan shield” (Ward and Wilson, 2017, Wei et al., 2003). 
Therefore, we investigated the interplay between the selection of glycans which block antibody 
epitopes and those which are recognised by bnAbs to better understand how this may drive 
V3/glycan evolution in viral escape variants. 
 
4.3.3 N301 glycan plays a key role in glycan shield integrity of Du156.12 and not in 
CAP45.G3 
 
We investigated the role of the N301 glycan in maintaining glycan shield integrity in two 
viruses, CAP45.G3 and Du156.12. These two viruses were chosen because they are similar in 
many ways. They are both subtype C, CCR5-dependent viruses obtained from acute infection 
in female donors from KwaZulu-Natal, South Africa (Li et al., 2006, Williamson et al., 2003). 
They are both Tier 2 viruses (Seaman et al., 2010) but differ in their glycan shield composition. 
CAP45.G3 has PNGs at positions N301 and N334 whilst Du156.12 has PNGs at positions 
N301 and N332. To understand whether these differences affect the maintenance and protective 
function of their glycans shields we made viral mutants with all three glycan combinations 
(N301, N332 and N334) (Table 4.3).  
Table 4.3. Nomenclature used for pseudovirus mutants containing different combinations 








We tested these viral mutants with 64 randomly-selected sera from our cohort of chronically 
HIV-1-infected, ART-naïve participants to see how viral sensitivity shifts on removal or 
substitution of glycans. An increase in neutralisation sensitivity from one glycan variant to 
another was defined as a ≥3-fold increase in ID50, while a decrease in neutralisation was defined 
as a decrease in ID50 of ≥3 fold, a threshold others have previously used (Gray et al., 2011a). 
An increase in neutralisation sensitivity of a glycan-deleted variant was interpreted to be a 
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result of exposure of epitopes upon the removal of the glycan whilst a decrease in neutralisation 
sensitivity was interpreted to indicate that the removed glycan formed a key part of the epitope 
recognised by dominant antibodies in that serum sample. 
 
Strikingly, on removal of the N301 glycan from CAP45.G3 and Du156.12, Du156.12 was 
significantly more sensitive to neutralisation by a larger proportion of sera (p<0.0005, χ2 test) 
as compared to CAP45.G3 (Fig 4.4). Du156.12 became more sensitive to neutralisation by 
18/64 (28%) of sera upon removal of the glycan at position N301 whilst CAP45.G3 was only 
sensitive to 3/64 sera samples tested upon removal of the N301 glycan suggesting that the 
dependence on the glycan at N301 for neutralisation resistance differed between the two 
viruses.  
Figure 4.4 Removal of the N301 glycan increase neutralisation sensitivity of Du156.12 WT but 
not CAP45.G3 WT. Neutralisation of Du156301.332* and CAP45301.334* WT viruses and mutants without 
the N301 glycan was tested with 64 sera samples from HIV-1-infected individuals. Individual lines of 
the graph correspond to the change in sensitivity of one serum sample. Increases in neutralisation are 
shown in red lines and decreases in neutralisation are shown in blue lines. No change in neutralisation 
is shown in grey lines. The p value represents the difference in proportion of sera which Du156301.332* 
and CAP45301.334* had increased sensitivity to upon mutating out the N301 glycan. 
 
4.3.4 Removal of the N301 glycan increases Du156.12 neutralisation sensitivity 
irrespective of the presence of an N334 or N332 glycan 
 
To investigate whether the naturally-occurring N334 glycan in CAP45.G3 was compensating 
for the loss of the N301 glycan, we shifted the glycan from position N332 to N334 in Du156.12 
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to create Du156301.334. The N301 glycan was removed from both viruses containing N334 
glycans and the changes in sensitivity to sera were found to be similar as those of the WT 
viruses (Fig 4.5). Du156301.334 was still significantly more sensitive than CAP45301.334* WT to 
antibody neutralisation upon removal of the N301 glycan, with increased sensitivity to 19/51 
sera samples tested, despite the presence of the N334 glycan (Fig 4.5). 
 
 
Figure 4.5 N332 to N334 shift does not restore integrity of glycan shield upon removal of N301 
glycan in Du156.12. Differences in neutralisation sensitivity between Du156301.334 and CAP45301.334* 
(both viruses possessing glycans at position N334) with and without the N301 glycan were investigated 
by testing the viruses with 51 (Du156301.334) and 64 (CAP45301.334*) sera. Each line of the graph 
corresponds with the change in sensitivity of one serum sample. Individual lines of the graph correspond 
to the change in sensitivity of one serum sample. No change in neutralisation is shown in grey lines. 
The p value represents the difference in proportion of sera which Du156301.334 and CAP45301.334* had 
increased sensitivity to upon mutating out the N301 glycan. 
 
To determine whether the glycan at position N332, which is naturally found in Du156.12, was 
affecting the role of the N301 glycan in protecting Du156.12 from neutralisation but not 
CAP45.G3, we shifted the N334 glycan in CAP45.G3 to N332 (CAP45301.332) and tested this 
mutant for sensitivity to our sera samples. The removal of the N301 glycan on the CAP45301.332 
mutant result in increased sensitivity to 8 sera samples (as opposed to 3 with the naturally-
occurring N334 glycan (Fig 4.5)). Nonetheless, CAP45301.332 still exhibited N301 glycan-
dependent sensitivity to significantly fewer sera (p=0.028) than Du156301.332* (Fig 4.6).  
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Figure 4.6 Shifting the glycan at N334 to N332 in CAP45.G3 does not substantially affect its 
neutralisation sensitivity upon removal of the N301 glycan. Differences in neutralisation sensitivity 
of Du156301.332* and CAP45301.332 (both viruses possessing glycans at position N332) with and without 
the N301 glycan were investigated by testing the viruses with 64 sera samples. Each line of the graph 
corresponds with the change in sensitivity of one serum sample. Individual lines of the graph correspond 
to the change in sensitivity of one serum sample. No change in neutralisation is shown in grey lines.  
The p value represents the difference in proportion of sera which Du156301.332* and CAP45301.332 had 
increased sensitivity to upon mutating out the N301 glycan. 
 
Altogether, these data suggest that irrespective of the neighbouring glycan, the removal of the 
N301 glycan in Du156.12 creates a greater glycan shield “hole” resulting in more exposed 
epitopes as opposed to CAP45.G3 which maintains its glycan shield integrity in the absence of 
the N301 glycan. 
 
Although not the focus of the study, it should be noted that as expected, removal of the N301 
glycan resulted in a decrease in neutralising activity of some of the sera samples (blue lines, 
Figs 4.4-4.6). This is presumably because the dominant antibodies in those sera are dependent 
on the N301 glycan and therefore, its removal results in a decrease in neutralising activity. 
N301 glycan-dependent neutralisation by V3/glycan-specific antibodies has been observed in 
many studies (Walker et al., 2011, Mouquet et al., 2012, Garces et al., 2014, Sok et al., 2013). 
Differences between the proportions of sera with dominant antibodies targeting the N301 
glycan was relatively minor between Du156.12 and CAP45.G3.. 
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4.3.5 Glycans at positions N332 and N334 play in a role in blocking neutralising 
antibodies in sera 
 
We next assessed the role of the glycans at positions N332 and N334 on maintaining the 
integrity of the glycan shield and blocking Env neutralisation by antibodies in sera. To do this, 
we mutated out the N332 and N334 PNGs but retained the PNG at N301. The removal of the 
glycans at positions N332 and N334 had a smaller effect on Du156.12 sensitivity than 
removing the N301 glycan alone (Table 4.4). This again highlights that the N301 glycan is 
particularly essential in the maintenance of the Du156.12 glycan shield.  
 
Table 4.4 Effect of removal of either the 332 or 334 PNG on neutralisation sensitivity for 
both Du156.12 and CAP45.G3, while retaining the 301 PNG. 
 
Removal of the N332 and N334 glycans in CAP45.G3 hardly increased neutralisation 
sensitivity of the virus in the same way that the removal of the N301 glycan had little effect on 
CAP45.G3 sensitivity (Table 4.4). Therefore, we can conclude that the individual V3/glycans 
in CAP45.G3 are not playing dominant roles in the maintenance of the glycan shield of this 
virus on their own. 
 
4.3.6 Distinct differences between CAP45.G3 and Du156.12 sensitivity to mAbs after 
removal of N301 glycan 
 
We examined the impact of the removal of the N301 glycan on the neutralising activity of 
mAbs which target different bnAb epitopes on Env. First, we tested the Du156.12 and 
CAP45.G3 WT viruses and mutants lacking the N301 glycan with V3 loop specific mAbs. 
Both viruses were neutralised better in the absence of the N301 glycan (Table 4.5), which is 
expected as this glycan has been implicated in blocking underlying V3 loop epitopes as shown 
previously (Zolla-Pazner et al., 2015). Also, as expected, soluble CD4 (sCD4) was able to 
access the CD4-bs better upon removal of the N301 glycan, neutralising the mutants more 
potently as others have also shown (Zolla-Pazner et al., 2015, Koch et al., 2003, Binley et al., 
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2010) (Table 4.5). Interesting, b12 neutralised Du156.12 better than CAP45.G3 upon removal 
of the N301 glycan (Table 4.5). This again alludes to differences in the glycan shield 
maintenance of these two viruses. As an internal validation, controls of 10E8 (targets the 
MPER) and PG9 (targets the V2/apex) revealed that these two sites were not exposed by the 
removal of the N301 glycan, confirming that the shielding effect of this glycan is not the result 
of global changes in Env structure.  
 
Most striking in our mAb data was the result of the broad and potent neutralising antibodies 
which target the CD4-bs. We tested sensitivity of the WT viruses and mutants to VRC01, 
3BNC117 and NIH45-46. There was no difference in neutralisation between Du156301.332* and 
its N301A mutant to these bnAbs, consistent with a previous report that VRC01 neutralisation 
is not impeded by glycan-based shielding (Li et al., 2011). However, strikingly, neutralisation 
of CAP45301.334* by these three mAbs was substantially enhanced by the presence of the N301 
glycan, as CAP45301.334* was more resistant to these antibodies upon removal of the N301 
glycan (Table 4.5). To investigate the extent to which this effect was CAP45.G3-specific, we 
introduced N301A mutations into two neutralisation resistant viruses, 253-11 and QH343.A10. 
We found that the activity of 3BNC117 was dependent on the N301 glycan for QH343.A10 
whilst 253-11 was neutralised better without the N301 glycan by VRC01, 3BNC117 and sCD4, 
which suggests that the glycan is blocking the CD4-bs of this virus (Table 4.5). 
 
In summary, the mAb data confirm that there are differences in N301 glycan reliance by 
Du156.12 and CAP45.G3. The data also highlight that for some viral isolates (including 
CAP45.G3 and QH343.A10), the N301 glycan may be aiding in the binding and neutralisation 
by the potent VRC01, 3BNC117 and NIH45-46 bnAbs, suggesting a substantially different 
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Table 4.5 Effects of the removal of the N301 glycan on viral neutralisation by HIV-1-




















One of the challenges of an antibody-based HIV-1 vaccine based on bnAbs is that these 
antibodies are rare, only developing in a subset of HIV-1-infected individuals (Borrow and 
Moody, 2017). Understanding which broadly neutralising antibody (bnAb) targets on Envelope 
(Env) are associated with breadth and potency in natural infection may shift vaccine focus as 
it may be easier to elicit broadly neutralising responses towards these sites. Therefore, we used 
sera from unselected chronically HIV-1-infected individuals to investigate whether there was 
an association between breadth and potency and the targeting of the V3/glycans and V2/apex 
by moderately broad antibodies. We used sera instead of mAbs as these samples are a more 
representative model of the type of responses the vaccinated population will elicit unlike bnAbs 
which are relatively rarely produced and therefore, may be more challenging to elicit (Borrow 
and Moody, 2017).  
 
Despite reported polyreactivity of some anti-V3/glycan bnAbs (Liu et al., 2015), targeting this 
site in our cohort was associated with breadth and potency whilst we did not find an association 
with anti-V2/apex antibodies, despite their relative lack of self-reactivity (Liu et al., 2015) and 
their frequency in broadly neutralising sera (Walker et al., 2010). The Walker et al., study 
differs from ours as they only characterised broadly neutralising serum samples while we used 
unselected serum samples which had varying levels of breadth and potency. Self-reactivity has 
been considered an obstacle which limits the production of bnAbs (Verkoczy and Diaz, 2014), 
however, this study suggests that it is not generally a barrier in the human population for the 
production of antibodies which are moderate to broadly neutralising.   
 
As stated, no association was found with targeting the V2/apex epitope and breadth and 
potency. Antibodies targeting the V2/apex were less broad than antibodies which did not target 
this site (Fig 4.3). Although there are isolated bnAbs which target the V2/apex including PG9, 
PG16 (Walker et al., 2009), PGT 145 (Walker et al., 2011) and the CAP256-VR26 lineage 
(Doria-Rose et al., 2015), antibodies of such high breadth are rare (Moore et al., 2017) and it 
seems that commonly-elicited V2/apex antibodies in sera from unselected HIV-1-infected 
individuals fail to gain breadth and potency presumably due to the complexity needed by these 
antibodies to gain these characteristics (Doria-Rose et al., 2014). Most bnAbs which target the 
V2/apex have rare, long and anionic complementarity-determining regions in the heavy chain 
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3 (CDRH3) which are needed to penetrate the dense glycan shield of the HIV-1 Env (Moore et 
al., 2017). To date, only one broad antibody lineage has been discovered which targets this site 
and has CDRH3s of more normal, shorter length (Cale et al., 2017), however, the antibody 
with the highest breadth in this lineage could only neutralise 42% of panel viruses and therefore 
cannot be considered exceptionally broad. In our study, our threshold for breadth was 
neutralisation of 75% (18/24) of viruses in a highly neutralisation resistant virus panel which 
is plausibly a better goal for vaccine coverage. 
One limitation of our study is that we did not evaluate other bnAb Env targets including the 
CD4-bs (Burton et al., 1994), gp120-gp41 interface (Scharf et al., 2014, Falkowska et al., 2014, 
Huang et al., 2014) and the newly identified bnAb target, the fusion peptide (FP) (Kong et al., 
2016). The gp120-gp41 interface and FP epitopes are not well-characterised and therefore, 
mutational mapping based on current epitope knowledge would presumably not detect most 
antibodies targeting these sites. The CD4-bs is difficult to map through mutational mapping as 
mutating key residues which form this epitope inhibits viral entry (Platt et al., 1997), a process 
needed for the read-out of our assays (Montefiori, 2005). 
Altogether, our study shows that broad and potent responses are independently associated with 
the recognition of the V3/glycans and developing this target into an immunogen may aid in the 
ease of eliciting vaccine-grade bnAb responses. However, before designing an immunogen 
based on this target it is also important to understand the role of the V3/glycans in shielding 
antibody epitopes on Env. Commonly occurring neutralising antibodies in HIV-1-infected sera 
may play a role in the selection of glycans in viral populations. Therefore, we investigated the 
role of the V3/glycans N301, N332 and N334 on the maintenance of the glycan shield of two 
similar subtype C viruses, Du156.12 and CAP45.G3.  
Interestingly, the glycan at position N301 plays a more crucial role in maintaining the integrity 
of the glycan shield in Du156.12 than in CAP45.G3. It appears that the removal of the N301 
glycan forms a larger “hole” in the glycan shield of Du156.12, exposing both underlying and 
distal epitopes regardless of neighbouring glycans at positions N332 or N334. A recent study 
by McCoy et al. has shown that removal of specific glycans results in the formation of “glycan 
holes”, allowing antibodies which would not usually bind to neutralise the virus (McCoy et al., 
2016). Commonly-occurring neutralising antibodies in sera from natural infection which target 
epitopes shielded by the N301 glycan may be major contributors to selective pressure to 
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maintain the glycan in viral populations. This could be the reason the glycan is so prevalent in 
HIV-1 isolates across different subtypes (Travers, 2012).  
 
CAP45.G3, on the other hand, largely maintains its neutralisation resistance upon removal of 
the N301 glycan, regardless of whether an N332 or N334 glycan was present on the Env. Of 
note, CAP45.G3 contains a rare PNG at position N335. This glycan may be glycosylated 
instead of the N334 PNG on the virus. Little is known about the role of the N335 glycan in 
maintenance of the glycan shield and this should be explored further. However, this PNG is 
only present in <1% of viral isolates and individual mutation of this PNG did not result in 
increased sensitivity to sera in one study (MacLeod et al., 2016). 
 
The 301 PNG is found in 93% of viral isolates (Moyo et al., 2017) and therefore is likely 
playing a substantial role in the formation and maintenance of a glycan shield of high integrity. 
It would be interesting to determine the neutralisation resistance profiles of viruses naturally 
lacking the 301 PNG and those like CAP45.G3 who can afford to lose the glycan, presumably 
with limited neutralisation fitness cost. It may be worthwhile to investigate what alternative 
evasion strategy they may have evolved. 
 
The removal of the N301 glycan has been shown to increase neutralisation sensitivity to sCD4 
and CD4-bs targeting mAbs such as b12 (Binley et al., 2010, Zolla-Pazner et al., 2015, Koch 
et al., 2003), however only one prior published study has looked at the effect of the removal 
on this glycan on the new-generation, broad and potent antibodies targeting the CD4-bs. Li et 
al. 2011 found that the neutralisation sensitivity of virus PVO.4 to VRC01 did not change upon 
removal of the N301 glycan (Li et al., 2011) and concluded that neutralisation by this antibody 
was not affected by the N301 glycan.  
 
We show that the removal of the N301 has no effect on the neutralisation of Du156.12 by 
VRC01, 3BNC117 and NIH45-46, as expected based upon the results published by Li et al. 
However, these antibodies partially depended upon the presence of the N301 glycan to 
neutralise CAP45.G3 and QH343.A10 (for 3BNC117). This strongly suggests that the glycan 
shield in the region of the CD4-bs is constructed differently in CAP45.G3 (and likely 
QH343.A10) compared to Du156.12. This is further evidence suggesting that the N301 glycan 
is positioned differently in CAP45.G3 compared to Du156.12.  
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Although glycans such as N276 have been shown to play a role in neutralisation by CD4-bs-
specific antibodies (Wibmer et al., 2016, Balla-Jhagjhoorsingh et al., 2013), this is the first 
study to implicate the N301 glycan in CD4-bs antibody binding. Based on these data, it is 
plausible that some of the decreases in neutralisation upon removal of the N301 glycan by the 
sera we tested were due to the dominant VRC01-like antibodies in the sera. However, VRC01-
like antibodies are rarely found in unselected sera (Georgiev et al., 2013) and therefore, this is 
unlikely to explain our results. 
 
Our collaborators performed molecular dynamic simulations to predict what surface of the 
HIV-1 Env was occluded by the N301 glycan and how this differed between Du156.12 and 
CAP45.G3 (Moyo et al., 2017). In this model, removal of the N301 glycan resulted in increased 
solvent accessible surface area for Du156.12 compared to CAP45.G3, irrespective of the 
presence of an N332 or N334 neighbouring glycan (Moyo et al., 2017). Residues 323-325 in 
the V3 loop and residues 440 and 441 in the C4 region were more exposed in Du156.12 upon 
removal of the N301 glycan (Moyo et al., 2017), supporting our hypothesis of a larger glycan 
“hole” created by the removal of the N301 glycan from Du156.12 compared to CAP45.G3. 
The models did not identify increased exposure of CD4-bs residues which could be due to 
limitations in the modelling technique (Moyo et al., 2017). 
 
In summary, we show that in natural infection, antibodies targeting the V3/glycans are 
independently associated with neutralisation breadth and potency, presumably because they 
themselves are more likely to be broad and potent. Moderately broadly neutralising antibodies 
have been found to occur frequently in natural infection  (Hraber et al., 2014b). In aggregate, 
these responses can produce highly broad and potent responses (Scheid et al., 2009). Vaccine 
design strategies may need to shift to focus on the V3/glycan epitope as it may be easier to 
elicit broad responses to the V3/glycans than other epitopes such as the V2/apex. The challenge 
will be to design an immunogen that more closely resembles the V3/glycans high-mannose 
patch than generic, relatively unstructured glycans that are found on many human proteins. Our 
data also reveal that the contribution of the N301 glycan to neutralisation resistance differs 
between HIV-1 isolates. Some viral isolates such as CAP45.G3 may more easily escape 
antibody responses targeting the N301 glycan by losing the glycan whilst maintaining 
resistance towards antibodies which target underlying or distal epitopes. This immune evasion 
strategy has important implications in the efficacy of V3/glycan-based antibody infusion 
therapies as well as vaccines.
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Chapter 5: Conclusions and Perspectives 
HIV-1 escapes antibody neutralisation by a variety of methods including the addition of 
glycans (Moore et al., 2012), Envelope (Env) diversity (Korber et al., 2001), increasing loop 
lengths (Hraber et al., 2014a) and conformational masking (Kwong et al., 2002). However, 
these features do not easily explain the neutralisation resistance phenotypes of all viruses. As 
shown in this thesis, virus 253-11 is neutralisation resistant despite having loop lengths 
comparable to highly neutralisation sensitive (Tier 1) isolates (LANL, 2017) and despite having 
most of the amino acids normally required to form epitopes of key broadly neutralising 
antibody (bnAb) epitopes. Additionally, two key Env glycans, that 253-11 possesses but two 
neutralisation sensitive viruses lack, only marginally affect the resistance phenotype of 253-
11. Chapter 2 and Chapter 3 of this thesis describe data supporting the hypothesis that the
neutralisation resistance profile of 253-11 is primarily a result of an unusually tightly closed, 
compact Env trimer as compared to other Env trimers. The resistance mechanism of 
compactness described in this thesis can be viewed as unusually robust conformational 
masking in which the pre-fusion Env resists transient shifts to the open conformation and 
results in more effective shielding of neutralising epitopes. 
Moderately-neutralisation resistant, Tier 2, isolates contribute to the majority of viruses in 
circulation (Rademeyer et al., 2016, Seaman et al., 2010) and most HIV-1 antibody-based 
immunogenicity studies focus on eliciting responses towards Tier 2 viruses (Pauthner et al., 
2017). Although forming a small proportion of the HIV-1 population, there are neutralisation 
resistant, Tier 3 isolates in circulation (Seaman et al., 2010) and a protective global vaccine 
most likely would need to protect against such isolates too. If an HIV-1 vaccine were only able 
to neutralise Tier 1 or Tier 2 viruses it is plausible that some Tier 3 isolates would be 
preferentially capable of infecting and circulating in a vaccinated population. Therefore, the 
mechanisms used by Tier 3 isolates to evade neutralisation more efficiently than Tier 2 isolates 
may need to be further understood to build an immunogen capable of eliciting a response 
towards all viruses.  
Chapter 3 of this thesis describes the design of a recombinant SOSIP.664 Env trimer, based on 
the Tier 3 virus 253-11, in order to study what structural characteristics may be causing the 
high neutralisation resistance of the virus. The gp120 of 253-11 was smaller than those of most 
Chapter 5: Conclusions and Perspectives Page 105 
of the crystal structures it was compared to and its heptad repeat helices were closer to the 
trimer axis as compared to other trimers. These findings further suggest that 253-11 Env is 
compact. A future recommendation would be to test the 253-11 SOSIP trimer in 
immunogenicity studies, preferably in non-human primates (NHPs) as they closely resemble 
humans. No published work has tested any Tier 3 SOSIP.664 trimers in immunogenicity 
studies and this platform could lead to the elicitation of broadly neutralising responses. 
253-11 is not completely unique in its compactness phenotype. Tier 3 virus, CH120.6 (Cai et
al., 2017) has been described as preferentially remaining in a tight, closed structure which 
occludes antibodies. An important future step for this project would be to further delineate 
neutralisation resistance through the compactness mechanism by identifying and characterising 
more viruses with compact Envs. One potential method of identifying these viruses would be 
to test the effect of soluble CD4 (sCD4) on opening the trimer and exposing epitopes of non-
neutralising antibodies such as 17b. More compact viruses will likely need more sCD4 to open 
up the trimer while Tier 1 and Tier 2 viruses would need much less. High resolution structures 
and site-directed mutagenesis may further help identify the regions and specific residues 
responsible for the compactness phenotype. Another future recommendation for this project 
would be to determine whether compactness has a replicative fitness cost. This could be 
performed using Growth Competition Assays as previously described (Manocheewa et al., 
2015). This may give insight into why most HIV-1 isolates from chronic infection do not 
resemble 253-11. 
Chapter 4 of this thesis describes another key factor in neutralisation resistance: the glycans at 
the base of the V3 loop, usually referred to as the V3/glycans. Only a limited percentage of 
individuals develop bnAbs (Gray et al., 2009b, Stamatatos et al., 2009, Binley et al., 2008) and 
only 1% of HIV-1-infected individuals, “elite neutralisers” (Simek et al., 2009), develop the 
extremely broad and potent bnAbs  (Sather et al., 2012, Simek et al., 2009, Stamatatos et al., 
2009). The rarity of these antibodies in natural infection makes the development of such highly 
broad responses appear to be unlikely in the majority of vaccinated individuals. An 
understanding of bnAb epitopes that are preferentially targeted by moderately broad antibodies 
may focus immunogen development on sites that could potentially increase the probability of 
bnAb production. Chapter 4 of this thesis showed that the presence of antibodies targeting the 
V3/glycans and not the V2/apex was independently associated with antibody breadth and 
potency in our cohort of HIV-1-infected individuals in South Africa. 
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Using sera from unselected chronically infected individuals has the advantage that they may 
better represent antibody responses that can be elicited from vaccinated individuals. From the 
conclusions of this study and work from others who have created V3/glycan-based scaffolds 
(Zhou et al., 2014), the V3/glycans seem to be an achievable vaccine target.  
Although vaccine efforts should include protection from Tier 3 viruses, Tier 2 viruses still 
make up the majority of HIV-1 isolates in circulation (Rademeyer et al., 2016, Seaman et al., 
2010). Therefore, understanding the mechanisms used by Tier 2 viruses to gain their 
moderately neutralisation resistant profiles may be important in immunogen design to ensure 
the highest coverage possible for this Tier. A major role of the Env glycans is to protect the 
virus from neutralisation (Wei et al., 2003), even though some bnAbs have evolved to target 
these carbohydrates (Doores, 2015). This leads to the possibility that antibody-associated 
pressure may select for or against the presence of particular glycans. Antibodies whose epitopes 
contain or depend upon particular glycans may select for the absence of those glycans while 
antibodies whose epitopes are blocked by the same glycan may select for their presence. In 
Chapter 4 of this thesis, the effect of the removal of the glycan at position N301 on two subtype 
C Tier 2 viruses, CAP45.G3 and Du156.12, was investigated. CAP45.G3 maintained its 
resistant phenotype upon removal of the glycan at position N301 whilst Du156.12 become 
remarkably more sensitive to neutralisation. These data suggest that some viruses, such as 
CAP45.G3, can maintain neutralisation resistance in the absence of this glycan, which may aid 
in their ability to escape glycan-specific antibody responses.  
The antibody neutralisation resistance of some viruses, like Du156.12, is more affected by the 
loss of the N301 glycan, which presumably creates a hole in the glycan shield leading to 
increased neutralisation susceptibility. Loss of the N301 glycan in PVO.4 (Li et al., 2011), loss 
of the N241 glycan in BG505 (McCoy et al., 2016) and loss of the N197 glycan in JR-FL 
(Crooks et al., 2015) made these viruses more susceptible to antibody neutralisation. These 
studies support our findings that the loss of a single glycan can dramatically increase 
neutralisation sensitivity.  
As shown in a recent study by Zhou et al., Env trimers which are deglycosylated at specific 
sites have the potential to be used as priming immunogens to elicit anti-CD4 binding site (CD4-
bs) antibodies (Zhou et al., 2017) and therefore future studies on the removal of the N301 
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glycan may also be useful in the development of priming immunogens to elicit pre-cursor 
antibodies toward the CD4-bs. “Natural lineage vaccines” would use multiple recombinant Env 
trimers based on longitudinal env sequences usually from individuals who have developed 
bnAbs (Sanders and Moore, 2017). However, not all the longitudinal env sequences may be 
amenable to recombinant trimer design (Sanders and Moore, 2017). The method of glycan 
removal may be advantageous due to it being an approach that does not depend upon the details 
of a chosen lineage and therefore eliminates the difficulty of developing Env precursor 
recombinant trimers as immunogens to elicit germline antibodies. 
In summary, this thesis describes important advances in the understanding of the mechanisms 
used by HIV-1 to escape from antibody neutralisation. Compactness is the key mechanism that 
253-11 and plausibly additional Tier 3 viruses may use to prevent neutralisation and evade the
immune response. Although it was already known that glycans play an important role in 
shielding Env from neutralisation, this thesis highlights that the dependency upon key glycans 
for protection from antibodies varies between HIV-1 isolates. Interestingly, some viruses likely 
have compensatory mechanisms to ensure that even in the absence of certain glycans, they are 
still able to retain the neutralisation resistance that glycans afford them. Altogether, the 
knowledge gained from this thesis may aid in the design of an HIV-1 vaccine able to protect 
against neutralisation resistant viruses. The data also has implications on passive immunisation 
strategies as immune evasion by the loss of glycans while retaining resistance must be 
considered to avoid antibody therapy failure. 
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